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ABSTRACT 
 
A variety of methodologies developed in our research group has inspired the three 
separate projects reported. First, the total synthesis of (±)-quebrachamine was performed 
in 13 steps and 17.8% overall yield. Highlights of the synthesis include an efficient 
preparation of a functionalized indole core via a [3+2] annulation cycloaddition reaction 
between a functionalized nitrile and donor-acceptor cyclopropane and a photo induced 9-
membered ring closure.   
Secondly, we have reported the most efficent and highest yielding route to several 
tetrahydroisoquinocarbazoles, where the core was prepared in six steps from tryptophol 
in 51% overall yield. This work highlights for the first time the synthetic utility of the 
dipolar C-2 alkylation of 3-substituted indoles with 2-alkoxycyclopropanoate esters. The 
synthesis also features a selective SmBr2-HMPA promoted ring closure of an aldehyde 
onto a sterically congested trisubstituted alkene.   
 Lastly, we have developed efficient syntheses towards several fragments of 
biselide A, which could be used to explore both ring closing metathesis and relay ring 
closing metathesis to construct the 14-membered macrolactone. The trans-THF ring was 
furnished by using our second generation Co(nmp)2 catalyst in a Mukaiyama oxidative 
cyclization, while the chloroalkene moiety was introduced with a chloropalladation 
reaction. Key steps in the synthesis of the southern fragment included a Sharpless 
asymmetric kinetic resolution, or a diastereoselective aldol reaction. Significant synthetic 
efforts toward biselide E have also been reported. We have designed an efficient method 
to access the western fragment, which also employed our second generation Co(nmp)2 
catalyst in a Mukaiyama oxidative cyclization to furnish the trans-THF ring. A proficient 
method towards the eastern fragment was also designed, using a Suzuki coupling reaction 
as the key step.  
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INTRODUCTION: Importance of Total Synthesis 
 
 In order to appreciate total synthesis, one needs to consider how synthetic 
chemistry has impacted the world around us. Everything from pharmaceuticals, high-tech 
materials, polymers, fertilizers, pesticides, personal care products, and even our food, has 
been impacted by organic chemistry. One of the main driving forces for chemists is 
having the ability to create molecules that have some useful application.  
 Synthetic chemists take inspiration from Mother Nature, with the hopes that we 
can access molecules found in nature, but to also access derivatives of those molecules, 
which can be tremendously useful. Since most natural products are found in miniscule 
amounts and are often difficult to obtain, accessing them through synthetic means can be 
incredibly important in obtaining useful quantities so that we can study their properties. 
This leads to their development as useful compounds or potential pharmaceuticals.  
 When isolation chemists find a natural product that has an interesting biological 
activity, the structure of that molecule can be determined using the numerous tools to 
facilitate structural elucidation, like NMR, IR, UV-Vis, and HRSM. While these 
techniques can be used to determine a compound’s structure with great deal of certainty, 
we can only be sure of its absolute structure through synthetic means. 
 Once we have an efficient way to access a target molecule, we can use that route 
to also access derivatives, providing a collection of related molecules that we can study 
for their unique properties and biological activity, which is the basis of drug design. 
 Arguably, one of the most important opportunities that total synthesis offers 
chemists the chance to discover and invent new chemistry. During the course of a total 
synthesis, you are bound to come across challenges that must be overcome to ultimately 
reach your goal. We oftentimes refer to chemical transformations as tools in our synthetic 
toolbox. But what if your toolbox doesn’t provide the specific tool you require? It’s these 
times that provide chemists with the greatest opportunity to develop new ideas and 
methods to achieve a synthetic goal. This is how synthetic chemisty grows and develops. 
 Lastly, total synthesis, in my opinion is one of the most rigorous ways to train a 
synthetic chemist because it challenges their creative thinking, while continually problem 
solving, and exposes them to a wide variety of chemical transformations and techniques.  
2 
 
2 
 
CHAPTER 1: The Total Synthesis of (±)-Quebrachamine 
 
1.1 Introduction  
 
 The primary objectives of the Pagenkopf research group are methodology 
development and application in the synthesis of natural products. Of particular interest is 
the construction of various heterocycles such as pyrroles and indoles due to their 
abundance in biologically active compounds. A powerful strategy for the synthesis of 
these heterocycles has been developed by our group involving a formal [3+2] dipolar 
cycloaddition of donor-acceptor 2-alkoxycyclopropanoate esters.
1
  
The first application of this cycloaddition methodology was demonstrated in the 
total synthesis of (±)-goniomitine (1-4), where a [3+2] dipolar cycloaddition between 
functionalized nitrile 1-1 and donor acceptor (DA) cyclopropane 1-2 was utilized to 
construct the indole core (Scheme 1.1).
2
 We believed the utility of this methodology 
could be further demonstrated by building on these initial discoveries and synthesizing 
(±)-quebrachamine (1-5), which is another member of the aspidosperma family.
3
   
 
 
Scheme 1.1 Aspidosperma alkaloids 
 
1.2 [3+2] Annulation Reaction 
 
 Our interest towards (±)-quebrachamine (1-5) stemmed from the potential 
application of our [3+2] dipolar cycloaddition methodology involving DA cyclopropanes. 
The versatility and reactivity of cyclopropanes make them useful building blocks in 
3 
 
3 
 
organic synthesis. Although there are several known applications with unactivated 
cyclopropanes,
4
 functional groups are more commonly installed around the ring to 
increase their reactivity. Electron accepting groups activate the ring opening in a 
Michael-type nucleophilic attack, while electron donating substituents do so upon 
reaction with an electrophile (Figure 1.1, examples 1 and 2). The most reactive 
cyclopropanes contain vicinal acceptor and donor groups
5
 which promote the formation 
of a 1,3-dipole intermediate (Figure 1.1, example 3).    
 
 
Figure 1.1 Cyclopropane activation 
 
 Due to the dual electronic properties exhibited by the 1,3-zwitterionic 
intermediate of the opened cyclopropane, the annulation may involve many reaction 
partners including nitriles,
6
 pyridines,
7
 indoles,
8
 and other dipolarophiles.
9
 A general 
pyrrole synthesis was developed in our research group where DA cyclopropanes undergo 
[3+2] dipolar cycloaddition reactions with nitriles when appropriately activated by a 
Lewis acid such as TMSOTf (Scheme 1.2).
1,6
 The annulation sequence likely consists of 
a [3+2] cycloaddition involving the nitrilium ion intermediate, formed in a Ritter type 
process where the nitrile attacks the oxocarbenium ion (Scheme 1.2). An intramolecular 
cyclization occurs between the enolate and the resulting nitrilium ion, followed by 
condensation and tautomerization steps in the construction of the tetrasubstituted pyrrole, 
while maintaining absolute regiochemical control.  It should be noted that if the 
4 
 
4 
 
cyclopropane contains a fused cyclohexyl ring (R
1
/R
2
: -(CH2)4-), the [3+2] annulation 
yields a tetrahydroindole which upon oxidation provides access to substituted indoles. 
 
 
Scheme 1.2 Pyrrole synthesis 
 
1.3 Biological Activity of Quebrachamine  
 
Quebrachamine belongs to a large family of Aspidosperma alkaloids, with only a 
few members that possess biological activity. Although quebrachamine is one of the least 
structurally complex alkaloids in its class, it exhibits potent bioactivity including α-
adrenergic blocking behavior in urogenital tissue.
10
 It was found to reduce smooth muscle 
contractions in human prostate, rabbit corpus spongiosum and cavernosum, as well as 
guinea pig vas deferens, making quebrachamine a potential drug candidate for erectile 
impotence and benign prostatic hyperplasia (BPH).   
 
1.4 Previous Syntheses of Quebrachamine  
 
While quebrachamine (1-5) exhibits attractive pharmacological properties, its 
interesting framework has inspired considerable and sustained synthetic efforts, with the 
5 
 
5 
 
first total synthesis reported in 1963 by Stork and Dolfini.
11
 The synthesis of this natural 
product has continued to challenge chemists as it features a quaternary carbon center, 
fused piperidine functionality, and a 9-membered ring. Several previous total syntheses 
will be discussed, including the first racemic version, followed by some more recent 
asymmetric contributions. Some of the syntheses take inspiration from proposed 
biosynthetic pathways towards quebrachamine, which include naturally abundant starting 
materials like amino acids and tryptamine. 
 
1.4.1 Previous Syntheses of (±)-Quebrachamine  
 
 The first total synthesis of (±)-quebrachamine was described by Stork and Dolfini 
in 1963 (Scheme 1.3).
11
 Their synthesis commenced with a four step sequence from 
butyraldehyde 1-6 to form amide 1-7. This crystalline product was reduced to a primary 
amine with lithium aluminum hydride and subsequent treatment with acid gave the 
bicyclic ketone 1-8. Acylation of the resulting amine with chloroacetyl chloride followed 
by treatment with potassium tert-butoxide afforded lactam 1-9. After converting the 
lactam to the corresponding amine (1-10) in a three step process, a Fischer indole 
cyclization was conducted with phenylhydrazine to give pentacyclic amine 1-11. Finally, 
reductive cleavage of 1-11 with potassium borohydride furnished (±)-quebrachamine (1-
5). 
  
 
Scheme 1.3 Stork and Dolfini’s synthesis of (±)-quebrachamine 
6 
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 A number of years after the first total synthesis of (±)-quebrachamine, Zoretic and 
co-workers published their approach toward the construction of the natural product 
(Scheme 1.4).
12
 Their synthetic efforts began with 4-formylcapronitrile (1-12), and 
through a series of functional group manipulations ultimately furnished amine 1-13. 
Here, the authors treated the piperidine compound with β-indolylacetyl chloride, 
affording a lactam ester which was immediately subjected to saponification reaction 
conditions to provide carboxylic acid 1-14 in 44% yield over two steps.  
 
 
Scheme 1.4 Zoretic’s synthesis of (±)-quebrachamine 
  
 Upon heating the carboxylic acid (1-14) in the presence of polyphosphoric acid 
(PPA), the desired Friedel-Crafts product was obtained in an excellent 87% yield. It is 
interesting to note that PPA catalyzed cyclizations of related β-indolealkanoic acids onto 
the C-2 position of the indole typically give the desired products in high yield for 7-
member ring formation (up to 95%), whereas the 6-, 8-, and 9-membered rings form in 
low yields comparatively (30-55%). The authors speculated that the unusually high yield 
they observed indicates a possible participation of the amide nitrogen. It is suspected that 
perhaps the nitrogen cyclizes on the carboxylic acid first, generating a five membered 
transition state and a quaternary ammonium salt, consequently lowering the entropy of 
the molecule and promoting the intramolecular cyclization onto the C-2 of the indole. 
The synthesis was completed upon reduction of 1-15 with lithium aluminum hydride in 
refluxing dioxane in 6% yield. Although (±)-quebrachamine was obtained in low yield, 
the synthesis demonstrated an interesting approach to the 9-membered ring via a Friedel-
Crafts acylation.    
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 A more recent synthesis was reported in 2007 by the Coldham research group.
13
 
Their work relied on the construction of tricyclic amine 1-23 via a highly efficient 
cyclization/cycloaddition cascade methodology, which they applied to the synthesis of 
(±)-quebrachamine (Scheme 1.5). The synthesis began with acetal protection of 
dibromoketone 1-16; followed by a base induced elimination to furnish protected enone 
1-17 in 82% yield over two steps. Alkylation of butanenitrile with LDA proceeded 
smoothly to give nitrile 1-18, which was subsequently alkylated with 1-bromo-3-
chloropropane, constructing the quaternary center in 1-19. The resulting nitrile was 
reduced with DIBAL in 82% yield, providing the pivotal cyclization precursor (1-20).  
   
 
Scheme 1.5 Coldham’s synthesis of (±)-quebrachamine 
 
 Treatment of 1-20 with glycine and 10-CSA generated ylide 1-21 in situ, which 
participated in an intramolecular cycloaddition to give the tetracyclic product 1-22 in 
79% yield. Hydrolysis of the acetal was promoted upon treatment with acid, with 
concurrent isomerization of the enolizable carbon center providing the cis/cis ketone 1-
23. (±)-Quebrachamine (1-5) was completed after Fischer indole synthesis gave the 
desired fused indole, followed by reductive ring opening in 39% yield over two steps. 
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1.4.2 Previous Asymmetric Syntheses of Quebrachamine  
 
 Nearly two decades after Stork and Dolfini’s first total synthesis of (±)-
quebrachamine, Takano reported the first asymmetric synthesis of (+)-quebrachamine 
using L-glutamic acid as a chiral template (Scheme 1.6).
14
 L-Glutamic acid (1-24) was 
first modified by the same reaction sequence developed by Yamada and co-workers.
15
 
After detritylation of 1-25 under acidic conditions, the resulting lactone was hydrolyzed 
using NaOH and oxidized with sodium metaperiodate, which gave hydroxy-lactone 1-26 
in 60% over three steps. Condensation with tryptamine in acetic acid gave rise to lactam 
1-27 as a 1:1 mixture of epimers in 74% yield. Primary alcohol 1-28 was then generated 
after treatment of 1-27 with diborane-dimethyl sulphide in THF followed by oxidation 
with basic hydrogen peroxide. Reduction of lactam 1-28 proceeded in 46% yield, and 
converted to pentacyclic quaternary amine 1-30 over two steps. The quaternary salt was 
then reduced (NH3 (liq), Na), giving rise to (+)-quebrachamine in 65% over three steps.  
 
 
Scheme 1.6 Takano’s synthesis of (+)-quebrachamine 
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 One year later in 1981, Takano reported an enantioselective route to both (+) and 
(−)-quebrachamine using a single chiral synthon 1-25 (Scheme 1.7).16 He provided a 
route to both enantiomers of quebrachamine, while utilizing the sequence of steps to form 
1-25 as described in his earlier publication.
14
 His synthesis of (−)-quebrachamine ((−)-1-
5) began with detritylation of 1-25 under acidic conditions, followed by ozonolysis to 
access aldehyde 1-31. A Pictet-Spengler condensation was performed with tryptamine 
under acidic conditions, producing lactam 1-32 in 47% yield (1:1 epimeric mixture) over 
two steps. After epoxide formation (DEAD, PPh3), a rearrangement was induced to 
generate an aldehyde which was immediately reduced to give alcohol 1-34 with lithium 
aluminum hydride in 11% yield over three steps. The synthesis then converged with 
Takano’s previously reported synthesis for (+)-quebrachamine (see Scheme 1.6) to 
ultimately furnish (−)-quebrachamine ((−)-1-5). 
 
 
Scheme 1.7 Takano’s synthesis of (−)-quebrachamine 
 
 Recent advancements in chiral olefin metathesis have inspired an enantioselective 
synthesis of (+)-quebrachamine, featuring a catalytic ring closure of an achiral triene as 
the key step (Scheme 1.8).
17
 Synthesis of the RCM precursor is accomplished in a four 
step sequence, initiated by a Pictet-Spengler condensation of divinylamide fragment 1-36 
(prepared in six steps and 34% overall yield from commercially available α-
acetylbutyrolactone 1-35) and tryptamine to give tetracycle 1-37 in 79% yield. After 
amide reduction with lithium aluminum hydride, the resulting amine 1-38 was acylated 
with allyl chloroformate and subsequently reduced with NaCNBH3 to cleave the C-N 
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bond to give 1-39 in 94% yield. Finally, the tricyclic triene 1-40 was secured in 88% 
yield after carbamate 1-39 was treated with 2.0 mol % Pd(PPh3)4. With triene 1-40 in 
hand, Schrock, Hoveyda and co-workers efficiently performed the key enantioselective 
ring closing metathesis with chiral Mo-monoaryloxide catalyst 1-41 with >98% 
conversion, 84% yield and 96% ee. Catalytic hydrogenation with PtO2 under H2 
atmosphere of terminal alkene 1-42 afforded (+)-quebrachamine in 97% yield. 
 
 
Scheme 1.8 Schrock and Hoveyda’s synthesis of (+)-quebrachamine 
 
 
 
 
 
 
11 
 
11 
 
1.5 The Total Synthesis of (±)-Quebrachamine 
 
1.5.1 Retrosynthesis 
 
 Our initial retrosynthetic analysis identified two bonds in the 9-membered ring as 
potential key disconnections, which could be formed using a Friedel-Crafts acylation or 
N-alkylation reaction, simplifying the target to advanced intermediate 1-43 (Scheme 1.9).  
Previous work from the (±)-goniomitine synthesis
2
 provided a route to 1-43, which was 
obtained by oxidation of the tetrasubstituted pyrrole 1-3, which was generated from the 
[3+2] cycloaddition involving functionalized nitrile 1-1 and cyclopropane 1-2
5
.  
 
 
Scheme 1.9 Retrosynthetic strategy 
 
1.5.2 Functionalized Nitrile  
 
Nitrile 1-1 was prepared in a five step sequence, as previously reported in our 
group (Scheme 1.10).
2
 Commercially available δ-valerolactam underwent a one-pot, 
double alkylation to install the ethyl and benzyl groups. Following the installation of the 
quaternary center using 2-(2-bromoethoxy)tetrahydro-2H-pyran (1-46), 1-47 underwent 
hydrolysis (PTSA, MeOH). The resulting primary alcohol 1-48 was halogenated and 
directly converted to the target nitrile 1-1 by a microwave assisted displacement reaction 
with sodium cyanide. The microwave reaction (120 °C, 8 h) was found to be an efficient 
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alternative to classic displacement conditions (82 °C, 72 h), producing the desired nitrile 
with a comparable yield and in a significantly shorter reaction time.  
 
 
Scheme 1.10 Synthesis of nitrile annulation partner 1-1 
 
1.5.3 Construction of the Core of Quebrachamine 
 
The [3+2] cycloaddition reaction between functionalized nitrile 1-1 and DA 
cyclopropane 1-2 in the presence of TMSOTf gave cycloadduct 1-3 in 74% yield 
(Scheme 1.11). The cycloaddition reaction was followed by oxidation with palladium on 
carbon, which provided the indole core (1-50) in an exceptional 98% yield. The ester, an 
artifact from the cycloaddition, was removed via a microwave assisted decarboxylation, 
and the resulting lactam (1-51) was deprotected without difficulty, thus setting the stage 
for the formation of the 9-membered ring.  
 
 
Scheme 1.11 Construction of the core of quebrachamine 
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1.5.4 Cyclization and Completion 
 
1.5.4.1 Friedel-Crafts Method 
 
The formation of 9-membered rings is notoriously difficult, but armed with a 
ready supply of indole 1-43, several approaches were investigated. Our initial synthetic 
plan to access the 9-membered ring involved a Friedel-Crafts acylation followed by a 
Wolff-Kishner reduction. Preparation of the cyclization precursor involved reduction of 
lactam 1-43, N-alkylation of the resulting amine (1-52) with ethyl bromoacetate and 
saponification (Scheme 1.12). The resulting carboxylic acid (1-53) was subjected to 
typical Friedel-Crafts acylation conditions by screening a wide array of catalysts and 
varying the reaction temperatures (−30 °C and 25 °C). Unfortunately, all efforts to 
cyclize the precursor using these methods resulted in substrate decomposition. 
 
 
Scheme 1.12 Synthesis of the Friedel-Crafts precursor and cyclization attempts 
 
1.5.4.2 Mitsunobu Method 
 
Our failure to form the 9-membered ring via a Friedel-Crafts reaction compelled 
us to explore a different approach involving a Mitsunobu cyclization. In order to 
construct this type of ring closing precursor, a hydroxyethyl side-chain needed to be 
introduced at the C-3 position of indole 1-51. Previous work in our research group by 
Morales in the synthesis of (±)-goniomitine, involved a two-step sequence where indole 
was treated with oxalyl chloride in the presence of base, followed by methanol to obtain 
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methyl oxoester 1-54 (Scheme 1.13, Method 1).
18
 However, all attempts to selectively 
reduce the oxoester to the corresponding alcohol (1-55) without affecting the lactam were 
unsuccessful. An alternative route was utilized involving a Mannich type amine 
methylation and displacement with sodium cyanide (1-56), followed by double reduction 
to the target alcohol (Scheme 1.13, Method 2). This method was undesirable due to the 
lengthy reaction sequence and low overall yields, so an alternative method was pursued 
to construct the hydroxyethyl side-chain required to access quebrachamine.   
 
 
Scheme 1.13 Previous hydroxyethyl installation methods 
 
 There are several known examples of ethylene oxide being used in a one-step 
alkylation process; however, simple substrates undergo alkylation with modest yields 
while more highly functionalized examples, comparable to (±)-quebrachamine, result in 
unacceptably low yield.
19
 Although the literature does not provide much encouragement, 
we were confident we could optimize the reaction and began a model study.  
Our model study began with the N-silyl protection of 2-methyl indole to ensure C-
3 selectivity by eliminating competitive N-alkylation (Table 1.1). The trimethylsilyl 
protecting group was ideal as it can be conveniently removed during purification on silica 
gel, avoiding an additional deprotection step. Initial attempts for the side-chain 
installation involved treating protected indole 1-57 with an excess of ethylene oxide in 
the presence of a Lewis acid in order to activate the epoxide for ring opening.  
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Table 1.1 Hydroxyethyl side-chain model study 
 
Entry Lewis acid
a
 Solvent Yield (%)
d
 
1 InBr3 THF
b
 0 
2 Yb(OTf)3 THF
b
 0 
3 Sc(OTf)3 THF
b
 0 
4 TMSOTf THF
b
 0 
5 InBr3 Et2O
b
 20 
6 InCl3 Et2O
b
 19 
7 Et2AlCl Et2O
b
 10 
8 BF3·OEt2 Et2O
b
 20 
9 Yb(OTf)3 Et2O
c
 23 
10 Sc(OTf)3 Et2O
c
 21 
11 TMSOTf Et2O
c
 0 
12 MgI2 Et2O
c
 0 
13 InBr3 Et2O
c
 27 
14 SnCl4 (50 mol %) Et2O
c
 45
e
 
15 SnCl4 Et2O
c
 26 
16 SnCl4 (100 mol %) Et2O
c
 43
e
 
17 AlMe3 Et2O
c
 19 
18 InBr3 benzene/Et2O
c
 17 
19 InBr3 CH2Cl2/Et2O
c
 24 
20 InBr3 MTBE
c
 36 
a 5 mol % unless otherwise noted. b Reaction flask was sealed with a septum. c 
Reaction flask was sealed with a plastic cap. d All remaining starting material 
recovered, with almost no decomposition observed unless otherwise noted.  
e No starting material recovered.   
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While no reaction was observed with THF as the solvent (entries 1-4), switching 
to Et2O resulted in small amounts of the desired product (1-58) as well as recovered 
starting material (as 2-methyl indole) with little decomposition. Due to the high volatility 
of ethylene oxide, we had suspected that it may be escaping the reaction mixture, so the 
flasks were capped to provide an air-tight seal which resulted in a 7% increase in yield 
(entries 5 vs. 13). In an effort to push the reaction to completion, reaction times were 
increased from 12 h up to 7 days with no increase in yield. Further investigation involved 
screening several Lewis acids where InBr3 and SnCl4 showed the most promising results 
(entries 13-16); however, no starting material was recovered when SnCl4 was used, so 
InBr3 was selected as the optimal Lewis acid. Finally, numerous solvent systems were 
explored with the highest yield observed when methyl tert-butyl ether (MTBE) was used 
(entry 20). 
Encouraged by our progress, we applied the optimized conditions from the model 
study to the substrate (1-51). Our synthetic strategy began with an attempt to N-silylate 
indole 1-51 in order to ensure C-3 selectivity by eliminating competitive N-alkylation. 
However, all efforts to protect the indole nitrogen were unsuccessful. As a result, we 
suspected that the substrate would undergo the C-3 selectivity we desired without the 
need for N-protection. As predicted, the hydroxyethyl side-chain installation was 
completely C-3 selective and furnished indole 1-55 in 33% yield, with no recovered 
starting material (Table 1.2, entry 1).   
 
Table 1.2 Hydroxyethyl side-chain installation 
 
Entry Base (4 equiv) Yield (%) 
1 -  33
a
 
2 NaH 38 
3 KH 55 
a No BHT added.  
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We speculated that the low yield could be due to competing radical side reactions, 
so a radical scavenger (BHT) was added. In a final effort to optimize the reaction, base 
was added to assist the alkylation which resulted in a remarkable 22% increase in overall 
yield (Table 1.2, entries 1 vs. 3). At this point we had developed the most efficient and 
highest yielding method for C-3 hydroxyethyl installation of an indole compared to other 
published methods utilizing ethylene oxide.
19
 It should also be noted that this one-step 
installation was more efficient (one step vs. five steps) and higher yielding (55% vs. 
31%) then the alternative synthetic route (Scheme 1.13).
18
  
With the hydroxyethyl side-chain installed, the Mitsunobu cyclization precursor 
(1-59) was prepared upon deprotection of indole 1-55 (Scheme 1.14). Lactam 1-59 was 
then subjected to Mitsunobu conditions, but the desired cyclization product was not 
observed. Instead, the reaction led to the formation of spirocycle 1-60, which was the 
result of attack through the C-3 position. Different reaction conditions were employed 
including varying reaction temperatures, concentration factors, and addition rate, but all 
attempts led to spirocycle formation (1-60).  In an effort to make the lactam nitrogen 
more nucleophilic, 1-59 was reduced to its corresponding amine 1-61 and subjected to 
Mitsunobu reaction conditions; however, this led to substrate decomposition. The 
nucleophilicity of the indole was detrimental to the desired cyclization, but attempts to 
attenuate the indole nucleophilicity by installing a variety of protecting groups was 
unsuccessful due to the sterically hindering side-chain. 
 
 
Scheme 1.14 Mitsunobu cyclization attempts 
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1.5.4.3 SN2 Method 
 
Turning our focus to a possible SN2 reaction to close the ring, indole 1-59 was 
converted to halide derivatives (1-62 and 1-63) and treated with a base (Scheme 1.15).  
When NaH was employed, only spirocycle 1-60 was isolated, whereas treatment with     
t-BuOK promoted substrate decomposition. At this stage, the SN2 approach was 
abandoned due to the detrimental and unavoidable nucleophilicity of the indole and a 
new route was explored. 
 
Scheme 1.15 SN2 cyclization attempts 
 
1.5.4.4 Literature Inspired Method   
 
 Our attention turned to a related example in the literature where Lesma and co-
workers constructed a similar 9-membered ring in the total synthesis of (+)-20R-15,20-
dihydrocleavamine (1-66) from cyclization precursor 1-64 (Scheme 1.16).
20
 Our 
synthesis began by protecting amine 1-52 with a Boc or Cbz group. Using the ethylene 
oxide method developed earlier, the hydroxyethyl side-chain was installed on both 
protected amine derivatives (1-67 and 1-68). The two primary alcohols 1-69 and 1-70 
were then converted to leaving groups with MsCl and the amines were deprotected, 
where H2 and Pd/C was used to remove the CBz group, while the Boc group was 
19 
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removed with TFA. Unfortunately, both reactions resulted in complex mixtures with no 
trace of the desired products.  
 
 
Scheme 1.16 Lesma inspired cyclization attempt 
 
1.5.4.5 Chloroacetamide Method 
 
Given the disappointment with our previous strategies to construct the 9-
membered ring, another approach was taken. The new synthetic plan was designed to 
take advantage of the nucleophilic indole, where we had previously seen attack through 
the C-3 position. In our initial approaches, this nucleophilicity was detrimental to the 
desired reactivity, whereas it would be required in our new strategy. First, alkylation of 
piperidine 1-52 with chloroacetyl chloride was achieved in 96% yield (Scheme 1.17). 
Treatment of the resulting chloroacetylated amine 1-71 with NaH or allylmagnesium 
bromide both led to complex mixtures with trace amounts of undesired N-cyclization. 
This outcome was unexpected since in earlier strategies, the C-3 position of the indole 
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was observed to be the most nucleophilic site, and all previous efforts to protect the 
indole were unsuccessful due to steric effects of the side-chain.   
 
 
Scheme 1.17 Chloroacetamide indole cyclization attempt 
 
1.5.4.6 Photocyclization Method 
 
After extensive exploration of classic alkylation and acylation strategies, our final 
approach involved a photo induced ring closure. Chloroacetamide photocyclizations can 
be utilized in the formation of strained medium-sized lactams.
21
 A number of Witkop 
photocyclizations
22
 have been reported in the synthesis of Vinca and Strychnos alkaloids 
via chloroacetamide indole derivatives (Scheme 1.18).
23
 It is worth noting that simple 
substrates, such as isotryptamine derivatives (1-72),
23d
 cyclize in high yield (example 1), 
however, substrates with the complexity comparable to that of (±)-quebrachamine, do so 
in low to modest yields (example 2).
23b,e,f 
 
 
Scheme 1.18 Reported photocyclizations of 2-indolylalkyl N-chloroacetamides 
 
21 
 
21 
 
Remarkably, exposure of chloroacetylated amine 1-71 to 254 nm irradiation in 
basic solution assembled the 9-membered ring in an unprecedented 85% yield (Scheme 
1.19). The cyclization mechanism likely involves photoexcitation and electron transfer 
steps leading to an initial diradical species 1-76.
24
 Upon chloride ionization and 
electronic redistribution, cyclization of 1-77 occurs at C-3 which is the most favorable 
position based on the geometry between the indole and the side-chain as well as the 
calculated spin density.
24
 Lastly, the indole was rearomatized upon proton loss and the 
final cyclization product (1-78) was obtained. Delighted with this result, the synthesis 
was completed by reducing lactam 1-78 with LiAlH4, securing (±)-quebrachamine (1-5) 
in 93% yield. 
 
 
Scheme 1.19 Photocyclization and completion  
 
1.6 Summary 
 
In summary, the total synthesis of (±)-quebrachamine (1-5) has been 
accomplished in 13 steps and 17.8% overall yield. Highlights of the synthesis include an 
efficient preparation of a functionalized indole core via a [3+2] cycloaddition reaction 
between a functionalized nitrile and donor-acceptor cyclopropane. This synthesis also 
utilized a Witkop photo induced 9-membered ring cyclization in an unprecendented yield, 
which demonstrated the utility of this type of ring closure in the total synthesis of 
complex natural products.   
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1.7 Experimental 
 
1.7.1 General Considerations 
 
 All reactions were run under an argon atmosphere unless otherwise indicated. 
Flasks were oven dried and cooled in a dessicator prior to use unless water was used in 
the reaction. Solvents and reagents were purified by standard methods.
1
 Acetonitrile, 
dichloromethane, tetrahydrofuran, diethylether, dimethylformamide, toluene, and 
benzene were purified by passing the solvents through activated alumina columns. 
Ethanol and methanol were distilled over magnesium prior to use. Mesitylene, MeNO2, 
EtNO2, Et3N, (iPr)2NH, NEt(iPr)2 and hexamethylphosphoramide (HMPA) were dried by 
refluxing under CaH2 prior to distillation. The solution of nBuLi was titrated prior to use 
by Suffert method.
2
 LDA was freshly prepared before use by the dropwise addition of 
nBuLi in hexane (1.00 mmol, 2.50 M) to a solution of N,N-diisopropylamine (1.05 mmol) 
in THF (5.00 ml) at 0 °C. All other chemicals were of reagent quality and used as 
obtained from commercial sources unless otherwise noted. The progress of reactions 
were monitored by thin layer chromatography (TLC) performed on F254 silica gel plates. 
The plates were visualized by staining with ceric ammonium molybdate (CAM)
3
 or p-
anisaldehyde. Column chromatography was performed with Silica Flash P60 60 Å silica 
gel from Silicycle according to the Still method.
4
 
 The 
1
H and 
13
C NMR data were obtained on Varian INOVA 400 or 600 
spectrometers. All spectra were obtained in deuterated chloroform and were referenced to 
the singlet at δ 7.25 ppm for 1H spectra and the center peak of the triplet at δ 77.0 ppm for 
13
C spectra. When peak multiplicities are given, the following abbreviations are used: s, 
singlet; d, doublet; dd, doublet of doublets; ddd, doublet of doublet of doublets; ddt, 
doublet of doublet of triplets; dq, doublet of quartets; t, triplet; tt, triplet of triplets; td, 
                                                 
1
 Armarego, W.L.F.; Perrin, D. D. Purification of Laboratory Chemicals; 4
th
 Ed.; Oxford; 
Boston : Butterworth Heinemann, 1996. 
2
 Suffert, J. J. Org. Chem. 1989, 54, 509–510. 
3
 See footnote 50 in: Gao, Y.; Hanson, R.M.; Klunder, J.M.; Ko, S.Y.; Masamune, H.; 
Sharpless, K.B. J. Am. Chem. Soc. 1987, 109, 5765. 
4
 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923–2925. 
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triplet of doublets; q, quartet; quin, quintet; m, multiplet; br, broad; app, apparent. EI 
mass spectra were obtained on a Finnigan MAT 8200 spectrometer at an ionizing voltage 
of 70 eV. Melting points were obtained in an Electrothermal Mel-Temp and are 
uncorrected. The microwave reactions were conducted in an Initiator reactor from 
Biotage. The photocyclization was performed in a Rayonet Photochemical Reactor 
(Model RPR-100) equipped with 16 quartz tube, low pressure Hg lamps. 
 
1.7.2 Experimental Procedures 
 
3-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-propionitrile (1-1) 
Crude chloride 1-49 was dissolved in MeCN (120 mL) and NaCN (5.80 g, 
119 mmol) was added.  The solution was heated to 120 °C in a microwave 
reactor for 8 h (900 rpm stirring). The mixture was allowed to cool to RT and washed 
with brine. The organic layer was then dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as light yellow oil (71%, 
9.59 g, over two steps). Rf 0.16 (33% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  
7.33–7.26 (m, 3H), 7.24–7.20 (m, 2H), 4.65 (d, J = 14.4 Hz, 1H), 4.44 (d, J = 14.4 Hz, 
1H), 3.19 (t, J = 6.0, 2H), 2.52–2.36 (m, 2H), 2.03 (ddd, J = 5.8, 10.3, 13.8 Hz, 1H), 
1.90–1.72 (m, 5H), 1.66–1.53 (m, 2H), 0.88 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) 172.8, 137.0, 128.3, 127.6, 127.1, 120.0, 50.2, 47.2, 44.0, 33.4, 30.0, 29.1, 19.0, 
12.6, 8.0. HRMS m/z 270.1739 (calcd for C17H22N2O, 270.1732). 
 
2-[2-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-ethyl]-4, 5, 6, 7-
tetrahydro-1H-indole-3-carboxylic acid ethyl ester (1-3) 
To a solution of nitrile 1-1 (6.77 g, 25.0 mmol) and the 
cyclopropane 1-2 (14.3 g, 72.0 mmol) in EtNO2 (9.50 mL) at –30 °C, TMSOTf (4.72 mL, 
26.3 mmol) was added dropwise. After 16 h, 75.0 mL of EtOAc was added and then the 
mixture was poured into a half saturated solution of NaHCO3 (150 mL). The 
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3 
x 15.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
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filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as white solid (74%, 8.07 g). Rf 0.28 (33% EtOAc/hexanes); mp 119–120 °C 
(hexanes/EtOAc crystal); 
1
H NMR (400 MHz, CDCl3)  8.42 (br s, 1H), 7.32–7.26 (m, 
2H), 7.24–7.19 (m, 3H), 4.62 (d, J = 14.6 Hz, 1H), 4.55 (d, J = 14.6 Hz, 1H), 4.23 (q, J = 
7.2 Hz, 2H), 3.29 (ddd, J = 6.4, 10.5, 14.3 Hz, 1H), 3.23–3.18 (m, 2H), 2.69–2.66 (m, 
2H), 2.56 (ddd, J = 4.7, 10.5, 14.3 Hz, 1H), 2.48–2.44 (m, 2H),  2.03 (ddd, J = 4.7, 10.5, 
13.4 Hz, 1H), 1.86–1.72 (m, 10H), 1.61 (ddd, J = 7.2, 14.3 Hz, 1H), 1.31 (t, J = 7.3 Hz, 
3H), 0.88 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 175.3, 166.3, 138.9, 137.5, 
128.6, 127.9, 127.8, 127.3, 125.9, 118.1, 108.7, 58.8, 50.6, 47.9, 45.6, 38.3, 31.8, 28.9, 
23.6, 23.4, 23.0, 22.6, 19.8, 14.6, 8.6. HRMS m/z 436.2719 (calcd for C27H36N2O3, 
436.2726). 
 
(±)-Quebrachamine (1-5) 
Lactam 1-78 (9.00 mg, 0.03 mmol) in THF (2.00 mL) was added to 
a cooled (0 °C) suspension of LiAlH4 (6.00 mg, 0.15 mmol) in 1.00 
mL THF. The solution was allowed to warm to RT slowly and then refluxed for 3 h.  The 
mixture was cooled to 0 °C and poured into a half saturated solution of Na∙K∙Tartrate 
(15.0 mL). After stirring for 1 h at RT, the heterogeneous mixture was separated and the 
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as a white solid (93% yield, 8.00 mg). Rf  
0.39 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3)  7.69 (br s, 1H), 7.47 (d, J = 7.0 Hz, 
1H), 7.26 (dd, J = 7.0, 1.5 Hz, 1H), 7.08 (td, J = 7.0, 1.5 Hz, 1H), 7.05 (td, J = 7.0, 1.5 
Hz, 1H), 3.24 (br d, J = 11.7 Hz, 1H), 2.92 (ddd, J = 4.4, 11.4, 16.0 Hz, 1H), 2.83 (ddd, J 
= 2.9, 4.4, 15 Hz, 1H), 2.75–2.64 (m, 2H), 2.46–2.44 (m, 1H), 2.41 (ddd, J = 2.9, 4.4, 
11.4 Hz, 1H), 2.32 (td, J = 11.5, 4.4 Hz, 1H), 2.23 (td, J = 11.3, 3.2 Hz, 1H), 1.91 (dd, J = 
7.0, 14.0 Hz, 1H), 1.62–1.54 (m, 2H), 1.49 (d, J = 11.7 Hz, 1H), 1.32–1.27 (m, 2H), 
1.23–1.20 (m, 1H), 1.17–1.08 (m, 2H), 0.84 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, 
CDCl3)  139.9, 134.8, 128.9, 120.2, 118.7, 117.4, 109.9, 108.7, 56.7, 55.1, 53.2, 37.1, 
25 
 
25 
 
34.8, 33.5, 32.1, 22.7, 22.4, 21.9, 7.8. HRMS m/z 282.2085 (calcd for C19H26N2, 
282.2096). 
 
3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-2-one (1-43) 
A solution of lactam 1-51 (100 mg, 0.28 mmol) in THF (7.00 
mL) and t-butanol (0.30 mL) was cooled to –78 °C and liquid 
ammonia (5.00 mL) was added to the solution.  Sodium metal (33.0 mg, 1.43 mmol) was 
cut into small portions, washed with dry hexanes and added to the ammonia mixture. The 
reaction mixture was stirred at –78 °C for 10 min and then solid NH4Cl (200 mg) was 
added. The reaction was allowed to warm up to RT while the ammonia evaporated 
completely. Water (10.0 mL) was added and the heterogeneous mixture was separated. 
The aqueous layer was extracted with CH2Cl2 (3 x 15.0 mL). The combined organic 
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated 
under reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as white solid (93% yield, 70.0 mg). Rf  
0.12 (80% EtOAc/hexanes); mp 170–172 °C; 1H NMR (400 MHz, CDCl3)  8.44 (br s, 
1H), 7.49 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 8.2 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 7.03 (t, J 
= 7.6 Hz, 1H), 6.20 (s, 1H), 5.91 (br s, 1H), 3.32–3.29 (m, 2H),  2.86 (ddd, J = 5.8, 11.1, 
15.2 Hz, 1H), 2.68 (ddd, J = 4.1, 11.1, 14.6 Hz, 1H), 2.13 (ddd, J = 4.7, 11.7, 14.0 Hz, 
1H), 1.86–1.75 (m, 6H), 1.64 (ddd, J = 7.0, 14.6, 28.7 Hz, 1H), 0.91 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  177.1, 139.9, 136.1, 128.6, 120.8, 119.6, 119.3, 110.5, 
99.1, 45.1, 42.7, 37.7, 31.2, 29.1, 23.7, 19.7, 8.5. HRMS m/z 270.1726 (calcd for 
C17H22N2O, 270.1732). 
 
1-Benzyl-3-ethylpipidin-2-one (1-45) 
A solution of freshly distilled -valerolactam (19.8 g, 200 mmol) in THF 
(530 mL) was cooled to –78 °C and nBuLi (2.05 equiv) in hexane was added dropwise. 
Iodoethane (12.1 mL, 150 mmol) was then added dropwise and allowed to stir at –78 °C 
for 1 h, followed by the addition of benzylbromide (31.6 mL, 266 mmol). The reaction 
was then allowed to warm to RT over 16 h. The solution was poured into a half saturated 
solution of NH4Cl (530 mL). The heterogeneous mixture was separated and the aqueous 
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layer was extracted with EtOAc (3 x 100 mL). The combined organic layers were washed 
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced 
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for 
elution provided the title compound as light yellow oil (89%, 38.6 g). Rf 0.23 (25% 
EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  7.29–7.19 (m, 5H), 4.55 (s, 2H), 3.14 
(dd, J = 4.8, 2.2 Hz, 2H), 2.27 (ddd,  J = 5.2, 9.4, 14.0 Hz, 1H), 2.00–1.86 (m, 2H), 1.84–
1.75 (m, 1H), 1.70–1.47 (m, 3H), 0.93 (t, J = 7.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
172.4, 137.4, 128.3, 127.7, 126.9, 50.0, 47.2, 42.7, 25.6, 24.7, 21.4, 11.3. HRMS m/z 
217.1465 (calcd for C14H19NO, 217.1467). 
 
1-Benzyl-3-ethyl-3-[2-(tetrahydropyran-2-yloxy)-ethyl]-piperidin-2-one 
(1-47) 
Lactam 1-45 (16.3 g, 75.0 mmol) was dissolved in 200 mL of THF and 
cooled to –78 °C.  A freshly prepared solution of LDA (1.05 equiv) in THF (75.0 mL) 
was then added dropwise and allowed to stir for 15 min. The solution was allowed to 
warm to –10 °C over 15 min and cooled back to –78 °C. The tetrahydropyranyl ether of 
2-bromoethanol (17.3 g, 82.5 mmol) was then added slowly with a dropping funnel and 
the resulting solution was allowed to slowly warm to RT 16 h. The mixture was then 
poured into an ice cold half saturated solution of NH4Cl (200 mL). The heterogeneous 
mixture was separated and the aqueous layer was extracted with EtOAc (3 x 40.0 mL). 
The combined organic layers were washed with brine, dried (MgSO4), filtered through 
Celite and concentrated under reduced pressure. Purification by flash chromatography on 
silica gel using EtOAc-hexanes for elution provided the title compound as yellow oil 
(92%, 24.1 g). Rf 0.24 (33% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  7.33–7.23 
(m, 5H), 4.66–4.48 (m, 3H), 3.89–3.82 (m, 2H), 3.54–3.44 (m, 2H), 3.19–3.16 (m, 2H), 
2.13–2.02 (m, 1H), 1.88–1.75 (m, 7H), 1.72–1.65 (m, 1H), 1.63–1.49 (m, 5H), 0.89 (t, J 
= 7.3 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 174.3, 137.7, 128.4, 127.9, 127.1, 99.1, 
98.8, 64.5, 64.3, 62.5, 62.3, 50.5, 47.6, 44.1, 37.1, 31.6, 30.8, 29.7, 25.4, 19.7, 8.7.  
HRMS m/z 345.2297 (calcd for C21H31NO3, 345.2304).  
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1-Benzyl-3-ethyl-3-(2-hydroxyethyl)-piperidin-2-one (1-48) 
A solution of tetrahydropyranyl lactam 1-47 (34.5 g, 100 mmol) in methanol 
(360 mL) was cooled by an ice-brine bath and p-toluenesulphonic acid 
monohydrate (2.72 g, 14.7 mmol) was added as a solid and stirred for 4 h. The resulting 
solution was neutralized with solid NaHCO3 and the volatiles were removed under 
reduced pressure. The yellow residue was dissolved in EtOAc and water (200 mL, 1:1). 
The heterogeneous mixture was separated and the aqueous layer was extracted with 
EtOAc (3 x 50.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as yellow oil (92%, 24.0 g). Rf 0.13 (50% EtOAc/hexanes); 
1
H NMR (400 
MHz, CDCl3)  7.33–7.28 (m, 2H), 7.26–7.21 (m, 3H), 4.61 (d, J = 14.7 Hz, 1H), 4.54 
(d, J = 14.7 Hz, 1H), 3.97-3.95 (m, 1H), 3.92–3.87 (m, 1H), 3.68–3.60 (m, 1H), 3.20 (t, J 
= 5.0 Hz, 2H), 1.92–1.83 (m, 2H), 1.80–1.74 (m, 4H), 1.72–1.58 (m, 2H), 0.85 (t, J = 7.6 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 176.4, 137.1, 128.6, 127.9, 127.3, 58.9, 50.7, 
47.8, 44.1, 40.4, 31.2, 29.8, 19.1, 8.1. HRMS m/z 261.1730 (calcd for C16H23NO2, 
261.1729). 
 
1-Benzyl-3-(2-chloro-ethyl)-3-ethyl-piperidin-2-one (1-49) 
A solution of alcohol 1-48 (13.1 g, 50.0 mmol) in CH2Cl2 (100 mL) was 
cooled to 0 °C and Et3N (14.6 mL, 105 mmol) was added dropwise, 
following the addition of MsCl (4.12 mL, 52.5 mmol). The ice bath was removed and the 
solution was allowed to warm to RT over 3 h. The mixture was then poured into a half 
saturated solution of NaHCO3 (80.0 mL). The heterogeneous mixture was separated and 
the aqueous layer was extracted with CH2Cl2 (3 x 25.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. The product was immediately converted to nitrile 1-1 without further 
purification. Rf 0.40 (33% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  7.33–7.26 (m, 
2H), 7.24–7.20 (m, 3H), 4.61 (d, J = 14.6 Hz, 1H), 4.50 (d, J = 14.6 Hz, 1H), 3.68–3.56 
(m, 2H), 3.18 (t, J = 6.1 Hz, 2H), 2.16 (ddd, J = 5.8, 10.7, 13.7 Hz, 1H), 2.00 (ddd, J = 
5.8, 10.7, 13.7 Hz, 1H), 1.86–1.73 (m, 4H), 1.71–1.65 (m, 1H), 1.62–1.53 (m, 1H), 0.88 
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(t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 173.23, 137.3, 128.5, 127.9, 127.2, 
50.4, 47.5, 44.9, 41.3, 41.2, 30.7, 29.8, 19.4, 8.4. HRMS m/z 279.1389 (calcd for 
C16H22ClNO, 279.1390).  
 
2-[2-(1-Benzyl-3-ethyl-2-oxopiperidin-3-yl)-ethyl]-1H-
indole-3-carboxylic acid ethyl ester (1-50)  
Tetrasubstituted pyrrole 1-3 (4.38 g, 10.0 mmol) was added to a 
suspension of palladium on carbon (5% Pd/C, 665 mg) in mesitylene (100 mL) and 
heated to reflux for 24 h. The mixture was cooled and the palladium was filtered through 
a pad of silica gel and Celite.  After the solution was concentrated under reduced 
pressure, purification by flash chromatography on silica gel was performed using EtOAc-
hexanes for elution, which provided the title compound as a white solid (98%, 4.24 g). Rf 
0.18 (33% EtOAc/hexanes); mp = 134–136 °C (hexanes / EtOAc crystal); 1H NMR (400 
MHz, CDCl3)  9.69 (br s, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.30–7.12 (m, 8H), 4.69 (d, J = 
14.6 Hz, 1H), 4.54 (d, J = 14.6 Hz, 1H), 4.39 (q, J = 7.0 Hz, 2H), 3.62 (ddd, J = 6.4, 9.9, 
14.0 Hz, 1H), 3.29–3.19 (m, 2H), 2.82 (ddd, J = 5.3, 9.9, 14.6 Hz, 1H), 2.17 (ddd, J = 
5.3, 9.9, 14.6 Hz, 1H), 1.93–1.80 (m, 6H), 1.66 (ddd, J = 7.6, 15.2, 28.7 Hz, 1H), 1.45 (t, 
J = 7.0 Hz, 3H), 0.89 (t, J = 7.3 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  175.4, 166.2, 
149.0, 137.2, 134.9, 128.7, 127.8, 127.4, 126.9, 122.1, 121.3, 111.0, 103.4, 59.3, 50.8, 
47.9, 45.9, 37.5, 31.6, 28.9, 22.9, 19.6, 14.6, 8.5. HRMS m/z 432.2419 (calcd for 
C27H32N2O3, 432.2413). 
 
1-Benzyl-3-ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-2-one 
(1-51) 
Indole 1-50 (4.32 g, 10.0 mmol) was dissolved in ethanol (85.0 
mL) and a solution of sodium hydroxide (4.00 g, 100 mmol) in water (85.0 mL) was 
added.  The mixture was heated to 150 °C in a microwave reactor for 3 h (900 rpm 
stirring).  The mixture was cooled it was neutralized with 1.00 M HCl. The volatiles were 
removed under reduced pressure and the residue was dissolved in 60.0 mL of EtOAc.  
The solution was extracted with EtOAc (3 x 60.0 mL). The combined organic layers were 
washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
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reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as yellow solid (69%, 2.49 g). Rf 0.27 
(33% EtOAc/hexanes); mp 96–98 °C; 1H NMR (400 MHz, CDCl3)  8.46 (br s, 1H), 
7.50 (d, J =  8.2 Hz, 1H), 7.32–7.22 (m, 6H), 7.09 (app t, J = 7.6 Hz, 1H), 7.04 (app t, J = 
7.6 Hz, 1H), 6.20 (s, 1H), 4.66 (d, J = 14.6 Hz, 1H), 4.53 (d, J = 14.6 Hz, 1H), 3.22 (t, J = 
5.3 Hz, 2H), 2.86 (ddd, J = 5.8, 10.5, 15.2 Hz, 1H), 2.66 (ddd, J = 4.7, 10.5, 15.2 Hz, 
1H), 2.19 (ddd, J = 4.1, 10.5, 13.5 Hz, 1H), 1.88–1.77 (m, 6H), 1.68 (ddd, J = 7.6, 14.6, 
28.7 Hz, 1H), 0.90 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  174.9, 140.1, 
137.5, 136.1, 128.6, 127.9, 127.3, 120.9, 119.6, 119.4, 110.5, 99.1, 50.6, 47.8, 45.6, 37.9, 
31.5, 29.2, 23.8, 19.6, 8.5. HRMS m/z 360.2203 (calcd for C24H28N2O, 360.2202). 
 
2-[2-(3-Ethyl-piperidin-3-yl)-ethyl]-1-H-indole (1-52) 
A solution of lactam 1-43 (100 mg, 0.28 mmol) in THF (15.0 
mL) was cooled to 0 °C and Red-Al (2.80 mmol of 65 wt% in 
toluene) was added dropwise.  The flask was adapted with a reflux condenser and the ice 
bath removed.  The solution was allowed to warm to RT slowly and then refluxed for 12 
h.  The mixture was cooled to 0 °C and poured into a half saturated solution of 15.0 mL 
Rochelle’s salt (Na·K·tartrate). After stirring for 1 h at RT, the heterogeneous mixture 
was separated and the aqueous layer was extracted with EtOAc (5 x 15.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using a gradient solvent system with EtOAc and then MeOH-EtOAc was performed, 
which provided the title compound as orange oil (93% yield, 67.0 mg). Rf  0.03 (10% 
MeOH in EtOAc); 
1
H NMR (400 MHz, CDCl3)  9.01 (br s, 1H), 7.51 (dd, J = 1.5, 7.0 
Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.09 (dt, J = 1.9, 7.6 Hz, 1H), 7.04 (dt, J = 1.4, 7.3 Hz, 
1H), 6.23 (s, 1H), 4.22 (br s, 1H), 2.96–2.90 (m, 1H), 2.75–2.69 (m, 2H), 2.67–2.62 (m, 
2H), 2.50 (d, J = 12.4 Hz, 1H), 1.94 (ddd, J = 6.5, 10.2, 14.1 Hz, 1H), 1.66 (ddd, J = 6.7, 
10.2, 14.1 Hz, 2H), 1.55–1.25 (m, 6H), 0.85 (t, J = 5.3 Hz, 3H); 13C NMR (100 MHz, 
CDCl3)  140.3, 136.0, 128.7, 120.7, 119.6, 119.3, 110.4, 99.0, 54.0, 46.6, 34.6, 33.8, 
32.9, 28.3, 21.9, 21.5, 7.1. HRMS m/z 256.1931 (calcd for C17H24N2, 256.1939). 
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{3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-1-yl}-acetic 
acid ethyl ester (1-52b) 
Amine 1-52 (109 mg, 0.42 mmol) was dissolved in MeCN 
(30.0 mL) and then NEt(iPr)2 (96.0 μL) was added slowly dropwise followed by 
ethylbromoacetate (62.0 μL).  The solution was allowed to stir for 14 h and then poured 
into 15.0 mL 1.00 M HCl. The heterogeneous mixture was separated and the aqueous 
layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers were 
washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (82% yield, 119 mg). Rf 
0.67 (10% MeOH in EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.79 (br s, 1H), 7.53 (d, J = 
7.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.11 (td, J = 7.4, 1.5 Hz, 1H), 7.07 (td, J = 7.3, 1.2 
Hz, 1H), 7.25 (d, J =1.2 Hz, 1H), 4.26 (d, J = 8.0 Hz, 1H), 4.22 (d, J = 8.0 Hz, 1H), 3.17 
(q, J = 16.0 Hz, 2H), 2.74–2.64 (m, 3H), 2.51 (d, J = 11.0 Hz, 1H), 2.31–2.27 (m, 1H), 
2.18–2.11 (m, 1H), 1.99 (d, J = 11.0 Hz, 1H), 1.81–1.71 (m, 1H), 1.68–1.56 (m, 2H), 
1.52–1.43 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H), 1.28–1.18 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ  171.2, 140.9, 136.1, 128.8, 120.5, 119.5, 119.2, 110.4, 
98.8, 62.0, 60.5, 60.0, 54.8, 35.9, 33.6, 33.1, 29.0, 22.1, 21.7, 14.2, 7.2. HRMS: m/z 
342.2358 (calcd. for C21H30N2O2, 342.2307). 
 
{3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidin-1-yl}-acetic 
acid (1-53) 
Ester 1-52b (85.0 mg, 0.25 mmol) was dissolved in EtOH 
(5.00 mL) and 2.00 M NaOH (0.25 mL) was added slowly dropwise.  The solution was 
allowed to stir for 8 h and then neutralized with 1.00 M HCl and the solution was 
concentrated under reduced pressure. The residue was dissolved in EtOAc and water 
(20.0 mL, 1:1) and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (73% 
yield, 57.0 mg). Rf 0.05 (10% MeOH in EtOAc); 
1
H NMR (400 MHz, CDCl3) δ  10.67 
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(br s, 1H), 7.45 (d, J = 7.2 Hz, 1H), 7.33 (br. s, 1H), 7.05–6.94 (m, 2H), 6.12 (br. s, 1H), 
3.80–2.62 (m, 1H), 3.58–3.45 (m, 1H), 3.42–2.13 (m, 2H), 2.95–2.76 (m, 1H), 2.54–2.41 
(m, 1H), 2.39–2.25 (m, 1H), 2.18–1.82 (m, 2H), 1.16–1.35 (m, 3H), 1.34–1.16 (m, 3H), 
0.99–0.83 (m, 2H), 0.75 (br s, 3H); 13C NMR (100 MHz, CDCl3) δ  168.2, 139.9, 136.4, 
128.4, 120.5, 119.4, 119.0, 111.0, 98.6, 59.5, 58.7, 53.9, 35.7, 31.6, 30.8, 29.6, 21.6, 18.9, 
6.7. HRMS: m/z 314.1988 (calcd. for C19H26N2O2, 314.1994).  
 
1-Benzyl-3-ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-
ethyl}-piperidin-2-one (1-55) 
Indole 1-51 (25.0 mg, 0.06 mmol) was dissolved in 0.20 mL 
MTBE and cooled to −25 °C and potassium hydride (9.60 mg, 0.24 mmol) was added as 
a solution in 0.50 mL MTBE.  InBr3 (21.0 mg, 0.06 mmol) and BHT (1.00 mg, 0.005 
mmol) were then added, followed by 45.0 μL (0.90 mmol) of ethylene oxide in 0.30 mL 
MTBE.
5
 The flask was capped and the solution as allowed to stir at 0 °C for 12 h.  The 
solution was allowed to warm to RT and the ethylene oxide evaporated. The solution was 
poured into 10.0 mL water and the heterogeneous mixture was separated and the aqueous 
layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers were 
washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as yellow oil (55% yield, 13.0 mg). Rf 
0.55 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ  8.59 (br s, 1H), 7.50 (d, J = 7.6 Hz, 
1H), 7.32–7.23 (m, 6H), 7.11 (dd, J = 7.5, 1.3 Hz, 1H), 7.07–7.03 (m, 1H), 4.68 (d, J = 
14 Hz, 1H), 4.54 (d, J = 14 Hz, 1H), 3.83 (t, J = 6.4 Hz, 2H), 3.29–3.21 (m, 2H), 2.96 (td, 
J = 6.4, 2.3 Hz, 2H), 2.91–2.85 (m, 1H), 2.53 (ddd, J = 14, 10, 4.0 Hz, 1H), 2.17 (ddd, J 
                                                 
5
 Ethylene oxide is very toxic and great care should be taken when using it. The tank 
should be secured inside a fumehood with the appropriate regulator. The set-up 
involved connecting the regulator with a tube, equipped with a needle. This needle was 
inserted into a 25 mL flask with a septum. The flask was also equipped with needle 
connected to a bubbler, which vented to the fumehood. The ethylene oxide gas was 
then passed through the flask at −30 °C. Once a small amount of ethylene oxide was 
condensed, a known amount of solvent (MTBE) was added and the solution was 
brought up in a syringe to determine the total volume. The concentration was then 
calculated and the appropriate amount was added to the reaction mixture.     
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= 13, 13, 3.9 Hz, 1H), 1.83–1.65 (m, 8H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ  175.1, 137.4, 135.6, 128.6, 128.3, 127.9, 127.4, 121.1, 119.0, 117.9, 110.6, 
106.6, 62.8, 50.74, 47.9, 45.8, 38.3, 31.6, 28.9, 27.8, 21.6, 19.5, 8.5. HRMS m/z 404.2474 
(calcd for C26H32N2O2, 404.2464). 
 
2-Methyl-1-(trimethylsilyl)-1H-indole (1-57) 
2-Methylindole (300 mg, 2.28 mmol) was dissolved in 4.00 mL THF and 
cooled to −78 °C. nBuLi (0.90 mL, 2.28 mmol, 2.51 M) and allowed to stir 
for 1.5 h at −78 °C. TMSCl (0.35 mL, 2.74 mmol) was added and the solution was 
allowed to stir at RT for 16 h. The solution was poured into 10.0 mL water and mixture 
was separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure to give the title compound as colorless oil (92% 
yield, 427 mg). 
1
H NMR (400 MHz, CDCl3) δ 7.50-7.47 (m, 2H), 7.09-7.06 (m, 2H), 
6.31 (s, 1H), 2.48 (s, 3H), 0.60 (s, 9H).   
 
2-(2-Methyl-1H-indol-3-yl)-ethanol (1-58) 
Indole 1-57 (24.0 mg, 0.12 mmol) was dissolved in 0.40 mL MTBE 
and cooled to −25 °C. InBr3 (3.20 mg, 0.01 mmol) and BHT (2.00 mg) 
were then added, followed by 90.0 μL of ethylene oxide in 0.60 mL MTBE.5  The flask 
was capped and the solution as allowed to stir at 0 °C for 12 h.  The solution was allowed 
to warm to RT and the ethylene oxide evaporated. The solution was poured into 10.0 mL 
water and the heterogeneous mixture was separated and the aqueous layer was extracted 
with EtOAc (5 x 10.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (36% yield, 8.00 mg). Rf 0.30 (50% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3) δ  7.85 (br s, 1H), 7.52 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 7.6 Hz, 1H), 
7.15–7.07 (m, 2H), 3.84 (t, J = 6.5 Hz, 2H), 2.97 (t, J = 6.5 Hz, 2H), 3.29 (s, 3H), 1.51 
(br s, 1H); 
13
C NMR (100 MHz, CDCl3) δ  135.3, 132.4, 12.7, 121.1, 119.3, 117.9, 110.3, 
107.5, 62.8, 27.7, 11.7.  
33 
 
33 
 
3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}-
piperidin-2-one (1-59) 
The title compound was obtained from compound 1-55 using the 
standard benzyl deprotection reaction conditions described above in the procedure to 
obtain compound 1-43. This procedure provided the title compound as colorless oil (91% 
yield). Rf 0.40 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ  8.85 (br. s, 1 H), 7.50 (d, J 
= 7.4 Hz, 1 H), 7.26–7.24 (m, 1 H), 7.10–7.02 (m, 2 H), 6.10 (br. s, 1 H), 3.84 (t, J = 6.4 
Hz, 2 H), 3.24–3.20 (m, 2 H), 2.99–2.94 (m, 2 H), 2.83 (ddd, J = 5.9, 12.0, 14.0 Hz, 1 H), 
2.49 (ddd, J = 2.3, 12.0, 16.0 Hz, 1 H), 2.42 (br. s, 1 H), 2.10–2.02 (m, 1 H), 1.80–1.68 
(m, 5 H), 1.65–1.54 (m, 2 H), 0.86 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3) 
δ  177.2, 137.2, 135.5, 128.3, 120.9, 118.8, 117.9, 110.6, 106.6, 62.6, 45.1, 42.6, 38.2, 
31.4, 28.7, 27.8, 21.4, 19.6, 8.3. HRMS: m/z 314.1985 (calcd. for C19H26N2O2, 
314.1994).  
 
3-Ethyl-3-{3-[(E)-2-(1-methyl-cyclopropyl)-phenylimino]-
propyl}-piperidin-2-one (1-60) 
Procedure A: A solution of PPh3 (25.0 mg, 0.09 mmol) and 
DIAD (19.0 mg, 0.09 mmol) in 2.00 mL of THF was maintained at RT for 30 min and 
then cooled to 0 °C. A solution of indole 1-59 (20.0 mg, 0.063 mmol) in THF (0.75 mL) 
was added and stirred for 12 h at RT. The heterogeneous mixture was separated and the 
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using 
EtOAc/hexanes for elution provided the title compound as yellow oil (56% yield). 
Procedure B: A solution of indole 1-62 or 1-63 (0.05 mmol) in THF (8.00 mL) was 
added to a slurry of NaH in 1.60 mL of THF. The solution was heated to reflux for 30 
min, cooled and then poured into 10.0 mL of water. The heterogeneous mixture was 
separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc/hexanes for elution provided the title compound as yellow oil (60% yield). 
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Rf 0.18 (5% MeOH in EtOAc). 
1
H NMR (400 MHz, CDCl3)  δ  7.65 (d, J = 7.4 Hz, 1 H), 
7.30 (t, J = 7.7 Hz, 1 H), 7.15 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 6.8 Hz, 1 H), 5.61 (br s, 1 
H), 3.29 (dt, J = 5.8, 1.9 Hz, 2 H), 2.48 (ddd, J = 5.9, 11.2, 15.1 Hz, 1 H), 2.25 (ddd, J = 
5.4, 11.0, 16.0 Hz, 1 H), 2.07–2.01 (m, 2 H), 1.97–1.93 (m, 1 H), 1.90–1.68 (m, 7 H), 
1.63–1.54 (m, 2 H), 0.89 (t, J = 7.5 Hz, 3 H); 13C NMR (100 MHz, CDCl3) δ 177.1, 
137.0, 135.3, 127.8, 127.1, 119.1, 117.5, 110.7, 107.0, 45.3, 44.7, 42.7, 37.8, 31.2, 28.9, 
28.2, 21.4, 19.5, 8.4.  
 
2-{2-[2-(3-Ethyl-piperidin-3-yl)-ethyl]-1H-indol-3-yl}-ethanol 
(1-61) 
*Note: The title compound was not confirmed by spectroscopic 
characterization, and was only suspected using the following procedure.*  
Compound 1-59 was subjected to the reduction reaction conditions described above in the 
procedure to obtain compound 1-52. This procedure provided an orange oil (suspected 
93% yield). Rf 0.03 (100% EtOAc). NMR or HRMS of this compound was not possible 
due to its instability.  Characterized by TLC and used immediately.  
 
3-{2-[3-(2-Chloro-ethyl)-1H-indol-2-yl]-ethyl}-3-ethyl-
piperidin-2-one (1-62) 
*Note: The title compound was not confirmed by spectroscopic 
characterization, and was only suspected using the following procedure.*  
Alcohol 1-59 (30.0 mg, 0.09 mmol) was dissolved in CH2Cl2 (1.00 mL) and cooled to 0 
°C.  MsCl (10.0 μL, 0.13 mmol) and Et3N (40.0 μL, 0.29 mmol) were added dropwise. 
The solution was allowed to stir for 3 h and then poured into a half saturated solution of 
NaHCO3 (10.0 mL). The heterogeneous mixture was separated and the aqueous layer was 
extracted with EtOAc (5 x 10.0 mL). The combined organic layers were washed with 
brine, dried (MgSO4), filtered through a pad of silica over Celite and concentrated under 
reduced pressure providing a yellow oil (suspected 52% yield, 48.0 mg). Rf 0.41 (5 % 
MeOH in EtOAc). Due to the instability of this compound, NMR and HRMS were not 
obtained. Characterized by TLC and used immediately.  
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3-{2-[3-(2-Bromo-ethyl)-1H-indol-2-yl]-ethyl}-3-ethyl-
piperidin-2-one (1-63) 
*Note: The title compound was not confirmed by spectroscopic 
characterization, and was only suspected using the following procedure.*  
Alcohol 1-59 (43.0 mg, 0.13 mmol) was dissolved in CH2Cl2 (0.60 mL), to which CBr4 
(68.0 mg, 0.20 mmol) and PPh3 (52.0 mg, 0.19 mmol) were added.  The solution was 
allowed to stir for 3 h and the solution was concentrated under reduced pressure. The 
residue was filtered through a pad of silica over Celite and concentrated under reduced 
pressure providing colourless oil (suspected 95% yield, 48.0 mg). Rf 0.2 (5% MeOH in 
EtOAc). Due to the instability of this compound, NMR and HRMS were not obtained. 
Characterized by TLC and used immediately.  
 
3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidine-1-carboxylic 
acid benzyl ester (1-67) 
Amine 1-52 (17.0 mg, 0.07 mmol) was dissolved in CH2Cl2 
(3.00 mL), to which NEt(iPr)2 (23.0 μL, 0.13 mmol) and freshly distilled benzyl 
chloroformate (14.0 μL, 0.10 mmol) were added. The solution was allowed to stir for 16 
h and then poured into 10.0 mL water. The heterogeneous mixture was separated and the 
aqueous layer was extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (82% yield, 21.0 mg). Rf 
0.38 (30% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3) δ  8.84 (br s, 1H), 7.50 (d, J = 
7.6 Hz, 1H), 7.37–7.24 (m, 6),  7.10–7.01 (m, 2H), 6.20 (s, 1H), 5.27 (d, J = 12 Hz, 1H), 
5.14 (d, J = 12 Hz, 1H), 3.93–3.91 (m, 1H), 3.42–3.38 (m, 0.5H), 3.31–3.27 (m, 0.5H), 
3.10–3.07 (m, 0.5H), 3.00–2.94 (m, 0.5H), 2.76–2.58 (m, 3H), 1.75–1.68 (m, 1H), 1.57–
1.25 (m, 7H), 0.91 (t, J = 7.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ  156.2, 140.6, 
128.8, 128.5, 128.1, 127.8, 121.0, 120.7, 119.6, 119.2, 110.4, 99.1, 98.9, 67.3, 51.8, 45.2, 
36.3, 34.6, 32.8, 28.4, 22.5, 21.4, 7.1. HRMS m/z 390.2291 (calcd for C25H30N2O2, 
390.2307).  
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3-Ethyl-3-[2-(1H-indol-2-yl)-ethyl]-piperidine-1-carboxylic 
acid tert-butyl ester (1-68) 
Amine 1-52 (25.0 mg, 0.09 mmol) was dissolved in CH2Cl2 
(2.00 mL), to which Et3N (16.0 μL, 0.12 mmol) and Boc2O (21.0 μL, 0.09 mmol) were 
added. The solution was allowed to stir for 35 min and then poured into 10.0 mL water. 
The heterogeneous mixture was separated and the aqueous layer was extracted with 
CH2Cl2 (5 x 10.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (83% yield, 28.0 mg). Rf 0.66 (100% EtOAc); 
1
H NMR (400 
MHz, CDCl3)  δ  8.98 (br s, 1H), 7.50 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 7.6 Hz, 1H), 7.08–
7.00 (m, 2H), 6.19 (s, 1H), 3.97 (d, J = 12 Hz, 1H), 3.90 (d, J = 12 Hz, 1H), 3.39 (br s, 
0.5H), 3.18 (br s, 0.5H), 2.86–2.80 (m, 1H), 2.73–2.62 (m, 2H), 2.54 (d, J = 13 Hz, 1H), 
1.58–1.54 (m, 4H), 1.52 (s, 9H), 1.50–1.41 (m, 4H), 0.92–0.89 (m, 2H); 13C NMR (100 
MHz, CDCl3)  δ  146.7, 140.9, 128.7, 120.6, 119.5, 119.0, 110.4, 98.7, 85.2, 59.2, 50.9, 
45.6, 34.9, 32.7, 28.7, 28.5, 27.4, 22.6, 21.5, 7.1.. HRMS m/z 356.2468 (calcd for 
C22H32N2O2, 356.2464).  
 
3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}-
piperidine-1-carboxylic acid benzyl ester (1-69) 
The title compound was obtained from compound 1-67 using 
the alkylation reaction conditions described above in the procedure to obtain compound 
1-55. This procedure provided the title compound as colorless oil (34% yield, 65% based 
on recovered starting material). Rf 0.25 (30% EtOAc/hexanes); 
1
H NMR (400 MHz, 
CDCl3)  δ  9.00 (br s, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.35–7.30 (m, 6H), 7.12–7.03 (m, 
2H), 5.30 (d, J = 12 Hz, 1H), 5.13 (d, J = 12 Hz, 1H), 4.09 (d, J = 13 Hz, 1H), 4.02 (d, J 
= 13 Hz, 1H), 3.85–3.82 (m, 2H), 2.97–2.94 (m, 2H), 2.88–2.82 (m, 1H), 2.73–2.69 (m, 
1H), 2.59 (d, J = 13 Hz, 1H), 1.66–1.42 (m, 9H), 1.37–1.29 (m, 1H), 0.93 (t, J = 7.4 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3)  δ 156.4, 138.0, 136.5, 135.5, 128.6, 128.4, 128.1, 
127.8, 120.9, 118.9, 117.9, 110.5, 109.8, 67.4, 62.9, 51.5, 45.3, 36.5, 34.8, 32.6, 28.9, 
27.8, 21.4, 20.4, 7.2. HRMS m/z 434.2536 (calcd for C27H34N2O3, 434.5705).  
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3-Ethyl-3-{2-[3-(2-hydroxy-ethyl)-1H-indol-2-yl]-ethyl}-
piperidine-1-carboxylic acid tert-butyl ester (1-70) 
The title compound was obtained from compound 1-67 using the 
alkylation reaction conditions described above in the procedure to obtain compound 1-55. 
This procedure provided the title compound a colorless oil (21% yield, 63% based on 
recovered starting material). Rf 0.51 (100 % EtOAc); 
1
H NMR (400 MHz, CDCl3)  δ   
9.08 (br s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.23–7.20 (m, 1H), 7.10–7.02 (m, 2H), 4.12–
4.08 (m, 1H), 3.99–3.97 (m, 1H), 3.84 (t, J = 6.6 Hz, 2H), 2.98–2.93 (m, 2H), 2.76–2.64 
(m, 2H), 2.46–2.42 (m, 1H), 1.67–1.55 (m, 13H), 1.49–1.40 (m, 6H), 0.92 (t, J = 7.2 Hz, 
3H). HRMS m/z 400.2718 (calcd for C24H36N2O3, 400.2726). Due to lack of material, a 
13
C NMR spectra was not obtained. 
 
2-Chloro-1-{3-ethyl-3-[2-(1-H-indol-2-yl)-ethyl]-
piperidin-1-yl}-ethanone (1-71) 
To a solution of amine 1-52 (40.0 mg, 0.16 mmol) in 
CH2Cl2 (8.00 mL) at 0 °C, tin (IV) chloride solution (0.34 mL, 1.00 M in CH2Cl2) was 
added slowly dropwise and allowed to stir for 10 min. Then, chloroacetyl chloride (12.4 
μL, 0.16 mmol) and 0.80 mL EtNO2 were added and the resulting solution was allowed 
to stir for 12 h at RT. The solution was poured into 15.0 mL of cold water and the 
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (5 
x 15.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (96% yield, 51.0 mg). Rf  0.57 (100% EtOAc); 
1
H NMR (400 
MHz, CDCl3)  8.70 (br s, 1H), 7.49 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.08 
(td, J = 1.2, 7.5 Hz, 1H), 7.02 (td, J = 1.1, 7.4 Hz, 1H), 6.18 (s, 1H), 4.24 (d, J = 13.3 Hz, 
1H), 4.16 (q, J = 12.0 Hz, 2H), 3.69 (ddd, J = 3.7, 13.1 Hz, 1H), 3.18 (ddd, J = 3.5, 10.2, 
13.8 Hz, 1H), 2.77 (dt, J = 3.1, 12 Hz, 1H), 2.70–2.62 (m, 2H), 1.69–1.58 (m, 5H), 1.53–
1.36 (m, 3H), 0.92 (t, J = 7.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  166.0, 140.3, 
136.2, 128.7, 120.7, 119.5, 119.2, 110.6, 98.9, 50.3, 47.8, 41.2, 37.1, 34.6, 33.0, 28.5, 
22.6, 22.0, 7.1. HRMS m/z 332.1647 (calcd for C19H25N2OCl, 332.1655). 
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10-Oxoquebrachamine (1-78) 
A solution of chloroacetamide indole 1-71 (58.0 mg, 0.17 mmol) 
and Na2CO3 (28.0 mg, 0.26 mmol) in 4.00 mL EtOH and 3.00 mL 
water was placed in a quartz vessel (11.0 cm tall, 1.20 cm diameter) 
equipped with a septa.  The vessel was degassed with Ar for 15 min and then suspended 
in the center of a Rayonet Photochemical Reactor. The solution was irradiated for 140 
min, and the solution was concentrated under reduced pressure. The residue was 
dissolved in EtOAc and water (20.0 mL, 1:1) and the aqueous layer was extracted with 
EtOAc (5 x 10.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as a white solid (85% yield, 43.0 mg). Rf  0.53 (100% EtOAc); 
1
H NMR (600 
MHz, CDCl3)  7.75 (br s, 1H), 7.70 (d, J = 7.02 Hz, 1H), 7.22 (dd, J = 1.7, 7.0 Hz, 1H), 
7.10 (m, 2H), 4.63 (dd, J = 2.3, 12.9 Hz, 1H), 4.42 (d, J = 14.0 Hz, 1H), 4.03 (d, J = 14.0 
Hz, 1H), 3.60 (d, J = 14.0 Hz, 1H), 2.83–2.79 (m, 2H), 2.64 (ddd, J = 4.7, 10.2, 15.5 Hz, 
1H), 2.46 (ddd, J = 3.5, 12.9 Hz, 1H), 1.72–1.67 (m, 2H), 1.63–1.57 (m, 1H), 1.51 (d, J = 
15.8 Hz, 1H), 1.46–1.43 (m, 1H), 1.39 (m, 1H), 1.33 (ddd, J = 4.4, 13.3 Hz, 1H), 1.22–
1.16 (m, 1H), 0.86 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  170.2, 137.7, 
134.3, 129.6, 121.4, 119.9, 118.3, 110.0, 105.5, 53.7, 42.8, 38.6, 34.6, 32.3, 30.7, 28.8, 
20.8, 20.7, 7.3. HRMS m/z 296.1878 (calcd for C19H24N2O, 296.1889). 
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CHAPTER 2: Synthesis of Tetrahydroisoquinocarbazoles 
 
2.1 Introduction  
 
 Considerable synthetic attention has been directed at the development of efficient 
methods towards the construction and derivatization of indole containing compounds, as 
this important subunit is found in a plethora of biologically active natural products.
1
 Our 
research group has recently developed a methodology for C-2 alkylation of 3-substituted 
indoles with 2-alkoxycyclopropanoate esters to give useful indole products.
2
 These 
valuable intermediates feature ester and alkene functional group handles capable of 
further synthetic manipulation, particularly towards the synthesis of natural products and 
other biologically active compounds. Herein, we report the short syntheses of several 
related tetrahydroisoquinocarbazoles 2-1, 2-2 and 2-3 (Scheme 2.1) by employing the C-
2 alkylation of indoles with donor acceptor (DA) cyclopropanes 1-2 and a SmBr2−HMPA 
mediated reductive cyclization as key synthetic steps.
3
  
 
 
Figure 2.1 Application of C-2 alkylation of indoles with DA cyclopropane 1-2 
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2.2 C-2/C-3 Annulation and C-2 Alkylation of Indoles with 2-
Alkoxycyclopropanoate Esters 
  
 Our research group has developed a method for heterocycle synthesis via C-2/C-3 
annulation of indoles with 2-alkoxycyclopropanoate esters, affording a wide variety of 
substituted indoline compounds with high efficiency and stereocontrol.
2
 The annulation 
process likely involves the initial formation of an oxocarbenium ion promoted via a 
cyclopropane ring opening reaction upon treatment with a Lewis acid, such as a silyl 
triflate (Scheme 2.1). This zwitterionic intermediate is then attacked by indole, forming 
the first carbon-carbon bond. The silyl enolate then attacks the C-2 position of the indole, 
completing the annulation process. It is important to note that one of the stereocenters in 
the original cyclopropane (denoted by the asterisk) remains unchanged during the course 
of the reaction and is responsible for the formation of four new stereocenters. 
 
 
Scheme 2.1 C-2/C-3 Annulation of indoles with 2-alkoxycyclopropanoate esters 
 
 When the annulation conditions were applied to 3-substituted indoles, unexpected 
C-2 alkylated products were isolated. The mechanism likely involves the same Lewis 
acid activation of the DA cyclopropane and subsequent attack of the indole, again from 
the C-3 position (Scheme 2.2). In the case of 3-substituted indoles, C-2 alkylation 
products are observed. This reactivity may occur through an indirect process involving 
initial attack at the C-3 position followed by C-3 to C-2 migration and deprotonation 
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steps to give the indole alkylation product (shown in Scheme 2.2).
4
 However, a more 
direct electrophilic substitution attack through the C-2 position of the indole, followed by 
a deprotonation step has also been proposed, which takes advantage of the extended π-
system of the indole. This alternative mechanism, while plausible, is energetically 
unfavorable because it disturbs the aromaticity of the benzene ring.
4
 Finally, the C-2 
alkylation product is obtained after spontaneous condensation to form the double bond. 
 
 
Scheme 2.2 C-2 Alkylation of indoles with 2-alkoxycyclopropanoate esters 
 
2.3 Biological Activity  
 
 Fused indole compounds such as the Vinca alkaloids have inspired synthetic and 
medicinal interest in a large class of related tetrahydroisoquinocarbazole analogs, most of 
which exhibit interesting biological activity.
5,6
 Most members of this class of compounds 
have been found to be antiarrhythmic agents, which suppress ischemia induced 
ventricular arrhythmias.
5
 One of the most important clinical problems after acute 
myocardial infarction (MI) is sustained ventricular tachycardia (SVT), which often leads 
to sudden death. Suppression of SVT in patients is crucial, particularly in the first few 
days after an acute MI when the risk is the highest.
5
 Some members of this novel class of 
antiarrhythmic agents have emerged as promising candidates, where they have been 
proven to be effective in several animal models, and have attractive cardio hemodynamic 
profiles in canines. Among the most potent members of this class, RS-2135 (Figure 2.1, 
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(+)-2-4) has attracted the most attention because of its relatively low toxicity and it 
demonstrated antiarrhythmic effects lasting for at least 48 h after a coronary embolism 
with only 10 mg/kg (oral administration) in canine studies.
6
  
 
2.4 Previous Syntheses of Tetrahydroisoquinocarbazoles  
 
2.4.1 Previous Recemic Syntheses of Tetrahydroisoquinocarbazoles  
 
 Simoji and Hashimoto employed an elegant route towards a series of 
tetrahydroisoquinocarbazole compounds that employed an intramolecular Diels-Alder 
reaction and Curtius rearrangement to construct the core.
5a
 The general synthesis 
commenced with an transesterification with indolylpropenoate (2-5) using allyl alcohol 
and sodium hydride (Scheme 2.3). The resulting indole (2-6) was then acylated with acid 
chloride 2-7, leading to indole 2-8, as the cyclization precursor. Heating 2-8 promoted the 
stereoselective intramolecular Diels-Alder reaction, followed by migration of the double 
bond upon treatment with acid, giving carbazole 2-9.   
 
 
Scheme 2.3 Simoji and Hashimoto’s synthesis towards tetrahydroisoquinocarbazoles 
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 Deprotection of the ester moiety revealed carboxylic acid 2-10 in a moderate 
yield, which was subsequently chlorinated with thionyl chloride and treated with sodium 
azide. The resulting carboxylic azide underwent a Curtius rearrangement, benzyl 
protection to give a benzyl carbamate, and lastly, hydrogenation conditions were used to 
access the functionalized tetrahydroisoquinocarbazole (2-11). 
 
2.4.2 Previous Asymmetric Syntheses of Tetrahydroisoquinocarbazoles 
 
 Among the many members of tetrahydroisoquinocarbazoles, RS-2135 ((+)-2-4) 
has attracted the most synthetic attention due to its long lasting antiarrhythmic effects and 
low toxicity. Simoji and Hashimoto reported the first synthesis of the single enantiomer 
of RS-2135 ((+)-2-4) in 1992 (Scheme 2.4).
5b
 A racemic mixture of 2-11 (using the 
protocol described in Scheme 2.3) was condensed with Boc protected L-proline with the 
use of diethyl phosphoryl cyanide (DEPC) as a coupling reagent and triethylamine in 
52% overall yield.  The two diastereomers 2-12a and 2-12b were separated by column 
chromatography on silica gel and treated with hydrochloric acid to furnish optically pure 
enantiomers (+)-2-4 (RS-2135) and (−)-2-4, each in a modest 15% yield. 
 
 
Scheme 2.4 Simoji and Hashimoto’s synthesis towards (+)-2-4 (RS-2135) and (−)-2-4  
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 Simoji and Hashimoto improved their original strategy towards optically pure RS-
2135 ((+)-2-4) in 1996 by utilizing an enantiomerically pure acid chloride (2-14), which 
was prepared from an enzymatic kinetic resolution of a 2-substituted cyclohexan-1-ol 
followed by several other functional group manipulations (Scheme 2.5).
5c
 The synthetic 
strategy began with the acylation of indole 2-13 with a chiral acid chloride (2-14) to 
afford cyclization precursor 2-15 in 81% yield. The synthesis followed a similar reaction 
sequence as described in their earlier reports,
5a,b
 where indole 2-15 underwent an 
intramolecular Diels-Alder reaction when heated, followed by treatment with acid to 
promote the double bond migration and ester hydrolysis. Carboxylic acid 2-16 underwent 
Curtius rearrangement, formation of a benzyl carbamate and hydrogenation to furnish 
(+)-2-4 (RS-2135) in 60% yield over two steps. 
 
 
Scheme 2.5 Simoji and Hashimoto’s synthesis of RS-2135 
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2.5 Synthesis of Tetrahydroisoquinocarbazoles 
 
2.5.1 Retrosynthesis 
 
 From our initial retrosynthetic analysis, we identified a key disconnection 
between C-12 and C-12a as being strategically important, as it simplified the target core 
to indole 2-17, which is readily available from our C-2 alkylation methodology (Scheme 
2.6). It was anticipated that ring C could be constructed by several strategies, including 
hydrometallation of alkene 2-17, followed by appropriate ring closure conditions. The 
same disconnection would also allow radical cyclizations to be explored, such as 
selenoester or samarium(II) iodide mediated ring closures. The lactam bond could be 
constructed via a base induced cyclization with the indole nitrogen and ester moiety in 
intermediate 2-17, which would be accessed from a C-2 alkylation between 3-substituted 
indole 2-18 and DA cyclopropane 1-2. 
 
 
Scheme 2.6 Retrosynthetic analysis 
 
2.5.2 Constructing the Core 
 
2.5.2.1 Investigating the C-2 Alkylation of Various C-3 Substituted Indoles 
 
 The synthesis began by examining the C-2 alkylation of several C-3 substituted 
indoles with DA cyclopropane 1-2 (Scheme 2.7). The substituent in the C-3 position of 
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the indole was particularly significant since it would later serve as a functional handle to 
facilitate closure of ring C. This strategy began with the alkylation of indole 2-19, which 
proceeded in a modest 50% yield to give 2-20, accompanied with a large amount of 
decomposition. However, alkylation of indole 2-21 under the same conditions gave the 
desired product (2-22) in an improved 82% yield. Considering our C-2 alkylation 
methodology was employed early in our synthetic strategy, we continued our 
investigation towards the construction of the tetrahydroisoquinocarbazole core with 2-22.  
 
 
Scheme 2.7 C-2 Alkylation of 2-substituted indoles 
 
2.5.2.2 Lactam Formation and Hydrometallation Strategy  
 
 With indole 2-22 in hand, we opted to form ring D via a lactam cyclization. Upon 
treatment of ester 2-22 with DBU, the intramolecular cyclization proceeded smoothly in 
91% yield, providing tetracyclic core 2-23 as a key intermediate for the final ring closure. 
The initial approach for ring C assembly involved elaborating alkene 2-23 via 
hydroboration or hydrometallation strategies, potentially supplying a collection of 
suitable handles (OH, I) at C-12a with which to facilitate cyclization (Scheme 2.8).  
 
 
Scheme 2.8 Hydrometallation strategy 
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 Initial hydrometallation studies began with hydroboration as a possible route to 
ring C. Hydroboration is a highly regioselective reaction which would provide an 
intermediate borane at the least substituted carbon of the original alkene preferentially, 
allowing access to an alcohol after oxidation. Treatment with alkene 2-23 with BH3∙THF 
or 9-BBN, followed by oxidation with H2O2/NaOH led to substrate decomposition (Table 
2.1, entries 1 and 2).  
 
Table 2.1 Hydrometallation attempts with 2-23 
 
Entry Reagent(s) Result 
1 BH3∙THF; H2O2/NaOH Decomposition 
2 9-BBN; H2O2/NaOH Decomposition 
3 BH3∙THF; I2 No reaction 
4 9-BBN; I2 No reaction 
5 NaBH3OAc/I2 No reaction 
6 (Cp)2Zr(H)Cl/I2 No reaction 
 
 In an attempt to obtain the alkyl halide as a functional handle instead of the 
alcohol, we decided to explore a method by which the intermediate borane can be 
quenched with iodine. Unfortunately, treatment of 2-23 with BH3∙THF, NaBH3OAc or 9-
BBN, followed by an I2 quench gave no reaction (Table 2.1, entries 3-5).  
 An alternative hydrometallation method applicable towards 2-23 was a possible 
hydrozironation reaction. Alkylzironium(IV) complexes such as (η5-C5H5)2Zr(H)Cl have 
been shown to be useful intermediates in organic synthesis since they readily react with 
olefins in a regioselective manner.
7
 Regrettably, our hindered alkene 2-23 failed to 
participate in the hydrozironation reaction and all of the starting material was recovered 
(Table 2.1, entry 6). Unfortunately, all attempts at alkene functionalization with 2-23 led 
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to starting material recovery or substrate decomposition, which is likely due to 
unfavorable steric interactions of the bulky trisubstituted alkene. 
 
2.5.2.3 Mn(III)-Mediated Oxidative Cyclization Strategy 
 
 Our focus then turned to pentacyclic intermediate 2-24, which could be used to 
furnish tetrahydroisoquinocarbazole 2-1 by removal of one ester via decarboxylation, 
saponification of the remaining ester, and conversion to the amine using a Schmidt 
reaction. Then, a Mn(III)-mediated oxidative cyclization strategy could construct 
pentacycle 2-24 from diester 2-25 (Scheme 2.9).  
   
 
Scheme 2.9 Oxidative cyclization strategy 
 
 The radical cyclization mechanism is thought to involve initial enolization to give 
a Mn(III) enolate, followed by electron transfer with loss of Mn(II), generating an α-
diester radical. Typically malonate radicals of this kind demonstrate a preference for 5-
exo-cyclization with monosubstituted alkenes, whereas disubstituted alkenyl radicals 
afford a mixture of 5-exo- and 6-endo-cyclization. Substrates similar to 2-25 featuring a 
trisubstituted alkene undergo 6-endo-cyclization exclusively.
8
 
 Encouraged by these reports, we began investigating this route by protecting 3-
methylindole (2-26) with a Boc group, which proceeded smoothly under standard 
conditions in near quantitative yield (Scheme 2.10). The resulting indole 2-27 underwent 
a radical induced halogenation reaction with AIBN and NBS to install a bromine leaving 
group, followed by displacement with dimethylmalonate and NaH providing 2-29 in 78% 
yield over two steps. Subsequent removal of the Boc group revealed indole 2-30, setting 
the stage for the C-2 alkylation with DA cyclopropane 1-2. Unfortunately, all attempts to 
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furnish alkylation product 2-31 resulted in starting material recovery or substrate 
decomposition. Since diester 2-30 proved to be a poor reaction partner in the alkylation 
reaction, we proposed a similar route where the sequence of chemical transformations 
was revised. 
 
 
Scheme 2.10 Synthetic route towards diester 2-25: method 1 
 
 Our new approach involved alkylation of 3-methylindole with DA cyclopropane 
1-2, which furnished alkene 2-32 in an excellent 92% yield (Scheme 2.11). Lactam 
formation with DBU and dichloromethane proceeded in 98% yield to give 2-33, and 
installation of the bromine leaving group was performed upon treatment with AIBN and 
NBS. Unlike indole 2-28, the corresponding tetracyclic intermediate 2-34 was completely 
unstable, so the displacement reaction with dimethylmalonate was performed 
immediately, without isolation. All efforts to construct diester 2-25 in this manner were 
ineffective and only substrate decomposition was observed.  
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Scheme 2.11 Synthetic route towards diester 2-25: method 2 
 
2.5.2.4 Electrocyclization Strategy  
 
 Since our earlier approaches towards ring C were ineffective, we turned our focus 
to a possible electrocyclization reaction. Hexatrienes have been shown to readily 
participate in thermal or Lewis acid activated disrotatory 6π electrocyclizations, so we 
envisioned that this type of ring closure could also be possible with conjugated indole 2-
37 (Scheme 2.12). Retrosynthetically, we envisioned access to 
tetrahydroisoquinocarbazole 2-3 through a three step process including a 1,4-reduction of 
the α,β-unsaturated ester, saponification and Schmidt reaction, which would reveal 
pentacyclic intermediate 2-35. This intermediate would likely arise after double bond 
isomerization of 2-36, that could be accessed via a 6π electrocyclization of indole 2-37.  
 
 
Scheme 2.12 Electrocyclization strategy 
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 This approach to 2-37 began with a stabilized Wittig reaction using indole-3-
carboxaldehyde (2-38), which furnished a 17:1 E/Z ratio of conjugated indole 2-39 
(Scheme 2.13, method 1). This indole was then subjected to C-2 alkylation reaction 
conditions with DA cyclopropane 1-2, but all attempts resulted in decomposition and 
some starting material recovery. The strategy was then revised by changing the sequence 
of chemical transformations where the α,β-unsaturated ester would be installed later in 
the synthesis (Scheme 2.13, method 2). Unfortunately, the C-2 alkylation of indole-3-
carbinol (2-41) did not lead to any desired product (2-42), indicating that the alkylation 
methodology was substrate dependent. Failure to access the conjugated indole 2-37 also 
precluded the potential 6π electrocyclization as a means for the final ring closure. 
 
 
Scheme 2.13 Potential synthetic route towards 2-37 
 
2.5.2.5 Radical Cyclization: Selenoester Approach   
 
Since all of the early approaches for ring C assembly involved elaborating the 
alkene, reductive cyclization, or electrocyclization strategies, a revised strategy involved 
exploring a potential selenoester derived radical-mediated ring closure. Selenoesters have 
long been recognized as precursors to acyl radicals that actively participate in inter- and 
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intramolecular alkene addition reactions.
9
 Despite the preference for free radicals to 
undergo 5-exo-trig over 6-endo-trig cyclizations, Boger and co-workers demonstrated 
that in some cases the latter is favored.
9
 Where acyl radicals are formed, the radical may 
suffer from a competitive decarbonylation reaction, but this may never be observed if the 
rate of cyclization is much higher than that of decarbonylation. Typically, this 
decarbonylation process is avoided when unactivated alkenes such as 2-43 are used in the 
reaction (Scheme 2.14), however, the acyl radical derived from 2-44 provides a 
heteroatom stabilized primary radical which does not undergo cyclization, but instead 
proceeds through the decarbonylation pathway exclusively to give 2-45. Although our 
substrate could undergo competitive decarbonylation, we were encouraged with the 
prospect of an intramolecular alkene addition via an acyl radical. 
 
 
Scheme 2.14 Intramolecular alkene addition reactions via acyl radicals 
 
The synthesis of selenoester 2-47 commenced with the C-2 alkylation of 
commercially available tryptophol with cyclopropane 1-2 to give indole 2-50 in a 
moderate 70% yield (Scheme 2.15). However, closure of the D-ring with this 
intermediate under basic conditions was unsuccessful. Suspecting that the free alcohol 
was interfering in the lactamization process, acylated derivative 2-49 was employed 
instead, and the C-2 alkylation product was obtained in 86% yield. The resulting indole 
(2-51) was effectively converted to the lactam in 90% yield upon treatment with DBU. 
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Deprotection of alcohol 2-52 allowed access to indole 2-53, thus setting the stage to 
explore ring C construction.  
 
Scheme 2.15 C-2 Alkylation and lactam formation 
 
Selenoester 2-47 was then prepared in a three step sequence commencing with 
Swern oxidation of alcohol 2-53 (Scheme 2.16). The resulting aldehyde (2-54) underwent 
Pinnick oxidation (NaH2PO4·H2O, NaClO2, 1-methylcyclohexene, tBuOH), and the 
resulting carboxylic acid was treated with diphenyl diselenide and tributylphosphine, 
providing cyclization precursor 2-47 in 81% yield over three steps. An acyl radical (2-55) 
was generated with AIBN and Bu3SnH, but regrettably, stabilized radical 2-56 formed 
and promoted rapid decarbonylation, ultimately giving 3-methyl indole derivative 2-33 as 
the exclusive product.  
 
 
Scheme 2.16 Selenoester cyclization approach 
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2.5.2.6 Radical Cyclization: Samarium(II) Iodide Approach 
 
Operating through the aldehyde oxidation state appeared to be an attractive means 
to further explore a radical cyclization strategy while avoiding the undesired 
decarbonylation. In this regard, both inter- and intramolecular carbonyl-alkene/alkyne 
reductive coupling reactions mediated by samarium(II) iodide are well documented.
10
 
Both aldehydes and ketones participate as coupling partners, but a large majority of these 
radical induced cyclizations with aldehydes employ electrophilic α,β-unsaturated esters 
or allylic leaving groups including halides, sulfides, and sulfones.
11
 
The aldehyde cyclization precursor (2-54) was treated with 2.2 equivalents of    
0.1 M SmI2 in THF (Scheme 2.17). Two reaction products were obtained, including the 
desired secondary alcohol (2-1) and primary alcohol (2-53) resulting from aldehyde 
reduction in a 1.2:1.0 ratio and 80% overall yield (Table 2.2, entry 1).  
 
 
Scheme 2.17 Completion of several tetrahydroisoquinocarbazoles 
 
Efforts to optimize this cyclization involved exploring various additives such as 
Lewis bases (HMPA), proton sources (H2O, MeOH), and inorganic salts (LiBr), all of 
which have been documented to profoundly affect SmI2 mediated reactions.
10
 According 
to Flowers and co-workers, the oxidation potential of SmI2 alone is −1.33 V (vs. 
Ag/AgNO3 in THF), and was found to increase to a maximum of −2.05 V with four 
equivalents of added HMPA.
12
 When these conditions were applied to the intramolecular 
coupling reaction, an increase in selectivity toward cyclization over aldehyde reduction 
was observed (Table 2.2, entry 2). 
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Table 2.2 Optimization data for SmI2 cyclization  
Entry Additives (equiv)
a
 Ratio of 2-1:2-53 Yield (%)
b
 
1 - 1.2:1.0 80 
2 HMPA (8.8) 2.0:1.0 85 
3 H2O (22) >99:1 33 
4 MeOH (22) >99:1 42 
5 LiBr (8.8) 1.4:1.0 91 
6 LiBr (8.8), HMPA (110) >99:1 78 
a Relative to aldehyde 2-54, with 2.2 equivalents of 0.1 M SmI2 in each reaction. 
bCombined isolated yield of 2-1 and 2-53, for both steps starting from alcohol 2-53. 
 
Protic additives such as water and methanol have also been shown to influence 
similar radical processes, as they likely activate the reagent through metal coordination 
and protonate anionic intermediates.
13
 Although these proton sources improved 
selectivity for the cyclization product (2-1) over aldehyde reduction, significantly lower 
yields were accompanied with considerable decomposition (entries 3 and 4).   
 Inorganic salts such as LiBr have been shown to participate in displacement 
reactions with SmI2, producing SmBr2.
14
 Cyclizations with SmBr2 as a reducing agent 
provided a 1.4:1.0 mixture of 2-1:2-53, although in excellent 91% combined yield (entry 
5). Flowers also found that the addition of 50 equivalents of HMPA significantly 
improved the reducing ability of SmBr2 (−2.07 V for SmBr2 versus −2.63 V for SmBr2-
HMPA).
14
 Optimal results were achieved by a combination of several known additives, 
specifically LiBr and HMPA (entry 6). The SmBr2-HMPA reductant prepared under 
Flowers’ conditions displayed excellent selectivity (>99:1) for cyclization to 2-1 in 78% 
yield. The relative stereochemistry of 2-1 was confirmed by extensive NMR analysis.
15
  
To further illustrate the utility of this approach additional modifications were 
made to the functionalized core (Scheme 2.17). Oxidation of alcohol 2-1 with IBX 
proceeded smoothly to afford ketone 2-2, which was advanced to amine 2-3 after 
reductive amination. Presumably, other tetrahydroisoquinocarbazoles, including RS-
2135, can be accessed by elaboration of the starting indole or cyclopropane.  
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2.6 Summary 
 
In summary, we have reported the most efficent and highest yielding route to 
several tetrahydroisoquinocarbazoles, where the core (2-1) was prepared in six steps from 
tryptophol in 51% overall yield. This work highlights for the first time the synthetic 
utility of the dipolar C-2 alkylation of 3-substituted indoles with 2-
alkoxycyclopropanoate esters. The synthesis also features a selective SmBr2-HMPA 
promoted ring closure of an aldehyde onto a sterically congested trisubstituted alkene.  
This also provides an attractive route to other biologically active 
tetrahydroisoquinocarbazoles including the most potent member, RS-2135.  
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2.7 Experimental 
 
2.7.1 General Considerations 
  
 General experimental procedures were the same as provided in Chapter 1. 
 
2.7.2 Experimental Procedures 
 
12-Hydroxy-2,3,3a,3a1,4,11,12,12a-octahydroisoquinolino[2,1,8-
lma]carbazol-5(1H)-one (2-1) 
Lithium bromide (107 mg, 1.23 mmol) was dissolved in 3.00 mL 
degassed THF and added to a 0.10 M solution of SmI2 (3.10 mL, 0.31 mmol).
6
 After the 
dark purple mixture was allowed to stir for 3 min at RT, freshly distilled HMPA (2.60 
mL, 15.4 mmol) was added dropwise and stirred for an additional 5 min. Aldehyde 2-54 
(39.0 mg, 0.14 mmol) was then added over 3 min, as a solution in 1.00 mL of degassed 
THF, and the dark purple solution turned dark green. After 5 min at RT, the mixture was 
poured into a half saturated solution of NaHCO3 (5.00 mL). The heterogeneous mixture 
was separated and the aqueous layer was extracted with EtOAc (4 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (78% 
yield over two steps from alcohol 2-53, 30.0 mg). Rf  0.30 (50% EtOAc/hexanes); 
1
H 
NMR (400 MHz, CDCl3)  8.28-8.26 (m, 1H), 7.40-7.38 (m, 1H), 7.30-7.26 (m, 2H), 
3.81 (dt, J = 10.8, 4.5 Hz, 1H), 3.07 (dd, J = 14.8, 4.7 Hz, 1H), 2.80-2.71 (m, 2H), 2.58-
2.47 (m, 2H), 2.31-2.24 (m, 2H), 1.83-1.55 (m, 5H), 1.41-1.35 (m, 1H), 1.19-1.13 (m, 
1H); 
13
C NMR (100 MHz, CDCl3)  169.2, 137.7, 129.8, 125.9, 124.2, 123.9, 117.9, 
116.0, 111.2, 68.1, 42.8, 39.2, 38.1, 37.9, 31.4, 30.2, 24.2, 21.1. HRMS m/z 281.1427 
(calcd for C18H19NO2, 281.1416). 
                                                 
6
 SmI2 was made according to the following procedures: a) Curran, D. P.; Gu, X.; Zhang, 
W.; Dowd, P. Tetrahedron 1997, 53, 9023–9042. b) Concellon J. M.; Rodriguez-Solla, 
H.; Bardales, E.; Huerta, M. Eur. J. Org. Chem. 2003, 9, 1775–1778.  
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NOESY Interactions: 
   
gCOSY Interactions: 
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1,2,3,3a,4,12a-Hexahydroisoquinolino[2,1,8-lma]carbazole-
5,12(3a
1
H,11H)-dione (2-2) 
Alcohol 2-1 (15.0 mg, 0.05 mmol) was dissolved in DMSO (1.00 mL) 
and IBX (36.0 mg, 0.13 mmol) was added. The mixture was stirred at RT for 9 h. After 
the solution was cooled to 0 °C, it was diluted with a half saturated solution of NaHCO3 
(5.00 mL).  The mixture was filtered through a pad of Celite, and extracted with EtOAc 
(4 x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure provided the title 
compound as pale yellow oil. Rf 0.50 (50% EtOAc/hexanes); 
1
H NMR (400 MHz, 
CDCl3)  8.28 (dd, J =  6.9, 1.1 Hz, 1H), 7.37–7.26 (m, 3H), 3.68 (dt, J =  17.4, 1.6 Hz, 
1H), 3.37 (d, J = 17.4 Hz, 1H), 3.30-3.18 (m, 2H), 2.76 (dd, J = 17.6, 3.7 Hz, 1H), 2.56-
2.49 (m, 1H), 2.36-2.31 (m, 2H), 1.80-1.70 (m, 2H), 1.55-1.41 (m, 2H), 1.18-1.09 (m, 
1H); 
13
C NMR (100 MHz, CDCl3)  206.4, 168.9, 135.8, 135.5, 129.1, 124.9, 124.2, 
118.1, 116.1, 110.2, 43.2, 42.4, 39.9, 38.6 36.8, 29.2, 22.4, 22.0. HRMS m/z 279.1269 
(calcd for C18H17NO2, 279.1259). 
 
NOESY Interactions: 
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gCOSY Interactions: 
 
Proton Chemical Shift Interactions 
b
d
 3.68 (dt, J =  17.4, 1.6 Hz, 1H) a
u
 
b
u
 3.37 (d, J = 17.4 Hz, 1H) a
d
 
c 3.30-3.18 (m, 1H) f 
d
d
 2.76 (dd, J = 17.6, 3.7 Hz, 1H) d
u
, i 
d
u
 2.56-2.49 (m, 1H) d
d
, i 
f 3.30-3.18 (m, 1H) c, i 
g 2.36-2.31 (m, 2H) k 
i 1.80-1.70 (m, 1H) d
u
, j
d
, j
u
, f 
j
d
 1.80-1.70 (m, 1H) j
u
, i, k 
j
u
 1.18-1.09 (m, 1H) j
d
, i, k 
k 1.55-1.41 (m, 2H) g, j
d
, j
u
 
l 8.28 (dd, J =  6.9, 1.1 Hz, 1H) m 
m 7.37–7.26 (m, 1H) n, l 
n 7.37–7.26 (m, 1H) m, o 
o 7.37–7.26 (m, 1H) n 
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12-amino-2,3,3a,3a1,4,11,12,12a-octahydroisoquinolino[2,1,8-
lma]carbazol-5(1H)-one (2-3) 
Ammonium acetate (65.0 mg, 0.85 mmol) was added to ketone 2-2 
(24.0 mg, 0.08 mmol) in 3.00 mL MeOH and allowed to stir for 2 min. NaCNBH3 (5.00 
mg, 0.08 mmol) was then added as a solution in 1.00 mL MeOH and stirred for 22 h. The 
reaction mixture was concentrated under reduced pressure, and 5.00 mL H2O was added 
to the residue.  The mixture was basified with 15% NaOH solution and diluted with 10.0 
mL EtOAc. The heterogeneous mixture was separated and the aqueous layer was 
extracted with EtOAc (4 x 10.0 mL). The combined organic layers were washed with 
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the title compound as a white solid (69% over two steps from alcohol 2-3, 15.0 
mg). Rf 0.30 (50% EtOAc/hexanes); 
1
H NMR (600 MHz, CDCl3)  8.33 (d, J = 7.0 Hz, 
1H), 7.38 (d, J = 5.8 Hz, 1H), 7.30–7.25 (m, 2H), 3.98 (td, J = 9.7, 6.4 Hz, 1H), 3.20 
(ddd, J = 15.7, 6.0, 1.7 Hz, 1H), 2.78 (dd, J = 16.7, 3.8 Hz, 1H), 2.58–2.53 (m, 1H), 2.46 
(dd, J = 16.9, 12.8 Hz, 1H), 2.36–2.14 (m, 3H), 2.03-2.98 (m, 1H), 1.93–1.83 (m, 2H), 
1.74 (bs, 1H), 1.62–1.45 (m, 3H), 1.33–1.27 (m, 1H). 13C NMR (100 MHz, CDCl3)  
174.7, 129.84, 124.2, 123.8, 122.9, 118.0, 116.2, 115.8, 115.5, 72.2, 46.1, 41.1, 40.9, 
38.2, 31.5, 30.9, 27.4, 25.3. HRMS m/z 281.1410 (calcd for C18H20N2O + H
+
, 281.1654). 
 
NOESY Interactions: 
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gCOSY Interactions: 
 
Proton Chemical Shift Interactions 
a 3.98 (td, J = 9.7, 6.4 Hz, 1H) b
d
, b
u
, c 
b
d
 3.20 (ddd, J = 15.7, 6.0, 1.7 Hz, 1H) b
u
, a 
b
u
 2.58-2.53 (m, 1H) b
d
, a 
c 1.62-1.45 (m, 1H) a, f, g 
d
d
 2.78 (dd, J = 16.7, 3.8 Hz, 1H) d
u
 
d
u
 2.46 (dd, J = 16.9, 12.8 Hz, 1H) d
d
, i 
e
d
 1.74 (bs, 1H) - 
e
u
 1.62-1.45 (m, 1H) - 
f 2.36-2.14 (m, 1H) c, i 
g
d
 2.03-2.98 (m, 1H) k, g
u
, c 
g
u
 1.62-1.45 (m, 1H) k, g
d
, c 
i 1.93-1.83 (m, 1H) d
u
, j
d
, j
u
, f 
j
d
 1.93-1.83 (m, 1H) j
u
, i, k 
j
u
 1.33-1.27 (m, 1H) j
d
, i, k 
k 2.36-2.14 (m, 2H) g, j
d
, j
u
 
l 8.33 (d, J = 7.0 Hz, 1H) m 
m 7.30–7.25 (m, 1H) l, n 
n 7.30–7.25 (m, 1H) m, o 
o 7.38 (d, J = 5.8 Hz, 1H) n 
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3-(2-Nitroethyl)-1H-indole (2-19) 
NaBH4 (736 mg, 19.0 mmol) was added in two portions to a stirred 
solution of  3-(2-nitrovinyl)-1H-indole
7
  in 20.0 mL dry MeOH at RT. The solution was 
allowed to stir for 15 min and subsequently acidified to pH 6 with acetic acid. The 
solvent was removed under reduced pressure and the residue was dissolved in 10.0 mL 
H2O and 10.0 mL ethyl acetate. The heterogeneous mixture was separated and the 
aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as a white solid (90% yield, 228 mg). Rf 
0.52 (50% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.05 (br s, 1H), 7.57 (d, J = 
7.8 Hz, 1H), 7.38 (d, J = 7.4 Hz, 1H), 7.23 (td, J = 7.7, 1.3 Hz, 1H), 7.15 (td, J = 7.5, 1.1 
Hz, 1H), 7.07 (d, J = 2.5 Hz, 1H), 4.67 (t, J = 7.3 Hz, 2H), 3.49 (td, J = 7.3, 0.7 Hz, 2H). 
13
C NMR (100 MHz, CDCl3)  136.2, 126.6, 122.5, 119.9, 118.1, 111.41, 110.0, 75.7, 
23.6.  
 
Ethyl 2-(2-(3-(2-nitroethyl)-1H-indol-2-yl)cyclohex-2-enyl)acetate 
(2-20) 
To a solution of indole 2-19 (35.0 mg, 0.18 mmol) and the 
cyclopropane 1-2 (47.0 mg, 0.24 mmol) in MeNO2 (1.00 mL) at 0 °C, 
TMSOTf (77.0 μL, 0.42 mmol) was added dropwise. After 3 h at 40 °C, the reaction 
mixture was cooled to RT and poured into 10.0 mL of a half saturated solution of 
NaHCO3. The heterogeneous mixture was separated and the aqueous layer was extracted 
with EtOAc (3 x 10.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (50%, 33.0 mg). Rf 0.53 (35% EtOAc/hexanes); 
1
H NMR (400 
MHz, CDCl3)  8.17 (br s, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.18 
                                                 
7
 Commercially available, but can be prepared according to the following procedure: Di 
Giacomo, B.; Bedini, A.; Spadoni, G.; Tarzia, G.; Fraschini, F.; Pannacci, M.; Lucini, 
V. Bioorg. Med. Chem. 2007, 15, 4643–4650. 
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(td, J = 7.5, 1.4 Hz, 1H), 7.12 (td, J = 7.4, 1.2 Hz, 1H), 6.00 (td, J = 3.9, 1.6 Hz, 1H), 
4.63–4.58 (m, 2H), 4.04–3.95 (m, 2H), 3.60–3.52 (m, 1H), 3.48–3.41 (m, 1H), 3.06–3.00 
(m, 1H), 2.26–2.20 (m, 4H), 1.96–1.93 (m, 1H), 1.74–1.63 (m, 3H), 1.15 (t, J = 7.1 Hz, 
3H). 
13
C NMR (100 MHz, CDCl3)  136.9, 135.3, 132.3, 132.1, 128.1, 122.6, 120.2, 
118.1, 111.23, 106.5, 75.5, 60.8, 38.9, 34.6, 28.3, 26.0, 23.7, 19.2, 14.3. HRMS m/z 
356.1739 (calcd for C20H24N2O4, 356.1736).  
 
Methyl 3-(1H-indol-3-yl)propanoate (2-21) 
To a solution of indole (100 mg, 0.85 mmol) dissolved in MeCN 
(2.00 mL), methyl acrylate (154 μL, 1.70 mmol) was added, 
followed by TMSOTf (201 μL, 1.10 mmol) added dropwise. After 3 h at RT, the reaction 
mixture was poured into 10.0 mL of a half saturated solution of NaHCO3. The 
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3 
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as white solid (90%, 155 mg). Rf 0.45 (40% EtOAc/hexanes); 
1
H NMR (400 
MHz, CDCl3)  8.60 (br s, 1H), 7.62 (dd, J = 7.9, 0.7 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 
7.21 (td, J = 7.6, 1.3 Hz, 1H), 7.14 (td, J = 7.4, 1.2 Hz, 1H), 6.98 (d, J = 2.3 Hz, 1H), 3.69 
(s, 3H), 3.13 (t, J = 7.6 Hz, 2H), 2.75 (t, J = 7.4 Hz, 2H). 
13
C NMR (100 MHz, CDCl3)  
173.9, 136.2, 127.1, 121.9, 121.4, 119.3, 118.6, 114.8, 111.1, 51.5, 34.7, 20.6.  
 
Methyl 3-(2-(6-(2-ethoxy-2-oxoethyl)cyclohex-1-enyl)-1H-indol-
3-yl)propanoate (2-22) 
To a solution of indole 2-21 (48.0 mg, 0.26 mmol) and the 
cyclopropane 1-2 (94.0 mg, 0.47 mmol) in MeNO2 (1.50 mL) at 0 
°C, TMSOTf (174 μL, 0.96 mmol) was added dropwise. After 1.5 h at RT, the reaction 
mixture was poured into 10.0 mL of a half saturated solution of NaHCO3. The 
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3 
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
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chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (82%, 85.0 mg). Rf 0.53 (40% EtOAc/hexanes); 
1
H NMR (400 
MHz, CDCl3)  8.03 (br s, 1H), 7.54 (d, J = 7.8, 0.8 Hz, 1H), 7.29 (dt, J = 7.9, 1.0 Hz, 
1H), 7.14 (td, J = 7.5, 1.2 Hz, 1H), 7.08 (td, J = 7.2, 1.2 Hz, 1H), 5.99 (td, J = 3.9, 1.6 
Hz, 1H), 4.06–3.94 (m, 2H), 3.68 (s, 3H), 3.17–3.01 (m, 3H), 2.72–2.57 (m, 2H), 2.30–
2.18 (m, 4H), 1.94–1.88 (m, 1H), 1.72–1.63 (m, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR 
(100 MHz, CDCl3)  173.8, 173.1, 135.4, 135.2, 132.22, 131.1, 128.3, 121.8, 119.4, 
118.5, 111.4, 110.7, 60.4, 51.6, 38.7, 35.2, 34.1, 27.9, 25.8, 20.3, 18.9, 14.1.  
 
Methyl 3-(6-oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin-
12-yl)propanoate (2-23) 
DBU (1.20 mL, 8.10 mmol) was added to a stirred solution of 
indole 2-22 (1.00 g, 2.70 mmol) in 50.0 mL CH2Cl2 at RT. The solution was allowed to 
stir for 18 h and then poured into a 10% solution of CuSO4 and stirred for 20 min. The 
heterogeneous mixture was separated and the aqueous layer was extracted with CH2Cl2 (3 
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as a white solid (91% yield, 838 mg). Rf 0.58 (35% EtOAc/hexanes); 
1
H NMR 
(400 MHz, CDCl3)  8.49–8.46 (m, 1H), 7.51–7.49 (m, 1H), 7.34–7.26 (m, 2H), 6.34–
6.31 (m, 1H), 3.70 (s, 3H), 3.26–3.19 (m, 1H), 3.15–3.08 (m, 1H), 2.86 (dd, J = 16, 4.6 
Hz, 1H), 2.80–2.68 (m, 2H), 2.63–2.56 (m, 1H), 2.51 (dd, J = 16, 13 Hz, 1H), 2.39–2.29 
(m, 2H), 2.12–2.05 (m, 1H), 1.88–1.82 (m, 1H), 1.63–1.53 (m, 1H), 1.39–1.30 (m, 1H). 
13
C NMR (100 MHz, CDCl3)  173.2, 168.8, 133.9, 133.5, 130.6, 127.9, 127.7, 125.0, 
123.8, 118.1, 116.5, 115.8, 51.8, 41.3, 33.9, 33.7, 29.9, 26.3, 20.6. HRMS m/z 323.1517 
(calcd for C20H21NO3, 323.1521). 
 
tert-Butyl-3-methyl-1H-indole-1-carboxylate (2-27) 
3-Methylindole (367 mg, 2.80 mmol) was dissolved in 10.0 mL THF, and 
Boc anhydride (733 mg, 3.40 mmol) was added, followed by DMAP (34.0 mg, 0.28). 
The solution was allowed stir for 16 h at RT and poured into 10.0 mL of H2O. The 
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heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (3 
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as a white solid (99% yield, 642 mg). Rf 0.57 (35% EtOAc/hexanes); 
1
H NMR 
(400 MHz, CDCl3)  8.10 (br s, 1H), 7.51–7.47 (m, 1H), 7.34–7.21 (m, 3H), 2.27–2.26 
(m, 3H), 1.66–1.65 (m, 9H). 13C NMR (100 MHz, CDCl3)  169.1, 143.6, 135.3, 124.2, 
122.8, 122.2, 188.9, 116.3, 115.1, 28.2, 27.4, 9.6. 
 
tert-Butyl-3-(bromomethyl)-1H-indole-1-carboxylate (2-28) 
Indole 2-27 (600 mg, 2.60 mmol) was dissolved in 40.0 mL 
cyclohexanone (dried over 4Å molecular sieves), and brought to reflux. NBS (554 mg, 
3.10 mmol) and AIBN (19.0 mg, 11.0 mmol) were added in 3 portions over 3 min. After 
30 min at reflux, and another portion of AIBN (19.0 mg, 11.0 mmol) was added at once. 
After 2 h at reflux, the mixture was cooled to RT and the solids were filtered off and 
washed with hexanes. The solvent was removed under reduced pressure and the title 
compound was isolated as a yellow solid (98% yield, 790 mg). Rf 0.45 (35% 
EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.14 (d, J = 8.2 Hz, 1H), 7.68–7.66 (m, 
2H), 7.38–7.29 (m, 2H), 4.68 (s, 2H), 1.69–1.66 (m, 9H). Due to the instability of this 
compound, only 
1
H NMR was obtained and it was used immediately after preparation 
and TLC analysis. 
 
Dimethyl 2-((1-(tert-butoxycarbonyl)-1H-indol-3-yl)methyl) 
malonates (2-29) 
NaH (19.0 mg, 0.79 mmol) in 5.00 mL THF was added dimethylmalonate (96.0 μl, 0.84 
mmol) and stirred at RT for 3 h. Indole 2-28 (130 mg, 0.42 mmol) was added as a 
solution in 2.00 mL THF and allowed to stir at reflux for 36 h. The mixture was cooled to 
RT and poured into 20.0 mL H2O. The heterogeneous mixture was separated and the 
aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
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hexanes for elution provided the title compound as colorless oil (80% yield, 120 mg). Rf 
0.25 (35% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.10 (d, J = 7.2 Hz, 1H), 7.52 
(d, J = 8.4 Hz, 1H), 7.40 (br s, 1H), 7.30 (td, J = 7.7, 1.4 Hz, 1H), 7.23 (td, J = 7.4, 0.8 
Hz, 1H), 3.80–3.77 (m, 1H), 3.71 (s, 6H), 3.32 (d, J = 7.6 Hz, 1H), 1.65 (s, 9H). 13C 
NMR (100 MHz, CDCl3)  169.2, 149.5, 129.9, 124.4, 123.5, 122.4, 118.6, 116.6, 115.2, 
109.7, 83.5, 52.6, 51.8, 28.1, 24.2. HRMS m/z 361.1525 (calcd for C19H23NO6, 
361.1525). 
 
Dimethyl 2-((1H-indol-3-yl)methyl)malonates (2-30) 
Indole 2-29 (30.0 mg, 0.08 mmol) was dissolved in 3.00 mL 
CH2Cl2 with 300 mg SiO2, and solvent removed under reduced pressure. The silica with 
indole adhered onto the surface was heated to 50 °C while under reduced pressure (0.20 
mm Hg) for 1.5 h. The reaction mixture was cooled to RT and 10.0 mL CH2Cl2 added. 
The solution was filtered through Celite and the solution was concentrated under reduced 
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for 
elution provided the title compound as colorless oil (95% yield, 20 mg). Rf 0.31 (35% 
EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.02, (br s, 1H), 7.60 (d, J = 7.8 Hz, 
1H), 7.34 (d, J = 8.0 Hz, 1H), 7.19 (td, J = 7.5, 1.2 Hz, 1H), 7.13 (dd, J = 7.5, 1.1 Hz, 
1H), 7.03 (d, J = 2.3 Hz, 1H), 3.80 (t, J = 7.7 Hz, 1H), 3.69 (s, 6H), 3.40 (d, J = 7.6 Hz, 
1H). 
13
C NMR (100 MHz, CDCl3)  169.6, 136.1, 126.9, 122.5, 122.1, 119.5, 118.5, 
112.1, 111.1, 52.7, 52.5, 24.6. HRMS m/z 261.1010 (calcd for C14H15NO4, 261.1001). 
 
Ethyl 2-(2-(3-methyl-1H-indol-2-yl)cyclohex-2-enyl)acetate (2-32) 
To a solution of 3-methylindole (270 mg, 2.10 mmol) and the 
cyclopropane 1-2 (816 mg, 4.10 mmol) in MeNO2 (5.00 mL) at 0 °C, 
TMSOTf (1.50 mL, 8.20 mmol) was added dropwise. After 3 h at RT, the solution was 
poured into 20.0 mL of a half saturated solution of NaHCO3. The heterogeneous mixture 
was separated and the aqueous layer was extracted with EtOAc (3 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (92%, 
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565 mg). Rf 0.55 (35% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  7.96, (br s, 1H), 
7.51 (d, J = 7.8 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.14 (dd, J = 7.5, 1.3 Hz, 1H), 7.08 (td, 
J = 7.4, 1.1 Hz, 1H), 6.00 (td, J = 3.9, 1.5 Hz, 1H), 4.05–3.97 (m, 2H), 3.14–3.12 (m, 
1H),  2.36–2.31 (m, 1H), 2.30 (s, 3H), 2.55–2.19 (m, 3H), 1.93–1.88 (m, 1H), 1.72–1.66 
(m, 1H), 1.16 (t, J = 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3)  173.1, 135.1, 134.7, 
132.5, 130.3, 129.5, 121.6, 119.1, 118.4, 110.5, 108.3, 60.4, 38.7, 33.6, 27.9, 25.8, 18.6, 
14.1, 9.6.  
 
12-Methyl-3,4,4a,5-tetrahydroindolo[2,1-a]isoquinolin-6(2H)-one (2-
33) 
A solution of phenyl selenoester 2-47 (30.0 mg, 0.07 mmol) and AIBN 
(0.60 mg, 0.004 mmol) in benzene (8.00 mL) was heated to reflux. Tributyltin hydride 
(22.0 μL, 0.08 mmol) was then added to the reaction mixture, as a solution in 0.80 mL 
benzene over 1 h. After refluxing for 1.5 h, the solution was cooled to RT and 
concentrated under reduced pressure. The residue was purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution, to provide the title 
compound as white solid (72% yield, 12.0 mg). Rf 0.53 (33% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)  8.47-8.45 (m, 1H), 7.48-7.46 (m, 1H), 7.33-7.26 (m, 2H), 6.31-6.30 
(m, 1H), 2.85 (dd, J = 15.8, 4.5 Hz, 1H), 2.81-2.73 (m, 1H), 2.49 (dd, J = 15.9, 12.9 Hz, 
1H), 2.36 (s, 3H), 2.34-2.23 (m, 2H), 2.12-2.04 (m, 1H), 2.1.89-1.81 (m, 1H), 1.61-1.52 
(m, 1H), 1.35 (ddd, J = 12.8, 9.7, 2.9 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  168.8, 
133.8, 133.1, 131.8, 128.3, 127.9, 124.8, 123.7, 118.2, 116.4, 113.0, 41.4, 33.8, 30.0, 
26.2, 20.8, 10.7. HRMS m/z 251.1304 (calcd for C17H17NO, 251.1310). 
 
(E)-Ethyl-3-(1H-indol-3-yl)acrylate (2-39) 
To a solution of  indole-3-carboxaldehyde (174 mg, 1.20 mmol) 
dissolved in 20.0 mL toluene and 3.00 mL CH2Cl2, freshly prepared Ph3PCHCO2Et was 
added as a solid under a N2(g) cone. The reaction mixture was stirred at RT for 16 h and 
the solvent was removed under reduced pressure. The residue was purified by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as white solid (72%, 186 mg). Rf 0.55 (80% EtOAc/hexanes); 
1
H NMR (400 
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MHz, CDCl3)  8.60 (br s, 1H), 7.94–7.90 (m, 2H), 7.47 (d, J = 2.7 Hz, 1H), 7.42–7.40 
(m, 1H), 7.30–7.22 (m, 2H), 6.47 (d, J = 16 Hz, 1H), 4.27 (q, J = 7.0 Hz, 1H), 1.35 (t, J = 
7.1 Hz, 1H). 
13
C NMR (100 MHz, CDCl3)  168.3, 138.2, 137.1, 128.7, 125.3, 123.3, 
121.5, 120.5, 113.6, 113.5, 111.7, 60.1, 14.4.  
 
Se-phenyl-2-(6-oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-
a]isoquinolin-12-yl)ethaneselenoate (2-47) 
To a solution of aldehyde 2-54 (50.0 mg, 0.18 mmol) in tBuOH 
(1.26 mL), H2O (1.26 mL), and THF (1.00 mL), was added 0.90 mL 1-methyl-
cyclohexene. NaH2PO4·H2O (124 mg, 0.90 mmol) and NaClO2 (49.0 mg, 0.54 mmol) 
were then added to the reaction mixture as solids. The solution was stirred for 1 h, and 
then poured a half saturated solution of NaCl (10.0 mL). The heterogeneous mixture was 
separated and the aqueous layer was extracted with EtOAc (5 x 10.0 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. The carboxylic acid was dissolved in 3.00 mL 
CH2Cl2 and a solution of diphenyl diselenide (84.0 mg, 0.27 mmol) in 10.0 mL CH2Cl2 
was added and cooled to 0 °C.  Tributylphosphine (67.0 μL, 0.27 mmol) was then added 
dropwise, as a solution in 0.40 mL CH2Cl2. The reaction mixture was stirred at RT for 4 
h, and then poured into 10.0 mL H2O. The heterogeneous mixture was separated and the 
aqueous layer was extracted with CH2Cl2 (4 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as white solid (81% yield, three steps 
from alcohol 2-53, 66.0 mg). Rf 0.65 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3) 
 8.53-8.51 (m, 1H), 7.58-7.56 (m, 1H), 7.46-7.44 (m, 2H), 7.40-7.33 (m, 5H), 6.51-6.46 
(m, 1H), 4.19 (d, J = 16.8 Hz, 1H), 4.03 (d, J = 16.8 Hz, 1H), 2.92 (dd, J = 16.2, 4.5 Hz, 
1H), 2.88-2.78 (m, 1H), 2.59 (dd, J = 16.3, 13.2 Hz, 1H), 2.40-2.30 (m, 2H), 2.14-2.08 
(m, 1H), 1.91-1.83 (m, 1H), 1.63-1.52 (m, 1H), 1.41-1.32 (m, 1H). 
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3-(2-Acetoxyethyl)indole (2-49) 
Tryptophol (806 mg, 5.00 mmol) was dissolved in 10.0 mL pyridine 
and acetic anhydride (662 μL, 7.00 mmol) was added dropwise and allowed to stir for 15 
h at RT. The solution was poured into 40.0 mL H2O solution and stirred for 20 min. The 
heterogeneous mixture was separated and the aqueous layer was extracted with CH2Cl2 (4 
x 10.0 mL). The combied organic layers were washed with brine, dried (MgSO4), filtered 
through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (99% yield, 1.00 g). Rf 0.46 (50% EtOAc/hexanes); 
1
H NMR 
(400 MHz, CDCl3)  8.17 (br s, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.36 (d, J = 8.0 Hz, 1H), 
7.24 (dt, J = 7.5, 1.3 Hz, 1H), 7.18 (dt, J = 7.5, 1.1 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 4.40 
(t, J = 7.1 Hz, 1H), 3.14 (dt, J = 7.2, 0.8 Hz, 1H), 2.10 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3)  171.2, 136.1, 127.3, 121.9, 119.3, 118.7, 111.8, 111.1, 64.6, 24.7, 21.0. 
 
{2-[3-(2-Hydroxyethyl)-1H-indol-2-yl]-cyclohex-2-enyl}-acetic acid 
methyl ester (2-50) 
To a solution of tryptophol (80.0 mg, 0.49 mmol) and the 
cyclopropane 1-2 (127 mg, 0.64 mmol) in MeNO2 (2.00 mL) at 0 °C, 
TMSOTf (206 μL, 1.13 mmol) was added dropwise. After 1 h at RT, 5.00 mL of EtOAc 
was added and the mixture was poured into a half saturated solution of NaHCO3 (15.0 
mL). The heterogeneous mixture was separated and the aqueous layer was extracted with 
EtOAc (4 x 10.0 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as pale yellow oil (70% yield, 112 mg). Rf 0.44 (50% EtOAc/hexanes); 
1
H 
NMR (400 MHz, CDCl3)  8.07 (br s, 1H), 7.58 (dd, J = 7.8, 1.2 Hz, 1H), 7.30 (dt, J = 
8.0, 0.9 Hz, 1H), 7.15 (ddd, J = 8.1, 7.0, 1.3  Hz, 1H), 7.09 (ddd, J = 7.9, 6.9, 1.1 Hz, 
1H), 6.06 (td, J = 4.0, 1.6 Hz, 1H), 3.99-3.88 (m, 4H), 3.13-2.96 (m, 3H), 2.33-2.17 (m, 
4H), 1.93-1.88 (m, 1H), 1.72-1.62 (m, 4H), 1.11 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3)  173.1, 136.49, 135.2, 132.2, 131.4, 128.8, 121.9, 119.5, 118.7, 110.7, 108.8, 
63.0, 60.5, 38.8, 34.2, 28.3, 25.8, 18.9, 14.0.  
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{2-[3-(2-Acetoxyethyl)-1H-indol-2-yl]-cyclohex-2-enyl}-acetic acid 
methyl ester (2-51) 
To a solution of indole 2-49 (100 mg, 0.49 mmol) and cyclopropane 
1-2 (127 mg, 0.64 mmol) in MeNO2 (2.00 mL) at 0 °C, TMSOTf (206 
μL, 1.13 mmol) was added dropwise. After 1 h at RT, 5.00 mL of EtOAc was added and 
the mixture was poured into a half saturated solution of NaHCO3 (15.0 mL). The 
heterogeneous mixture was separated and the aqueous layer was extracted with EtOAc (4 
x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (86% yield, 155 mg). Rf 0.63 (50% EtOAc/hexanes); 
1
H NMR 
(400 MHz, CDCl3)  8.09 (br s, 1H), 7.60 (d, J = 7.2 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 
7.15 (td, J = 7.6, 1.3 Hz, 1H), 7.09 (td, J = 7.4, 1.3 Hz, 1H), 6.04 (td, J = 3.9, 1.4 Hz, 
1H), 4.33-4.23 (m, 2H), 4.04-3.96 (m, 2H), 3.17-2.99 (m, 3H), 2.32-2.19 (m, 4H), 2.04 
(s, 3H), 1.95-1.89 (m, 1H), 1.72-1.64 (m, 3H), 1.15 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3)  171.9, 171.1, 136.2, 135.1, 132.0, 131.4, 128.7, 121.9, 119.5, 118.7, 
110.7, 108.4, 64.6, 60.4, 38.6, 34.1, 27.9, 25.7, 24.3, 21.1, 18.8, 14.1.  
 
2-(6-Oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin-12-
yl)ethyl acetate (2-52) 
The title compound was obtained from indole 2-51 using the 
cyclization reaction conditions as described above in the procedure to obtain compound 
2-23. This procedure provided the title compound as a white solid (90% yield). Rf 0.54 
(50% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.49-8.47 (m, 1H), 7.56-7.54 (m, 
1H), 7.34-7.28 (m, 2H), 6.46 (dt, J = 4.7, 2.7 Hz, 1H), 4.38-4.28 (m, 2H), 3.26-3.18 (m, 
1H), 3.16-3.09 (m, 1H), 2.27 (dd, J = 16.2, 4.5 Hz, 1H), 2.85-2.74 (m, 1H), 2.52 (dd, J = 
16.2, 13.1 Hz, 1H), 2.40-2.26 (m, 2H), 2.12-2.06 (m, 1H), 2.05 (s, 3H), 1.90-1.82 (m, 
1H), 1.63-1.52 (m, 1H), 1.40-1.31 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  171.0, 168.8, 
134.6, 133.9, 131.1, 127.9, 127.8 125.1, 123.9, 118.3, 116.5, 112.8, 63.4, 41.4, 34.0, 29.9, 
26.3, 24.7, 21.0, 20.7. HRMS m/z 323.1529 (calcd for C20H21NO3, 323.1521). 
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12-(2-Hydroxyethyl)-3,4,4a,5-tetrahydroindolo[2,1-a]isoquinolin-
6(2H)-one (2-53) 
To a solution of indole 2-52 (70.0 mg, 0.22 mmol) in 8.00 mL MeOH 
was added 2.00 mL of 0.50 M K2CO3 solution (4.70 mmol). The solution was allowed 
stir at RT for 30 min. The solution was concentrated under reduced pressure, and then 
residue was dissolved in 10.0 mL EtOAc and 10.0 mL H2O. The heterogeneous mixture 
was separated and the aqueous layer was extracted with EtOAc (4 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as white solid (85% 
yield, 52.6 mg). Rf 0.35 (50% EtOAc/hexanes); 
1
H NMR (400 MHz, CDCl3)  8.47-8.45 
(m, 1H), 7.54-7.52 (m, 1H), 7.34-7.27 (m, 2H), 6.58-6.56 (m, 1H), 4.04-3.93 (m, 2H), 
3.18-3.07 (m, 2H), 2.84-2.71 (m, 2H), 2.40 (dd, J = 16.0, 12.9 Hz, 1H), 2.34-2.28 (m, 
2H), 2.10-2.04 (m, 1H), 1.87-1.80 (m, 1H), 1.70-1.68 (m, 1H), 1.61-1.50 (m, 1H), 1.36-
1.27 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  168.9, 134.8, 133.9, 131.3, 128.0, 127.6, 
125.0, 123.9, 118.5, 116.6, 113.9, 62.3, 41.2, 33.9, 29.9, 28.5, 26.3, 20.7. HRMS m/z 
281.1408 (calcd for C18H19NO2, 281.1416). 
 
2-(6-Oxo-2,3,4,4a,5,6-hexahydroindolo[2,1-a]isoquinolin-12-yl) 
acetaldehyde  (2-54) 
To a solution of oxalyl chloride (24.0 μL, 0.28 mmol) in 0.60 mL 
CH2Cl2 at −78 °C, DMSO (40.0 μL, 0.56 mmol) as a solution in 0.40 mL CH2Cl2 was 
added over 10 min. The solution was stirred at −78 °C for 1 h. A solution of alcohol 2-53 
(39.0 mg, 0.14 mmol) in 0.40 mL CH2Cl2 was then added over 15 min, and stirred at −78 
°C for 2 h. After the slow addition of Et3N (137 μL, 0.98 mmol) over 15 min, the solution 
was allowed to stir at −78 °C for 1 h, and then warmed to RT over 30 min. The reaction 
mixture was diluted with 5.00 mL CH2Cl2 and then poured into a half saturated solution 
of NaCl (15.0 mL). The heterogeneous mixture was separated and the aqueous layer was 
extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers were dried (MgSO4) 
and filtered through Celite. After the solution was concentrated under reduced pressure, 
the title compound was isolated as colorless oil and used immediately. Rf 0.61 (50% 
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EtOAc/hexanes).
 1
H NMR (400 MHz, CDCl3)  9.74 (t, J= 2.1, Hz, 1H), 8.50 (d, J = 8.0 
Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.37-7.28 (m, 2H), 6.27 (bs, 1H), 3.96 (dd, J = 16.6, 
1.7, Hz, 1H), 3.81 (dd, J = 16.8, 2.3, Hz, 1H), 2.89 (dd, J = 16.3, 4.6, Hz, 1H), 2.86-2.75 
(m, 1H), 2.53 (dd, J = 16.1, 13.2, Hz, 1H), 2.36-2.22 (m, 2H), 2.10-2.07 (m, 1H), 1.87-
1.83 (m, 1H), 1.61-1.50 (m, 1H), 1.37-1.28 (m, 1H); 
13
C NMR (100 MHz, CDCl3)  
198.5, 168.7, 135.9, 133.9, 130.6, 128.9, 127.7, 125.5, 124.2, 117.9, 116.6, 107.5, 41.3, 
40.6, 33.9, 29.8, 26.2, 20.6. 
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CHAPTER 3: Progress Towards the Total Synthesis Biselide A and E 
 
3.1 Introduction  
  
 Many research groups have developed efficient methods for the synthesis and 
derivatization of 2,5-trans-tetrahydrofuran (THF) rings due to their presence in a wide 
array of biologically active natural products, including biselide A and E (Figure 3.1).
1
 
One particularly useful strategy to form trans-THF rings was developed by Mukaiyama 
in 1990, which involves the oxidative cyclization of pentenols with a variety of cobalt 
catalysts.
2
 
 
 
Figure 3.1 Natural products containing trans-THF rings 
 
 The utility of the Mukaiyama oxidative cyclization has already been shown in our 
research group through the total synthesis of (−)-aplysiallene3 and bullatacin,4 where we 
envisioned the methodology could also be used to access biselide A and E (Figure 3.1). 
The cobalt catalysts employed by Mukaiyama (first generation catalysts) are effective in 
the methodology; however, our research group recently reported a second generation 
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catalyst that has been shown to provide the desired trans-THF products in higher yields 
and with significantly simplified purification compared to the first generation catalysts.
5
 
Herein, we report the progress towards the total synthesis of biselide A and E, where the 
second generation cobalt catalyst is employed for the formation of the trans-THF core in 
each target molecule.  
  
3.2 Mukaiyama Oxidative Cyclization  
 
3.2.1 First Generation Cobalt Catalysts  
 
 The Mukaiyama oxidative cyclization of pentenols has become one of the most 
useful methods for constructing trans-THF rings in good yields and excellent 
diastereoselectivity (>99:1 dr).
2
 While the mechanistic details of the oxidative cyclization 
are not well understood, Hartung has made significant mechanistic contributions and has 
proposed a generally accepted radical mechanism.
6
 The three cobalt catalysts employed 
by Mukaiyama are known as the first generation catalysts, and they feature ligands with 
acetylacetonate (acac) and amide moieties, with substituents including a piperidine ring 
(piper, 3-5), morpholine unit (modp, 3-6) and dibenzyl linkages (diBn, 3-7) (Figure 3.2). 
 
 
Figure 3.2 First generation cobalt catalysts  
 
 Our research group has applied the Mukaiyama oxidative cyclization of pentenols 
to generate the trans-THF rings found in two natural products, including bullatacin (3-
3),
4
 that contains a bridged bis-THF core (Scheme 3.1), and (−)-aplysiallene (3-4),3 which 
features a fused bis-THF ring core (Scheme 3.2). The total synthesis of bullatacin began 
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with a double allylation of diepoxide (R,R)-3-8, which was mono-acylated to 
desymmetrize the molecule. This cyclization precursor (3-9) underwent an efficient 
oxidative cyclization, catalyzed by Co(modp)2 in 82% yield. Protection of the resulting 
primary alcohol as the silyl ether, followed by removal of the acetate protecting group 
gave rise to another cyclization precursor, which furnished the second trans-THF ring (3-
11) in 79% yield and with complete stereocontrol. This advanced intermediate was then 
carried through a variety of chemical transformations to ultimately give bullatacin in 17 
total steps from epoxide (R,R)-3-8 and 13.3% overall yield. 
 
 
Scheme 3.1 Total synthesis of bullatacin 
 
 To further demonstrate the utility of the Mukaiyama oxidative cyclization, our 
group used the methodology to complete the first total synthesis of (−)-aplysiallene 
(Scheme 3.2).
3
 The core of the natural product was constructed in a similar fashion to the 
bullatacin synthesis, beginning with a double vinylation of diepoxide (S,S)-3-8. Mono-
acylation gave pentenol 3-12 which underwent the first Co(modp)2 catalyzed Mukaiyama 
oxidative cyclization to give trans-THF 3-13 in 80% yield. Following some protecting 
group manipulations, the second trans-THF ring (3-14) was also efficiently constructed 
using the oxidative cyclization. With the unique fused bis-THF ring core in place, the rest 
of the natural product was completed to give (−)-aplysiallene in 16 total steps in 2.3% 
overall yield. 
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Scheme 3.2 Total synthesis of (−)-aplysiallene 
 
3.2.2 Second Generation Cobalt Catalyst  
  
 Although the first generation cobalt catalysts (Figure 3.2) used in the Mukaiyama 
oxidative cyclization of pentenols provide trans-THF ring products in good yield and 
diastereoselectivity, there were oftentimes difficulties associated with the catalysts. 
During the course of the reaction, the first generation catalysts decompose into other 
active cobalt residues that catalyze undesired side-reactions, producing over-oxidation 
products and lowering the overall yield. After the reaction is complete, these cobalt 
residues are very difficult to remove from the trans-THF product even after purification 
by column chromatography, which result in difficulties with spectroscopic 
characterization due to the paramagnetic nature of cobalt. The problems associated with 
purifying the THF products from the first generation cobalt catalysts, urged our group to 
develop a new catalyst.
5
     
 Our initial approach towards a second generation cobalt catalyst involved using 
the first generation catalysts as a template, and modifying the amide substituent of the 
ligand to exhibit increased polarity. This method has been successful in a variety of areas 
including water soluble ligands and reagents, sulphonated phosphines, fluorous phases, 
ionic liquids.
7
 This strategy led us to replace the neutral morpholine unit found in the 
modp ligand (3-6) with a basic N-methyl piperazine (3-15), henceforth known as nmp 
(Figure 3.3, protonated ligands shown). The tertiary amine in nmp could be protonated by 
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acid or quaternarized by alkylation which would provide a convenient method of removal 
from the reaction mixture by aqueous work-up. 
 
 
Figure 3.3 First generation modp and second generation nmp ligands 
 
 The synthesis of Co(nmp)2 began with reaction of ethyl oxalyl chloride with N-
methyl piperazine and triethylamine, which furnished glyoxyalate 3-18 in 99% yield 
(Scheme 3.3). Claisen condensation of 3-18 with pinacolone followed by a non-aqueous 
acidic quench gave a 95% yield of the nmp ligand. Finally, complexation of the nmp 
ligand to cobalt was achieved in near quantitative yield using a modified procedure 
involving the addition of four equivalents of water. The second generation catalyst for the 
Mukaiyama oxidative cyclization, Co(nmp)2, is readily accessible as it can be prepared 
quickly on gram scale from inexpensive commercially available starting materials, using 
centrifugation as the only method of purification.
8
 
 
 
Scheme 3.3 Synthesis of Co(nmp)2 
  
 When Co(nmp)2 is employed in a cyclization reaction, purification can be 
accomplished using one of three methods, each catering to specific functional group 
sensitivity. The first two purifications involve the ligand’s ability to quaternize, due to the 
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basic N-methyl piperazine unit in Co(nmp)2. One method involves an acidic (pH 4) buffer 
wash,
9
 which allows the catalyst to move from the organic to the aqueous layer upon 
work-up. Alternatively, a neutral procedure was introduced for acid sensitive substrates 
which involve methylation using MeI followed by neutral aqueous workup.  
 The third purification method was developed after our group serendipitously 
discovered that Co(nmp)2 had an Rf of 0.00 in 100% ethyl acetate, whereas the first 
generation catalysts had similar Rf’s to the trans-THF products formed in the reaction. 
This finding allowed us to avoid an aqueous workup completely, by first removing the 
solvent from the reaction mixture under reduced pressure, dissolving the residue in ethyl 
acetate, and directly filtering the heterogeneous mixture through a pad of silica over 
Celite. This third purification method is the most convenient, results in the highest yields, 
and also caters to substrates that contain functionalities that are incompatible with acidic 
or methylating conditions. With all three work-up methods, trans-THF products are 
obtained in high purity as crude reaction mixtures. Additionally, pre-activation of 
Co(nmp)2 can be performed in order to facilitate the oxidative cyclization of peroxide 
sensitive substrates.
10
   
 The performance of the second generation catalyst Co(nmp)2 was compared to the 
first generation catalysts, and in all cases, cyclization reactions performed with Co(nmp)2 
resulted in increased yields and with fewer side-products. This second generation catalyst 
system also features a mild and simple isolation and purification procedure, proving to be 
a vast improvement over the first generation catalysts where removal of the cobalt 
residues are difficult or impossible. This highlights the superiority of our second 
generation catalyst Co(nmp)2, and its value in the synthesis of natural products containing 
trans-THF rings.  
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3.3 Biological Activity  
 
 The first members of the haterumalide family of natural products were isolated in 
1999 from an Okinawan sea sponge Ircinia sp. and ascidian Didemnidae sp. off of the 
coast of Japan,
11
 while several members of the biselide family were isolated years later 
from an Okinawan ascidian Didemnidae sp.
12
 Many of the haterumalides and biselides 
have been investigated for thier biological activity, where haterumalide NA (3-19) has 
attracted the most attention (Figure 3.4). Biselide A and E are closely related analogs, 
where a possible biosynthetic pathway to 3-1 from 3-2 may involve lactone disconnection 
of the 14-membered macrocycle where the carbonyl at C-1 may cyclize onto the alcohol 
at C-20 along with condensation to form the unsaturation at C-2/C-3 in Biselide E.    
 
 
Figure 3.4 Biselide A and E, haterumalide NA and haterumalide NA methyl ester 
 
 Haterumalide NA (3-19) was found to exhibit strong cytotoxity against murine 
lymphoma cell lines (P388 cells) with an IC50 of 0.32 μg/mL, while also demonstrating 
acute toxity with an LD99 of 0.24 g/kg in mice.
11 
The artificial analogue of 3-19, the C-19 
methyl ester of haterumalide NA (3-20), was also screened for its bioactivity and was 
found to demonstrate an IC50 of 0.14 μg/mL against human lung cancer cells (NCI-
H460).
11
 Biselide A (3-1), however, was shown to be most cytotoxic against human colon 
cancer cells (DLD-1) with an IC50 of 0.51 μg/mL.
11
 Unfortunately, the bioactivity of 
biselide E has yet to be explored.
12b
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3.4 Previous Syntheses of the Haterumalides and the Biselides  
 
3.4.1 Previous Syntheses Towards Haterumalide NA and its Derivatives  
 
 Among the related members of the haterumalide and biselide families, 
haterumalide NA (3-19) continues to attract the most synthetic attention due to its 
biological activity.
13
 Initially, spectroscopic analysis helped elucidate the relative 
stereostructure of 3-19, and the absolute stereochemistry was revised following the total 
synthesis of ent-haterumalide NA methyl ester (ent-3-20) in 2003 by Kigoshi and co-
workers.
13a
   
 
 
Scheme 3.4 Kigoshi’s progress towards ent-haterumalide NA methyl ester 
 
 Kigoshi’s synthesis began with the coupling of THF 3-22 (derived from 
commercially available (+)-2,3-O-isopropylidene-L-threitol) and Z-alkenylsilane 3-21, 
which was prepared from 3-butyn-1-ol (Scheme 3.4). The resulting substrate 3-23 
underwent a variety of chemical transformations to functionalize the side-chain (3-24), 
prior to TBS removal and acylation of the resulting alcohol. Acidic deprotection of the 
allylic alcohol and DMP oxidation furnished 3-25 in good yield.  
86 
 
86 
 
 
Scheme 3.5 Kigoshi’s total synthesis of ent-haterumalide NA methyl ester 
 
 Intramolecular Reformatsky-type reaction of 3-25, followed by DDQ oxidation of 
the PMB ether revealed the desired cyclized product 3-26 in a low 8% yield over the two 
steps (Scheme 3.5). Nozaki-Hiyama-Kishi coupling reaction of iodide 3-27 and the 
aldehyde derived from a DMP oxidation of 3-26 afforded ent-haterumalide NA methyl 
ester (ent-3-20) in 57% over two steps in an 11:1 diasteromeric ratio. Unfortunately, all 
attempts to hydrolyze the methyl ester to the carboxylic acid found in the natural product 
were unsuccessful. As such, the synthetic material was compared to the methyl ester 
derivative of haterumalide NA and was found to be its enantiomer. This discrepancy 
between the synthetic and natural material allowed Kigoshi to assign the correct absolute 
stereochemistry of the natural product. 
 It wasn’t until 2005 that Hoye and co-workers reported the first total synthesis of 
haterumalide NA as the natural enantiomer (Scheme 3.6).
13c
 In this report, advanced 
intermediate ene-yne 3-28 underwent an efficient Pd(II)-mediated chloroallylative 
cyclization in an overall 91% yield, albeit in a low isomeric ratio (1:1.4 Z/E, 38% of the 
desired Z-isomer 3-29). Luche reduction of the α,β-unsaturated ester (3-29) gave the 
desired alcohol as a single diastereomer, which was followed by protection of the 
secondary alcohol as an acetate and removal of the PMB ether under oxidative conditions 
to give ent-3-26 (the enantiomer of Kigoshi’s intermediate in Scheme 3.5) in 84% yield 
over three steps. Oxidation of the resulting primary alcohol set the stage for the Nozaki-
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Hiyama-Kishi coupling reaction with iodide 3-30. Hoye’s choice of iodoalkene, which 
featured a PMB ester instead of the methyl ester (3-27) used by Kigoshi was crucial to 
the completion of the molecule because he could successfully hydrolyze it, where 
Kigoshi failed to do so. This final transformation allowed Hoye and co-workers to 
complete the first total synthesis of haterumalide NA (3-19).   
 
 
Scheme 3.6 Hoye’s total synthesis of haterumalide NA 
  
3.4.2 Previous Attempts Toward the Synthesis of the Biselides 
 
 One year after Kigoshi and co-workers confirmed the absolute stereochemistry of 
haterumalide NA (3-19), they began to isolate several members of a related family of 
natural products, the biselides, from an Okinawan ascidian Didemnidae sp. Using 
spectroscopic analysis, the biselides were found to be oxygenated derivatives of the 
haterumalides, based on analogy to the haterumalide family.
12
 
12
Although the absolute 
stereochemistry of the biselides has yet to be confirmed by synthetic methods, there have 
been attempts towards their synthesis. Cossy and co-workers constructed the unique C1-
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C8 fragment of biselide E, where they envisioned a Suzuki-Miyaura coupling reaction to 
access the natural product.
14
  
  
 
Scheme 3.7 Cossy’s synthesis of RCM precursor 3-34  
 
 The synthesis of the fragment began with commercially available β-
trichloromethyl-β-propiolactone 3-31, which was converted to iodoalkene 3-32 in four 
steps (Scheme 3.7). This coupling partner then participated in a Stille cross-coupling 
reaction and was reduced with DIBAL to give diene 3-33. The alcohol was then 
functionalized with acryloyl chloride to give RCM precursor 3-34 in 91% yield.  
 
 
Scheme 3.8 Cossy’s synthesis of the C1-C8 fragment of biselide E 
 
 Acrylate 3-34 underwent efficient ring closing metathesis to afford γ-alkylidene 
α,β-unsaturated δ-lactone 3-35 in 77% yield (Scheme 3.8). Protection of the carbonyl 
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group (3-35) as a methyl acetal was achieved in two steps, which simultaneously 
removed the TES ether to reveal a secondary alcohol that was subsequently protected as 
an acetate group (3-36). The C1-C8 fragment of biselide E was then completed with a 
SmI2–mediated elimination reaction to form gem-dichloroalkene 3-37.  
 Kigoshi and co-workers have also recently reported the synthesis of the carbon 
backbone of biselide A, B, and E (Scheme 3.9),
15
 which was closely related to their 
previous syntheses towards the haterumalides.
13d
 Their first approach involved 
functionalizing the aldehyde sidechain in 65% yield over a three step sequence from 3-38 
(Horner-Wadsworth-Emmons olefination, DIBAL reduction, and silyl protection), to 
furnish iodo olefin 3-39 (Scheme 3.9, route 1).
15a
 The iodo alkene then participated in a 
Stille coupling reaction with tributyl(vinyl)tin, which gave terminal olefin 3-40. 
Dihydroxylation with OsO4 in aqueous acetone resulted in low regioselectivity at the 
terminal olefin over the internal variant, but still provided the desired diol 3-41 in 30% 
yield over the two steps. Oxidative cleavage of the diol (3-41) gave rise to aldehyde 3-42, 
which was carried forward to furnish the framework of the biselides. 
  Since their initial Stille/dihydroxylation protocol did not give an efficient route to 
the biselide core, Kigoshi and co-workers described an alternative approach (Scheme 3.9, 
route 2).
15b
 This new method began with advanced intermediate (3-38), which underwent 
a Horner-Wadsworth-Emmons olefination followed by DIBAL reduction, as described in 
their previous haterumalide syntheses.
13d
 After protection of the allylic alcohol 3-43 as a 
p-nitrobenzoyl group in 89% yield, a regioselective allylic oxidation installed the alcohol 
in 3-45 in 35% yield. Finally, a three step protocol was followed to give aldehyde 3-42, 
involving protection of the allylic alcohol as a TBDPS ether, cleavage of the PNB group, 
and DMP oxidation.  
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Scheme 3.9 Kigoshi’s studies toward aldehyde 3-42 
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 Kigoshi and co-workers then utilized aldehyde 3-42 as a precursor to the carbon 
backbone found in biselide A, B, and E (Scheme 3.10). The aldehyde was taken through 
the same chemical transformations as in the haterumalide syntheses, to access 
macrolactone 3-46.
15b
 Aldehyde 3-42 also underwent a series of transformations 
including a Wittig olefination, Stille cross-coupling and cyclization to form the α,β-
unsaturated lactone 3-47. Both intermediates (3-46 and 3-47) could be used to access 
biselide A, B, and E, as well as members of the haterumalide family.    
 
 
Scheme 3.10 Kigoshi’s studies toward the biselide framework from aldehyde 3-42 
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3.5 Progress Towards the Total Synthesis of Biselide A  
  
3.5.1 Retrosynthesis   
 
 Upon retrosynthetic analysis, biselide A could be disconnected into three 
fragments, including β-hydroxyacids 3-48 or 3-49 (the southern fragments), the trans-
THF core 3-50 or 3-51 (the northern fragments), and the side-chain 3-54 (Scheme 3.11). 
An esterification reaction followed by a RCM (with 3-48 and 3-50) or RRCM (with 3-49 
and 3-51) was envisioned to construct the 14-membered ring, while the side-chain (3-54) 
could be appended using the Nozaki-Hiyama-Kishi reaction as demonstrated in the 
haterumalide syntheses.
13
 The chloroalkenes (3-50 and 3-51) could be accessed via a 
chloropalladation reaction of 3-52, while the trans-THF ring could be furnished using the 
second generation cobalt catalyzed Mukaiyama oxidative cyclization with syn-diol 3-53. 
 
 
Scheme 3.11 Retrosynthesis of biselide A 
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3.5.2 Constructing the Northern Fragment  
 
3.5.2.1 Asymmetric Aldol Reactions  
 
 Chiral auxiliary mediated asymmetric aldol addition reactions have become a 
powerful method for asymmetric carbon-carbon bond formation.
16
 A key contribution in 
this field was supplied by Evans, in the development of the oxazolidinone aldol 
reaction.
17
 This highly diastereoselective method allows access to Evans’ syn and non-
Evans syn aldol products depending on the reaction conditions (Figure 3.5).  
 
 
Figure 3.5 Oxazolidinone aldol products 
 
 Asymmetric aldol reactions have seen a great deal of success when employing 
propionates (Figure 3.6, R
1
= Me), whereas acetate aldol reactions remain a challenge 
(R
1
= H). N-Acyloxazolidinones are among the most commonly used chiral auxiliaries to 
construct β-hydroxy acid derivatives. The α-substituent in the auxiliary (R1= Me) plays a 
key role in facial differentiation, which ultimately results in a single diastereomer 
product. Using boron enolates 3-55a and 3-55b, the aldol reaction can proceed via four 
Zimmerman-Traxler transition states. Assuming the aldehyde substituent R
2
 remains in 
the equatorial position, it must approach the enolate opposite to the bulky isopropyl 
substituent of the auxiliary, favoring transition states 1 and 4. Although undesirable 
dipole interactions somewhat disfavor transition state 4, unfavorable allylic strain 
interactions play a more influencial role in the resulting diastereoselectivity. The allylic 
strain observed between the isopropyl group and R
1 
disfavor transition state 4 over 
transition state 1 with the propionic enolate 3-55a, resulting in the formation of the Evans 
syn product exclusively (>20:1 of Evans syn:non-Evans syn). In the case of an acetate 
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aldol (3-55b, where R
1
= H), the aforementioned unfavorable allylic strain interactions are 
absent and poor selectivity is observed.  
 
Figure 3.6 Influence of the α-substituent in boron mediated aldol reactions 
 
 The poor diastereoselectivity observed with acetate aldol reactions (where R= H) 
has led to the development of several chiral auxiliaries that are designed to overcome the 
lack of α-substitution. Based on work developed by Evans, Nagao introduced a new class 
of N-acetyl-1,3-thiazolidine-2-thione auxiliaries that were shown to give aldol products 
with high diastereocontrol using tin(II) triflate as the Lewis acid (Figure 3.7).
18
 The same 
thiazolidinethione auxiliaries were later extended to give highly selective acetate aldols 
with dichlorophenylborane as the Lewis acid using sparteine as the base.
19
  
 
 
Figure 3.7 Chiral aldol auxiliaries 
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 Crimmins extended the use of Nagao’s auxiliary to include N-propionyl 
oxazolidinethiones and thiazolidinethiones with titanium(IV) chloride, where both the 
Evans syn and non-Evans syn products could be obtained by controlling the amount and 
nature of the base and Lewis acid.
20
 Based on those results, Olivo explored the same 
conditions to include acetate aldols while also employing a titanium enolate (Figure 
3.8).
21
 A closed transition state is formed when one or less than one equivalent of base 
relative to titanium(IV) chloride is employed, ultimately leading to the acetate syn 
product. However, if an excess of base is used, the thiocarbonyl of the chiral auxiliary is 
no longer coordinated to the titanium which leads to an open transition state that 
generates the acetate anti product.  
 
 
Figure 3.8 Titanium mediated aldol reactions 
 
3.5.2.2 Examining Asymmetric Aldol Reactions  
 
 In order to explore Olivo’s titanium mediated aldol addition in our synthesis, we 
first set out to synthesize a small set of thiazolidinethione auxiliaries, as described in the 
literature (Scheme 3.12). The synthesis of mesityl substituted auxiliary 3-58 began by 
treating (R)-tBuSONH2 (3-56) with anhydrous α-chloroacetylaldehyde and CuSO4 to 
generate imine 3-57 in 82% yield. Grignard addition with excess mesityl magnesium 
bromide in toluene followed by cyclization with carbon disulfide in basic water gave the 
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auxiliary in 58% over two steps.
22
 Two additional thiazolidinethione auxiliaries (3-61 and 
3-62) were prepared by a different method involving the reflux of amino alcohols 3-59 
and 3-60 with carbon disulfide in a basic ethanol solution.
18
 The chiral auxiliaries (3-58, 
3-61 and 3-62) were all subjected to acylation conditions to give 
acetylthiazolidinethiones 3-63, 3-64 and 3-65 in good yields. 
 
 
Scheme 3.12 Synthesis of thiazolidinethione auxiliaries 
 
 The synthesis of the northern fragment began with a titanium mediated aldol 
reaction with acetylthiazolidinethione 3-64 and aldehyde 3-67, which was prepared by 
mono-silylation
23
 and oxidation of 1,3-propanediol (Scheme 3.13). The asymmetric aldol 
gave the desired alcohol in 87% yield and modest diasteroselectivity (7:1 dr). 
Fortunately, the diastereomers were separable by column chromatography, allowing for 
isolation of diastereomerically pure 3-68. Cleavage of the auxiliary with N,O-
dimethylhydroxylamine hydrochloride gave rise to Weinreb amide 3-69 in 92% yield, 
with full recovery of auxiliary 3-61. The amide was subsequently treated with vinyl 
magnesiumbromide to furnish α,β-unsubstituted ester 3-70. Unfortunately, a syn-
reduction under Prasad reduction conditions (Et2BOMe, NaBH4) led to an inseparable 
mixture of diols (3-71 and 3-72), promoted by an uncontrollable silyl migration.   
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Scheme 3.13 Initial asymmetric aldol and silyl migration 
 
 To circumvent the silyl migration problem, an alternative route to the northern 
fragment of biselide A was explored. Rather than a protected alcohol as a 
functionalizable handle, we envisioned a more efficient substituent such as an alkyne that 
could be directly converted to the chloroalkene in the natural product. This new approach 
involved the use of acetylthiazolidinethione 3-64 again, but this time employed 
commercially available pent-4-ynal, in the asymmetric aldol reaction (Scheme 3.14). 
While the aldol reaction proceeded in modest diastereoselectivity (6:1 dr), the product (3-
74) was only obtained in 27% yield.  
 
 
Scheme 3.14 Aymmetric aldol with terminal alkyne present 
 
 We speculated that the terminal alkyne was interfering with the reaction process, 
so we investigated the same approach while employing a silyl protected alkyne (Scheme 
3.15). In this case, aldehyde 3-76 and acetylthiazolidinethione 3-64 furnished alcohol 3-
77 in 85% yield with modest diastereoselectivity (6:1 dr). In an attempt to increase the 
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diastereoselectivity, bulkier acetylthiazolidinethiones were used in the aldol reaction, 
where the best results were observed with tert-butyl substituted auxiliary 3-65 which 
gave a 10:1 ratio of diastereomers and similar yield. Interestingly, mesityl substituted 
acetylthiazolidinethione 3-63 produced the lowest diastereomeric ratio, suggesting that 
extensive steric bulk on the auxiliary may be detrimental to the diastereoselectivity in a 
titanium mediated aldol reaction when operating through an open transition state. While 
satisfied with the yield and selectivity observed with the tert-butyl substituted auxiliary 3-
65, separation of the diastereomers (3-78) proved to be tedious on large scale reactions 
(>2 mmol), so additional methods were explored. 
 
 
Scheme 3.15 Asymmetric aldol with 3-76 and a variety of acetylthiazolidinethiones  
 
3.5.2.3 Examining Braun’s HYTRA Auxiliary  
 
 We then turned our attention to Braun’s (S)-2-hydroxy-1,2,2-triphenylethyl 
acetate (HYTRA) auxiliary.
24
 This chiral auxiliary has been shown to provide excellent 
enantiofacial differentiation with doubly deprotonated HYTRA to a variety of aldehydes, 
obtaining β-hydroxy carboxylic acids in high yield and enantiopurity.  
 As such, we envisioned the use of Braun’s asymmetric aldol addition as a 
potential strategy towards the northern fragment of biselide A. Synthesis of the HYTRA 
auxiliary was performed according to Braun’s method of double Grignard addition into 
(S)-mandelate with freshly prepared phenylmagnesium bromide (Scheme 3.16).
25a
 
Esterification with acetic anhydride and scandium (III) triflate provided HYTRA acetate 
3-82 from diol 3-81 in 77% yield.
25b
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Scheme 3.16 Synthesis of Braun’s HYTRA acetate auxiliary 
 
 Braun found that moderate diastereoselectivities were obtained upon 
deprotonation with LDA at −78 °C, however, selectivity markedly improved when the 
lithium enolate was transmetallated with magnesium bromide and temperatures were 
decreased to −115 °C. With HYTRA acetate 3-82 in hand, the auxiliary was treated with 
two equivilents of LDA, transmetallated with magnesium bromide to form dianion 3-83, 
and treated with aldehyde 3-76 at −115 °C (Scheme 3.17). The aldol addition proceeded 
with superior diastereoselectivity (>20:1 dr), but only provided diol 3-84 in 53% yield, so 
alternative asymmetric aldol protocols were explored.  
 
 
Scheme 3.17 Asymmetric aldol with 3-76 and the HYTRA acetate auxiliary 
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3.5.2.4 Examining Evans’ Oxazolidinone Auxiliary  
 
 Having explored several asymmetric aldol reactions, we had found that 
thiazolidinethione auxiliaries gave relatively low diastereoselectivity in good yield, while 
HYTRA acetate auxiliaries gave superior selectivity in low yield. Encouraged that we 
could find a protocol that featured the best of both methods, we turned our attention to 
Evans’ well known boron mediated oxazolindinone aldol addition reaction.17 As 
previously mentioned, acetyloxazolindinone aldol reactions lack the allylic strain 
between the α-position and the auxiliary required to achieve high diastereoselectivity 
(Figure 3.6). One solution to this problem involves the temporary incorporation of an α-
substituent to afford high selectivity, but can be easily removed after the aldol reaction. 
Both methylthioacetate
17
 and chloroacetate
26
 oxazolindinones serve as effective 
auxiliaries in boron mediated asymmetric aldol reactions with a variety of aldehydes, 
furnishing β-hydroxy carbonyl adducts in high yield and diastereoselectivity. Removal of 
the temporary α-substituents under mild reductive conditions followed by cleavage of the 
recyclable auxiliary provides access to optically pure products.  
 To investigate this alternative to acetate aldols, we began by constructing both 
auxiliaries (R)- and (S)-3-86 from (R)- and (S)-phenylalanine (3-85) according to Evans’ 
original method (Scheme 3.18).
27
 Acetylation of the auxiliaries with chloroacetyl chloride 
proceeded to give (R)- and (S)-3-87, both in 92% yield.
28
 
 
 
Scheme 3.18 Synthesis of chloroacetate oxazolidinone auxiliaries 
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 The boron mediated aldol reaction was performed with (S)-3-87 and aldehyde 3-
76, and we were pleased to find the asymmetric transformation provided the desired α-
chloro-β-hydroxy product (3-88) in 78% yield as a single diastereomer (Scheme 3.19). 
Reductive cleavage of the α-chloro substituent with zinc dust and ammonium chloride 
provided alcohol 3-89 in near quantitative yield.
29
 Treatment with N,O-
dimethylhydroxylamine hydrochloride salt and Me3Al provided Weinreb amide 3-90 in 
80% yield and full recovery of auxiliary (S)-3-86. Finally, displacement of amide 3-90 
with vinyl magnesiumbromide furnished α,β-unsubstituted ester 3-91, which was 
converted to syn-diol 3-92 via Prasad reduction in 68% yield over two steps. 
 
 
Scheme 3.19 Synthesis of Mukaiyama cyclization precursor 3-92 
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 Mukaiyama cyclization precursor 3-92 was subjected to our second generation 
catalyst, Co(nmp)2, and tBuOOH in an oxygen atmosphere at 55 °C for 16 h, which 
furnished the trans-THF ring in 91% yield, with filtration as the only means of 
purification (Scheme 3.20). Protection of diol 3-93 as the PMP acetal proceeded in 93% 
yield, and terminal alkyne 3-95 was accessed upon treatment with basic methanol in near 
quantitative yield.  
 
 
Scheme 3.20 Synthesis of alkyne 3-95 
  
 Recalling the retrosynthetic plan, we envisioned either a RCM (involving 3-97) or 
RRCM (involving 3-99) to construct the 14-membered ring. Working towards RCM 
partner 3-97 first, alkyne 3-95 underwent successful chloropalladation with PdCl2, LiCl, 
and allyl chloride in 83% yield (Scheme 3.21). Then, regioselective PMP acetal cleavage 
of 3-96 with NaBH3CN in TFA/DMF cosolvent gave the desired RCM coupling partner 
(3-97) in trace amounts, along with significant substrate decomposition.
30
 
 Our attention then turned to accessing the RRCM coupling partner (3-99) from 
the same alkyne (3-95) which was used to access the RCM precursor 3-97. Beginning 
again with a chloropalladation reaction, except this time employing 3-chlorobut-1-ene, 
gave rise to the desired chloroalkene 3-98 in 46%. Unfortunately, attempts to execute the 
same acetal cleavage with 3-98 resulted in decomposition. Reproductivity issues with this 
approach along with lack of advanced material did not allow for further exploration of 
these potential coupling partners.   
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Scheme 3.21 Synthesis of northern fragments 3-97 and 3-99 
  
3.5.3 Construction of the Southern Fragment 
 
3.5.3.1 Sharpless Asymmetric Kinetic Resolution  
 
 The synthesis of the southern fragment required for a RCM (3-107) began by 
performing a Baylis-Hillman reaction with methyl acrylate and formaldehyde (Scheme 
3.22). The allylic alcohol 3-101 was subsequently protected as the TBS ether in 89% 
yield over two steps. Reduction of ester 3-102 with DIBAL, followed by Swern oxidation 
gave rise to allylic aldehyde 3-104, which underwent aldol addition with ethyl acetate to 
furnish racemic alcohol 3-105 in 74% yield over three steps.  
 To resolve the material, the racemic mixture was then subjected to Sharpless 
asymmetric kinetic resolution reaction conditions (Ti(OiPr)4, (+)-DET, TBHP). 
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Unfortunately, the desired enantiopure material ((R)-3-105) was obtained in a low 60% 
enantiomeric excess.
31
 Although the material did not have the level of enantiopurity that 
we desired, it could allow insight into the outcome of the ring closing metathesis reaction 
when coupled to northern fragment 3-97, so the material was carried forward. The allylic 
alcohol (R)-3-105 was protected as a TBS silyl ether (95%) and ester 3-106 was 
saponified under basic conditions to give coupling partner 3-107 in 96% yield.  
 
 
Scheme 3.22 Synthesis of southern fragment 3-107 
 
3.5.3.2 Constructing Aldehyde 3-114  
 
  While constructing RCM precursor 3-107, we concurrently worked towards 
making a related southern fragment (3-114) featuring a diene functionality designed to 
facilitate a relay ring closing metathesis reaction. Our approach towards 3-114 involved a 
Baylis-Hillman reaction between methyl acrylate and hex-5-enal (Scheme 3.23).  
 While Baylis-Hillman reactions are a powerful method to couple unsaturated 
carbonyl compounds with aldehydes, they often suffer from poor reaction rates 
particularly with unactivated aldehydes. Various methods have been employed to 
increase the rate of the reaction, including elevated temperature
32
 and pressure,
33
 
ultrasound
32
 and microwave irradiation,
34
 introduction of hydrogen bond donors (eg. 
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MeOH),
35
 phosphines,
36
 and quinuclidine based catalysts.
37
 A variety of these methods 
were examined with our substrates (Scheme 3.23), however, very low reaction 
conversions were observed. The optimal conditions were obtained with DABCO, 
Sc(OTf)3, and diethyl tartrate, a strategy developed by Aggarwal.
38
 Our Baylis-Hillman 
proceeded in 49% yield after 7 days of stirring at room temperature to furnish allylic 
alcohol 3-110.  
 
 
Scheme 3.23 Baylis-Hillman route toward aldehyde 3-114 
 
 This material was subjected to Mitsunobu reaction conditions (PNBOH, DIAD, 
PPh3) to give allylic alcohol 3-110. This reactivity could be described as an SN2' 
Mitsunobu, which could be the result of a tight ion pair. At this point, the PNB protecting 
group on 3-111 was exchanged for a more robust p-methoxybenzyl group in 68% yield 
over two steps. The resulting α,β-unsaturated ester 3-113 was then converted to aldehyde 
3-114 after reduction with DIBAL and Swern oxidation (72% yield over two steps).  
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 While pleased with the overall effectiveness of our initial route towards aldehyde 
3-114, we concurrently explored other methods to ultimately find the most efficient 
synthesis. Our second approach first involved PMB protection of α,β-unsaturated ester 3-
101 (previously synthesized in Scheme 3.22) in 82% yield using 4-methoxybenzyl-2,2,2-
trichloroacetimidate under acidic conditions (Scheme 3.24). The resulting ester 3-115 
was subjected to DIBAL reduction in 86% yield followed by Swern oxidation in near 
quantitative yield.  
 Aldehyde 3-116 was then treated with pent-4-enylmagnesium bromide to give 
allylic alcohol 3-117 in 75% yield. Interestingly, alcohol 3-117 did not undergo the 
expected SN2' reactivity under Mitsunobu reaction conditions, to give 3-118. Instead, the 
substrate followed the traditional SN2 pathway, resulting in p-nitrobenzoyl substituted 
alcohol 3-119, suggesting that the ester moiety in substrate 3-110 (Scheme 3.23) played a 
crucial role in directing the SN2' Mitsunobu reactivity.  
 
 
Scheme 3.24 Unsuccessful grignard addition route toward aldehyde 3-114 
 
 Our third and final approach toward aldehyde 3-114 began with a Wittig reaction 
between commercially available 2,2-dimethyl-1,3-dioxan-5-one (3-120) and 
hexenyltriphenylphosphonium iodide 3-121 (generated from 6-iodohex-1-ene in 94% 
yield), which led to acetal protected allylic diol 3-122 in 95% yield (Scheme 3.25).  
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Scheme 3.25 Synthesis of allylic alcohols as isomeric mixtures 
 
 Removal of the acetal under acidic conditions revealed diol 3-123 in near 
quantitative yield. From this point, we made attempts to selectively differentiate the 
alcohols through a variety of protecting group strategies. Silyl protection with a bulky 
TBS group provided a mixture of products, including a 3:1 inseparable mixture of E:Z 
alcohols (3-124). Bulkier silyl groups including TIPS and TBDPS did not significantly 
increase the ratio of products. Although this route produced an inseperable mixture of 
isomers, this method was high yielding and efficient, where large amounts of material 
could be carried forward.   
 Lastly, PMB protection was explored through treatment of diol 3-123 with 4-
methoxybenzyl-2,2,2-trichloroacetimidate under acidic conditions; however, no 
discrimination between the (E) and (Z)-alcohols was observed (Scheme 3.25, Method 1). 
Protecting the diol as a PMP acetal prior to DIBAL reduction however, produced a 2:1 
mixture of E:Z alcohols in 92% overall yield (Method 2). Although the geometric isomers 
were separable, these methods would not be an efficient way to access aldehyde 3-114.  
 Although both working routes (Baylis-Hillman method in Scheme 3.23 and 
alcohol differentiation method in Scheme 3.25) were not as efficient as we had hoped, 
they had given access to considerable amounts of 3-114, so we decided to continue our 
synthesis towards the southern fragment of biselide A.  
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3.5.3.3 Asymmetric Aldol Approach to the Southern Fragment 
 
 Analagous to the synthesis of the northern fragment, we envisioned accessing the 
southern piece via an asymmetric aldol while employing the same 
acetylthiazolidinethiones, but this time operating through the closed transition state to 
access acetate syn products (see Figure 3.8). The reaction with aldehyde 3-114 and 
acetylthiazolidinethiones 3-64 and 3-65, provided allylic alcohols 3-126 and 3-127, 
respectively, in modest yields and diastereomeric ratios (Scheme 3.26). The best results 
were achieved with tert-butyl auxiliary 3-65, where a 7:1 ratio of diastereomers (3-127) 
was obtained in 64% yield.  
 
 
Scheme 3.26 Asymmetric aldol with 3-114 and acetylthiazolidinethiones 
  
 Attempts to improve the asymmetric aldol involved exploring Braun’s HYTRA 
acetate auxiliary next, where the stereochemistry at the alcohol would require inversion 
(Scheme 3.27). Although 3-128 was obtained with exceptional diastereoselectivity, the 
reaction proceeded in poor yield, which was analogous to our previous findings with 
Braun’s auxiliary (see Scheme 3.17). 
 
 
Scheme 3.27 Asymmetric aldol with 3-114 and the HYTRA acetate auxiliary 
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 Given that superior yields and diastereoselectivities were achieved with 
chloroacetate oxazolidinone (S)-3-87 for the synthesis of the northern fragment, we were 
confident that a similar approach could also be utilized to access the southern fragment.  
Initial attempts involved an aldol addition between aldehyde 3-129 and auxiliary (R)-3-
87, which did not generate the desired adduct 3-130 but resulted in substrate 
decomposition (Scheme 3.28). It was suspected that silyl protecting groups were not 
compatible with the reaction conditions, so alternative protecting groups were explored. 
 
 
Scheme 3.28 Chloroacetate oxazolidinone auxiliary approach with aldehyde 3-129 
 
 Fortunately, aldehyde 3-114 containing a p-methoxybenzyl protecting group 
participated in the boron mediated asymmetric aldol reaction with (R)-3-87, furnished 
chlorohydrin 3-131 in 75% yield as a single diastereomer (Scheme 3.29). Pleased with 
the diastereoselectivity of this reaction, we decided to use this material to further explore 
the synthesis of southern fragment. 
 
 
Scheme 3.29 Chloroacetate oxazolidinone auxiliary approach with aldehyde 3-114 
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3.5.3.4 Attempts to Construct 3-134 
 
 Efforts toward the southern fragment of biselide A continued by subjecting the 
aldol adduct (3-131) to dehalogenation reaction conditions (Scheme 2.30). Unfortunately, 
a mixture of products was obtained from the reductive reaction including the desired 
product (3-132) and suspected ene-yne 3-133 as a 3:1 ratio, in an overall 86% yield.
39
 
 Attempts to attenuate the production of the suspected ene-yne 3-133 by varying 
the reaction temperature (−20 °C to RT), reaction times (10 seconds, 1 and 5 minutes), 
and water content (anhydrous and reagent grade MeOH), were all unsuccessful. 
Regrettably, further studies towards the southern fragment of biselide A (3-134) was not 
possible due to lack of material and time constraints. 
 
 
Scheme 3.30 Dechlorination of chlorohydrin 3-131 
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3.5.4 Future Work 
 
 With viable routes towards all four fragments (RCM partners 3-97 and 3-107 and 
RRCM partners 3-99 and 3-134), formation of the 14-membered macrocycle (3-135) 
could be investigated via an esterification and metathesis reactions (Scheme 3.31).   
 
 
Scheme 3.31 Future work towards biselide A 
 
 Regarding the methathesis ring closing strategy, Hoye and Wang have made 
contributions towards a very similar 14-membered macrocycle in their work towards the 
total synthesis of haterumalide NA.
13c,40
 Hoye’s initial attempts involved ring closing 
metathesis substrate 3-136 and relay substrate 3-137 but all of their attempts with Grubbs 
II catalyst failed to produce the desired macrocycle and were only met with starting 
material recovery (with RCM substrate 3-136), or substrate truncation with RRCM 
substrate 3-137 to give 3-138 (Scheme 3.32). Substrate truncation is the result of initial 
metathesis or relay event, where the corresponding ring closing event does not occur. 
With both RCM and RRCM reactions, dimerization was also detected.  
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Scheme 3.32 Hoye’s RCM and RRCM attempts 
 
 In order to investigate the effect of ring strain during the metathesis ring closing 
reaction, Hoye explored a similar macrocycle formation with “relaxed” substrates (3-139, 
3-140, and 3-141) that did not contain the trans-THF ring (Scheme 3.33). Remarkably, 
all of the “relaxed” substrates closed to the desired 14-membered lactones (3-142, 3-143, 
and 3-144). These results suggest that the there is significant ring strain in the bridged 
bicycle found due to the trans-THF ring.  
 
  
Scheme 3.33 Hoye’s RRCM with “relaxed” substrates 
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 In the event that our RCM/RRCM attempts do not give rise to our desired 14-
membered macrocycle, the use of a tether (3-145) would be employed in order to 
circumvent the suspected ring strain (Scheme 3.34). This 4-atom tether would expand the 
RRCM reaction to give an 18-membered macrocycle, which would likely have a 
significant decrease in ring strain, even with the trans-THF intact. Expanded substrate 3-
145 would give rise to macrocycle 3-146, which could then undergo saponification 
reaction to release the tether. The resulting substrate could furnish the required 14-
membered macrocycle (3-135) via lactonization. The synthesis would then conclude with 
a Nozaki-Hiyama-Kishi reaction to append the side-chain, followed by some protecting 
group manipulations. 
 
 
Scheme 3.34 Tethered RRCM reaction and completion of biselide A  
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3.6 Progress Towards the Total Synthesis of Biselide E  
 
3.6.1 Retrosynthesis   
 
 Synthetic efforts towards biselide A and E were performed concurrently, where 
we employed similar strategies to execute fragments of each natural product. Upon 
retrosynthetic analysis, biselide E was divided into three fragments, including the γ-
alkylidene α,β-unsaturated δ-lactone piece 3-147 (western fragment), the trans-THF core 
3-149 (eastern fragment), and side-chain 3-54 (Scheme 3.35). A Suzuki-Miyaura 
coupling reaction was envisioned between the eastern and western fragments, and the 
side-chain could be appended using the Nozaki-Hiyama-Kishi reaction as demonstrated 
in the haterumalide syntheses.
13
 The γ-alkylidene α,β-unsaturation in the western piece 
could be installed using a Pd-mediated cross-coupling reaction such as a Stille or Suzuki, 
while esterification could construct the lactone, simplifying the synthesis to haloalkene 3-
148. Finally, the eastern fragment could be furnished using the second generation cobalt 
catalyzed Mukaiyama oxidative cyclization with syn-diol 3-150. 
 
 
Scheme 3.35 Retrosynthesis of biselide E 
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3.6.2 Constructing the Western Fragment   
 
3.6.2.1 Stille Cross-Coupling Attempt  
 
 The synthesis of the western fragment began by mono-protecting 1,3-propanediol 
with p-methoxybenzyl bromide followed by oxidation to aldehyde 3-151 (Scheme 3.36). 
Wittig reaction with (carboethyoxy)iodomethylenephosphorane
41
 provided iodoalkene 3-
152, which was functionalized to the silyl ether (3-153) in 90% yield over two steps. 
Unfortunately, all attempts to perform a Stille cross-coupling reaction with either vinyl 
stannane 3-154 or stannylpropenoate 3-155
42
 resulted in recovery of starting material. 
Varying the palladium sources (Pd(MeCN)2Cl2 or Pd(PPh3)4), reaction temperatures, and 
introducing additives such as CuI, had no effect. In an effort to employ Cossy’s 
approach,
14
 ester 3-152 was subjected to Stille reaction conditions, however no reaction 
was observed. Given that 3-152 and 3-153 were resistant to Stille reaction conditions, a 
different Pd-catalyzed cross-coupling was explored. 
 
 
Scheme 3.36 Stille cross-coupling attempts 
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3.6.2.2 Suzuki Cross-Coupling  
 
 With vinyl iodide 3-153 in hand, we set out to explore the Suzuki cross-coupling 
reaction. Fortunately, our first attempt at coupling with vinyl borane
43
 (3-159) afforded 
the γ-alkylidene α,β-unsaturated ester (3-160) with complete stereoselectivity in 84% 
yield (Scheme 3.37). Treatment of ester 3-160 under acidic conditions resulted in silyl 
deprotection and concomitant cyclization to furnish the desired lactone 3-161 in 
quantitative yield. A two step procedure to protect the lactone as a methyl acetal (3-162) 
was then performed in 97% overall yield. Regrettably, this material could not be used to 
access the western fragment 3-164 because all attempts to remove the p-methoxybenzyl 
protecting group (both oxidative and lewis acidic conditions) caused substrate 
decomposition. At this time, we decided to explore a different protecting group that could 
accommodate the sensitive diene system. 
 
 
Scheme 3.37 Suzuki cross-coupling approach 
 
 To circumvent product decomposition observed previously, a TBDPS group was 
envisioned since it could prove robust enough to survive the subsequent chemistry, but 
labile enough to remove using mild conditions (TBAF). Propanediol was first 
desymmetrized by mono-silyl protection,
23
 followed by oxidation to access access 
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aldehyde 3-165 (Scheme 3.38). Similarly to the PMB derivative, the iodoalkene (3-166) 
was formed via stabilized Wittig olefination in 80% yield, followed by reduction of the 
ester and TBS protection of the resulting alcohol, giving 3-167 in 71% over three steps. 
 
 
Scheme 3.38 Synthesis of iodoalkene 3-167 
 
 With iodoalkene 3-167 in hand, the Suzuki cross-coupling reaction with vinyl 
borane 3-159 was executed in 80% yield with complete stereoselectivity to afford the γ-
alkylidene α,β-unsaturated ester 3-168 (Scheme 3.39). Cyclization to the lactone (3-169) 
was accomplished under acidic conditions in near quantitative yield. After protecting the 
lactone as a methyl acetal in a two step sequence, primary alcohol 3-163 was accessed 
effortlessly upon silyl deprotection with TBAF in 87% yield over three steps.  
 
 
Scheme 3.39 Progress toward western fragment 3-164 
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 In order to prepare the western fragment for Suzuki-Miyaura coupling to the 
eastern piece, an oxidation followed by a Horner-Wadsworth-Emmons reaction to install 
the dichloroalkene was required. Alcohol 3-163 was subjected to a variety of oxidation 
conditions (Swern, IBX, DMP), but unfortunately, substrate decomposition was observed 
in all cases, which may have been promoted by the instability of the diene system. 
 
3.6.3 Constructing the Eastern Fragment   
 
3.6.3.1 Evans’ Aldol  
 
 The strategy toward the eastern fragment of biselide E began with an Evans’ 
aldol, involving aldehyde 3-171, prepared in a two step sequence from ethylene glycol 
(Scheme 3.40). Standard boron mediated aldol conditions (Bu2BOTf, NEt(iPr)2, CH2Cl2) 
were employed with aldehyde 3-171 and chloroacetyloxazolidinone (S)-3-87, but 
substrate decomposition was observed. The labile silyl ether was suspected to be 
incompatible with the reaction conditions, so another protecting group was explored.  
  
 
Scheme 3.40 Evans’ aldol with aldehyde 3-171 
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 In order to circumvent product decomposition due to the unstable silyl ether, a 
PMB group was employed since it was suspected to be robust enough to survive the aldol 
reaction conditions. The synthesis began by desymmetrizing ethylene glycol by PMB 
mono-protection followed by IBX oxidation to give aldehyde 3-173 in 84% yield over 
two steps (Scheme 3.41). The aldol reaction in this case underwent a diastereoselective 
addition to give alcohol 3-176, not the desired 3-174, which could be used to access 
eastern fragment 3-175. This outcome was the result of aldehyde fragmentation to give 4-
methoxybenzaldehyde, which participated in the aldol reaction (Eq. 1).    
 
 
Scheme 3.41 Evans’ aldol with aldehyde 3-173 
 
 The unexpected setbacks with the Evans’ aldol prompted us to explore a 
protecting group that would provide even greater stability than a PMB. The p-
methoxyphenyl (PMP) group is quite robust and also lacks the methylene unit required 
for fragmentation. The synthesis began with a displacement reaction involving 4-
methoxyphenol and 2-chloroethanol, followed by oxidation of the resulting alcohol, 
giving aldehyde 3-178 in 84% yield over two steps (Scheme 3.38). Fortunately, the aldol 
reaction with oxazolidinone (S)-3-87 proceeded in 74% yield of the desired α-chloro 
aldol adduct 3-179 in >20:1 diastereoselectivity. 
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Scheme 3.42 Evans’ aldol with aldehyde 3-178 
 
3.6.3.2 trans-THF Formation  
 
 With aldol product 3-179 in hand, reduction with Zn dust and NH4Cl in MeOH 
rapidly removed the α-chloro substituent to give alcohol 3-180 in 93% yield (Scheme 
3.43). Cleavage of the auxiliary with N,O-dimethylhydroxylamine hydrochloride salt and 
Me3Al gave rise to Weinreb amide 3-181, which was converted to α,β-unsaturated ketone 
3-182 in good overall yield. A Prasad reduction (Et2BOMe, NaBH4) was then performed 
to reveal syn-diol 3-183 as the Mukaiyama oxidative cyclization precursor.   
 
 
Scheme 3.43 Progress towards eastern fragment 3-163 
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 Initial attempts to cyclize pentenol 3-183 under our standard cyclization 
conditions, were met with decomposition. Although cyclization reactions using Co(nmp)2 
have been shown to tolerate PMP substituents, we suspected it may be unstable under the 
oxidative conditions with this particular substrate. To circumvent this problem, 
preactivated catalyst was employed and the desired trans-THF product 3-184 was 
obtained in 87% yield. Protection of the diol as TBS ethers then provided the fully 
protected trans-THF fragment 3-185 in 90% yield. Unfortunately, complications with 
PMP removal and time constraints prevented further exploration of this route toward the 
Suzuki-Miyaura coupling partner 3-175.  
 
3.6.4 Future Work 
 
 With viable routes towards 3-163 and 3-185, future work would involve 
exploration of the remaining steps to ultimately access eastern and western fragments (3-
164 and 3-175, respectively, Scheme 3.44).  
 
 
Scheme 3.44 Future work towards biselide E 
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 To complete the total synthesis of biselde E would then involve investigation of 
the Suzuki-Miyaura coupling reaction between the two fragments, followed by side-chain 
installation via a Nozaki-Hiyama-Kishi reaction and some protecting group manipulation. 
 
3.7 Summary 
   
 In summary, we have developed efficient syntheses towards several fragments of 
biselide A, which could be used to explore both ring closing metathesis and relay ring 
closing metathesis to construct the 14-membered macrolactone.  The trans-THF ring 
found in each northern component (3-97 and 3-98) was furnished by using our second 
generation Co(nmp)2 catalyst in a Mukaiyama oxidative cyclization, while the 
chloroalkene moiety was introduced with a chloropalladation reaction. Key steps in the 
synthesis of the southern fragment 3-107 included a Sharpless asymmetric kinetic 
resolution, while a diastereoselective aldol reaction was utilized in our studies towards 
fragment 3-134. 
  Significant synthetic efforts toward biselide E have also been reported. We have 
designed an efficient method to access the western fragment using our second generation 
Co(nmp)2 catalyst in a Mukaiyama oxidative cyclization to furnish the trans-THF ring (3-
185). We have also developed a proficient method to an advanced intermediate of the 
eastern fragment (3-163) involving a Suzuki coupling reaction as the key step.  
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3.8 Experimental  
 
3.8.1 General Considerations 
  
  General experimental procedures were the same as provided in Chapter 1. 
 
3.8.2 Experimental Procedures  
 
 
(Z)-2-Hydroxy-5,5-dimethyl-1-(4-methylpiperazin-1-yl)hex-2-
ene-1,4-dione (nmp ligand, 3-15) 
A 500-mL round-bottomed one neck flask is charged with N-
methylpiperazine (8.90 mL, 80.0 mmol), diluted with 200 mL of CH2Cl2, and cooled to 0 
°C. To the cooled solution was added Et3N (11.2 mL, 80.0 mmol). Ethyl oxalyl chloride 
(8.90 mL, 80.0 mmol) is added dropwise via syringe over 10 min to the vigorously stirred 
solution.  After the addition, the heterogeneous solution is stirred at room temperature for 
16 h, and then poured slowly into a rapidly stirred solution of half saturated sodium 
bicarbonate (200 mL).  The solution is transferred to a 500 mL separatory funnel and the 
aqueous layer is extracted with CH2Cl2 (2 x 100 mL). The combined organic layers are 
washed with 100 mL of brine, dried over anhydrous MgSO4, filtered through a pad of 
Celite and concentrated by rotary evaporation (35 °C, 40 mmHg). The residue is then 
evacuated at 1.5 mmHg for 30 min to afford the title compound as colorless oil (99 % 
yield, 15.8 g). Rf 0.10 (66% EtOAc/Hex); 
1
H NMR (400 MHz, CDCl3) δ 4.30 (q, J = 7.2 
Hz, 2H), 3.64-3.61 (m, 2H), 3.43-3.41 (m, 2H), 2.42-2.40 (m, 4H), 2.29 (s, 3H), 1.33 (t, J 
= 7.1 Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ 162.7, 160.0, 62.0, 54.8, 54.1, 41.9, 41.2, 
14.0. IR (neat, cm
-1
): 2973, 2798, 1646, 1599, 1463, 1293, 1262, 1001, 737. HRMS 
[m/z+H
+
] 200.1163 (calcd for C9H16N2O3, 200.1161). 
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Ethyl 2-(4-methylpiperazin-1-yl)-2-oxoacetate (3-18) 
A 500-mL round-bottomed flask equipped with a 3-cm egg shaped stir 
bar containing glyoxyalate 3-15 (12.0 g, 60.0 mmol), was diluted with 
50.0 mL of THF, pinacolone (7.50 mL, 60.0 mmol) was added and the flask cooled to 0 
°C.  A separate 500-mL round-bottomed flask was charged with tBuOK (13.4 g, 120 
mmol) and diluted with 250 mL of THF. The tBuOK solution was added to the cooled 
glyoxyalate/pinacolone solution via cannula over 10 min.  After the addition, the solution 
was stirred at room temperature for 16 h. A solution of AcOH in CH2Cl2 (1.00 M, 150 
mL, 150 mmol) was added in one portion and the reaction was stirred for an additional 30 
min.  The reaction mixture was filtered through Celite and concentrated by rotary 
evaporation (35 °C, 40 mmHg). The residue was then evacuated at 1.5 mmHg for 30 min 
to afford the title compound as pale yellow oil (90 % yield, 13.7 g). Rf 0.15 (5% 
MeOH/EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 5.95 (s, 1H), 3.66-3.58 (m, 4H), 2.46-2.43 
(m, 4H), 2.31 (s, 3H), 1.19 (s, 9H). 
13
C NMR (100 MHz, CDCl3) δ 200.9, 185.3, 163.8, 
95.3, 55.1, 54.3, 45.8, 41.6, 27.2. IR (neat, cm
-1
): 3445, 2965, 2362, 1649, 1560, 1540, 
1458, 1108. HRMS [m/z+H
+
] 254.1644 (calcd for C13H22N2O3, 254.1630). 
 
(S,E)-N-(2-Chloroethylidene)-2-methylpropane-2-sulfinamide (3-57)  
2-Methyl-2-propanesulfinamide (1.00 g, 8.25 mmol) in 16.5 mL CH2Cl2 
was added CuSO4 (8.22 g, 51.5 mmol) followed by chloroacetaldehyde 
(777 mg, 9.90 mmol). The solution was allowed to stir for 24 h at RT, and then filtered 
through a pad of Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (82% yield, 1.23 g). Rf 0.58 (50% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)  8.03 (t, J = 4.5, 1H), 4.31 (d, J = 4.7, 2H), 1.21 (s, 9H); 
13
C NMR 
(100 MHz, CDCl3)  162.4, 57.5, 43.6, 22.4.  
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(R)-4-Mesitylthiazolidine-2-thione (3-58) 
To a solution of 1.34 M mesitylmagnesium bromide in Et2O (25.0 mL, 33.6 
mmol) at −78 °C was added imine 3-57 as a solution in 22.0 mL toluene 
over 45 min. The reaction mixture was then stirred for 3 h at −78 °C, 
quenched with 4.00 M HCl (16.8 mL, 67.3 mmol), warmed to RT and stirred for 3 h. The 
organic layer was then extracted with H2O (2 x 30.0 mL), and the combined aqueous 
layers were cooled to 0 °C, and 2.00 M NaOH solution was added until pH 11 was 
achieved. The aqueous layers were then extracted with EtOAc (3 x 50.0 mL), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. The residue was then dissolved in 33.7 mL of 
1.00 M KOH (33.7 mmol), and carbon disulfide (2.03 mL, 33.7 mmol) was added 
dropwise while stirring. The solution was heated to reflux for 16 h. Upon cooling to RT, 
30.0 mL CH2Cl2 was added. The aqueous layer was then extracted with CH2Cl2 (3 x 20.0 
mL), and the combined organic layers were washed with brine, dried (MgSO4), filtered 
through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as a white solid (58% yield over two steps, 925 mg). Rf 0.53 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.70 (bs, 1H), 6.86 (s, 2H), 5.82 (t, J = 
10.4, 1H), 3.63 (d, J = 3.6, 2H), 2.39 (s, 6H), 2.25 (s, 3H); 
13
C NMR (100 MHz, CDCl3) 
 199.3, 138.5, 136.6, 130.7, 129.4, 63.6, 37.5, 20.7, 20.5.  
 
(S)-4-Isopropylthiazolidine-2-thione (3-61)  
L-Valinol (16.2 g, 0.16 mol) in 715 mL of 5.00 M KOH (3.57 mol), was added 
carbon disulfide (76.0 mL, 1.26 mol) dropwise while stirring. The solution was 
heated to reflux for 3 days. Upon cooling to RT, 300 mL CH2Cl2 was added. The aqueous 
layer was then extracted with CH2Cl2 (3 x 100 mL), and the combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as a white solid (70% yield, 17.7 g). Rf 
0.62 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  8.66 (bs, 1H), 4.07−4.02 (m, 
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1H), 3.48−3.43 (m, 1H), 3.28−3.23 (m, 1H), 0.97 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.6 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3)  200.5, 69.9, 35.5, 31.7, 18.5, 17.9.  
 
(S)-4-tert-Butylthiazolidine-2-thione (3-62) 
The title compound was obtained from L-tert-leucinol using the same 
procedure that was used to obtain compound 3-61. This procedure provided 
the title compound as a white solid (68% yield). Rf 0.63 (50% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)  7.22 (bs, 1H), 4.00 (t, J = 8.8 Hz, 1H), 3.41 (dd, J = 8.9, 1.6 Hz, 
2H), 1.00 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  201.7, 73.3, 34.5, 34.4, 25.9.  
 
(R)-1-(4-Mesityl-2-thioxothiazolidin-3-yl)ethanone (3-63) 
The title compound was obtained from thiazolidin-2-thione 3-58 after an 
acylation reaction, as described above in the procedure to obtain compound 
3-64. This procedure provided the title compound as pale yellow solid (85% 
yield). Rf 0.73 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.84 (s, 2H), 6.34 
(t, J = 9.9, 1H), 3.54 (d, J = 11.3, 10.6, 1H), 3.33 (d, J = 11.3, 10.2, 1H), 2.69 (s, 3H) 2.39 
(bs, 6H), 2.24 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  201.4, 171.9, 137.8, 132.6, 128.8, 
127.2, 67.9, 32.4, 27.7, 20.8. 
 
(S)-1-(4-Isopropyl-2-thioxothiazolidin-3-yl)ethanone (3-64) 
Thiazolidin-2-thione 3-61 (4.00 g, 20.2 mmol) dissolved in 100 mL THF at 
−78 °C was added nBuLi (9.25 mL, 22.2 mmol, 2.40 M in hexanes) and 
stirred at −78 °C for 30 min. Acetyl chloride (1.58 mL, 22.2 mmol) was 
added dropwise and the solution was allowed to stir for 1 h at −78 °C, and then at RT for 
30 min. The reaction mixture was then quenched with 100 mL half saturated aqueous 
NH4Cl solution. The solution was allowed to warm to RT and the aqueous layer was then 
extracted with EtOAc (3 x 50.0 mL), and the combined organic layers were washed with 
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the title compound as yellow oil (97% yield, 3.90 g). Rf 0.74 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  8.66 (bs, 1H), 5.15−5.12 (m, 1H), 3.50 
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(dd, J = 11.3, 7.8 Hz, 1H), 3.00 (d, J = 11.3 Hz, 1H), 2.76 (s, 3H), 2.36 (dq, J = 13.5, 6.8 
Hz, 1H), 1.05 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 
 203.2, 170.7, 71.3, 30.8, 30.4, 26.9, 19.0, 17.7.  
 
(S)-1-(4-tert-Butyl-2-thioxothiazolidin-3-yl)ethanone (3-65) 
The title compound was obtained from thiazolidin-2-thione 3-62 after an 
acylation reaction, as described above in the procedure to obtain compound 
3-64. This procedure provided the title compound as yellow oil (94% yield). 
Rf 0.75 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.30 (d, J = 8.2 Hz, 1H), 
3.52 (dd, J = 11.7, 8.2 Hz, 1H), 3.09 (d, J = 11.7 Hz, 1H), 2.77 (s, 3H), 1.02 (s, 9H); 
13
C 
NMR (100 MHz, CDCl3)  205.3, 170.3, 72.0, 37.9, 30.4, 26.8.  
 
3-(tert-Butyldimethylsilyloxy)propan-1-ol (3-67a) 
To a flask containing dry NaH (1.10 g, 45.9 mmol) and 100 mL THF at 0 °C was added 
freshly distilled propanediol (3.50 g, 45.9 mmol) dropwise. After stirring for 45 min at 
RT, TBSCl (6.93 g, 45.9 mmol) was added slowly dropwise and allowed to stir for 
another 45 min. The solution was quenched with 100 mL 10% aqueous Na2CO3. The 
aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined organic 
layers were washed with brine, dried (MgSO4), and filtered through Celite. The solution 
was then concentrated under reduced pressure to give the title compound as colorless oil 
(100% yield, 8.75 g). Rf 0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  3.86-
3.79 (m, 4H), 2.61−2.59 (m, 1H), 1.77 (quin, J = 5.6 Hz, 2H), 0.89 (s, 9H), 0.07 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  62.9, 62.5, 34.2, 25.9, 18.2, −5.5.  
 
3-(tert-Butyldimethylsilyloxy)propanal (3-67) 
To a solution of oxalyl chloride (452 μL, 5.25 mmol) in 5.00 mL CH2Cl2 
at −78 °C, DMSO (747 μL, 10.5 mmol) as a solution in 3.00 mL CH2Cl2 was added over 
10 min. The solution was stirred at −78 °C for 40 min. A solution of alcohol 3-67a (500 
mg, 2.63 mmol) in 3.00 mL CH2Cl2 was then added over 15 min, and stirred at −78 °C 
for 40 min. After the slow addition of Et3N (2.56 mL, 18.4 mmol) over 15 min, the 
solution was allowed to stir at −78 °C for 40 min, and then warmed to RT over 30 min. 
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The reaction mixture was diluted with 10.0 mL CH2Cl2 and then poured into a half 
saturated solution of NaCl (20.0 mL). The heterogeneous mixture was separated and the 
aqueous layer was extracted with CH2Cl2 (5 x 10.0 mL). The combined organic layers 
were dried (MgSO4) and filtered through Celite. After the solution was concentrated 
under reduced pressure, the title compound was isolated as pale yellow oil (96% yield). 
Rf 0.72 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.79 (t, J = 2.2 Hz, 1H), 
3.97 (t, J = 6.1 Hz, 1H), 2.59 (td, J = 6.0, 2.2 Hz, 1H), 0.87 (s, 9H), 0.05 (s, 6H); 
13
C 
NMR (100 MHz, CDCl3)  202.0, 57.4, 46.6, 25.8, 18.2, -5.5.  
 
(R)-5-(tert-Butyldimethylsilyloxy)-3-hydroxy-1-((S)-4-
isopropyl-2-thioxothiazolidin-3-yl)pentan-1-one (3-68) 
TiCl4 (148 μL, 1.36 mmol) and NEt(iPr)2 (473 μL, 2.72 mmol) 
are added sequentially to a solution of auxilliary 3-64 (254 mg, 1.25 mmol) in 5.00 mL 
CH2Cl2 at −40 °C. After 1.5 h at −40 °C, the solution was cooled to −78 °C, and the 
aldehyde 3-67 (144 mg, 0.76 mmol) is added slowly dropwise. After 10 min at −78 °C, 
the reaction is quenched with the addition of 5.00 mL 1.00 M NaH2PO4·H2O and the 
solution was allowed to warm to RT. The aqueous layer was then extracted with CH2Cl2 
(3 x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as pale yellow oil (87% yield, 7:1 dr, 259 mg). Rf 0.53 (66% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.16−5.13 (m, 1H), 4.40−4.34 (m, 1H), 3.88−3.77 (m, 
2H), 3.53−3.46 (m, 3H), 3.29 (dd, J = 17.6, 8.9 Hz, 1H), 3.00 (d, J = 11.3 Hz, 1H), 
2.40−2.32 (m, 1H), 1.80−1.67 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H), 
0.87 (s, 9H), 0.05 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  202.9, 172.4, 71.5, 67.3, 61.4, 
45.6, 38.1, 30.8, 30.6, 25.9, 19.0, 17.7, −5.5. HRMS [m/z+H+] 392.8066 (calcd for 
C17H33NO3S2Si, 391.1671). 
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(R)-5-(tert-Butyldimethylsilyloxy)-3-hydroxy-N-methoxy-N-
methylpentanamide (3-69) 
Imidazole (85.0 mg, 1.25 mmol) and N,O-
dimethylhydroxylamine hydrochloride salt (49.0 mg, 0.50 mmol) were added 
sequentially to a stirred solution of alcohol 3-68 (97.0 mg, 0.25 mmol) in 3.00 mL 
CH2Cl2. The solution was allowed to stir for 20 h and then quenched with 10.0 mL half 
saturated aqueous NH4Cl solution. The aqueous layer was then extracted with CH2Cl2 (3 
x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (92% yield, 67.0 mg). Rf 0.25 (50% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)   4.27−4.20 (m, 1H), 3.95 (d, J = 2.7 Hz, 1H), 3.86−3.77 (m, 2H), 
3.68 (s, 3H), 3.18 (s, 3H), 2.66−2.57 (m, 2H), 1.77−1.57 (m, 2H), 0.88 (s, 9H), 0.06 (s, 
6H); 
13
C NMR (100 MHz, CDCl3)  173.4, 66.6, 61.2, 60.8, 38.7, 38.6, 31.8, 25.8, 18.2, 
−5.5. HRMS [m/z+H+] 292.1937 (calcd for C13H29NO4Si, 291.1866). 
 
(R)-7-(tert-Butyldimethylsilyloxy)-5-hydroxyhept-1-en-3-one 
(3-70) 
A 1.00 M solution of vinylmagnesium bromide in THF (1.53 mL, 1.53 mmol) was added 
to a solution of amide 3-69 (147 mg, 0.51 mmol) in 5.00 mL THF at −40 °C. After 4 h at 
0 °C, the reaction was quenched with 10.0 mL half saturated aqueous NH4Cl solution.  
The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as colorless oil (77% yield, 
100 mg). Rf 0.67 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.36 (dd, J = 
17.6, 10.6 Hz, 1H), 6.36 (dd, J = 17.6, 10.6 Hz, 1H), 6.23 (d, J = 17.6 Hz, 1H), 5.87 (d, J 
= 10.2 Hz, 1H), 4.35−4.28 (m, 1H), 3.88−3.75 (m, 2H), 3.63 (d, J = 2.7 Hz, 1H), 
2.85−2.72 (m, 2H), 1.73−1.58 (m, 2H), 0.88 (s, 9H), 0.06 (s, 6H); 13C NMR (100 MHz, 
CDCl3)  200.5, 136.9, 128.9, 67.2, 61.5, 46.3, 38.3, 25.9, 18.3, −5.5. HRMS [m/z+H
+
] 
259.1726 (calcd for C13H26O3Si, 258.1651). 
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(3R,5R)-3-(tert-Butyldimethylsilyloxy)hept-6-ene-1,5-diol  
(3-71) 
(3R,5R)-7-(tert-Butyldimethylsilyloxy)hept-1-ene-3,5-diol       
(3-72) 
Ketone 3-70 (50.0 mg, 0.19 mmol) in 2.00 mL THF and 0.50 mL MeOH was cooled to 
−78 °C, and Et2B(OMe) (213 μL, 1.00 M in THF, 0.21 mmol) was added. After stirring 
for 1 h at −20 °C, the solution was cooled to −78 °C, and NaBH4 (8.00 mg, 0.21 mmol) 
was added in portions. After stirring for 3 h at −78 °C, the reaction was quenched with 
5.00 mL half saturated aqueous NaHCO3 solution. The solution was allowed to warm to 
RT and the aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as a white solid (96% 
yield, 1:1 mixture of isomers, 48.0 mg). Desired isomer (3-72): Rf 0.48 (50% 
EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  5.82 (ddd, J = 16.9, 10.5, 5.3 Hz, 1H), 
5.30 (d, J = 16.9 Hz, 1H), 5.11 (d, J = 10.5 Hz, 1H), 4.44−4.42 (m, 1H), 4.15−4.11 (m, 
1H), 3.84−3.80 (m, 1H), 3.75−3.72 (m, 1H), 1.96 (dt, J = 14.0, 2.9 Hz, 1H), 1.72−1.64 
(m, 2H), 1.41 (dt, J = 14.1, 11.4 Hz, 1H), 0.89−0.87 (m, 12H), 0.68 (q, J = 8.0 Hz, 1H), 
0.05 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  139.1, 114.5, 114.5, 71.9, 67.9, 58.9, 40.2, 
39.1, 25.9, 18.4, 7.8, −5.5. HRMS [m/z+H+] 261.1893 (calcd for C13H28O3Si, 260.1808). 
 
(R)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-
yl)hept-6-yn-1-one (3-74) 
The title compound was obtained from auxilliary 3-64 and pent-
4-ynal using the aldol reaction conditions described above in the 
procedure to obtain compound 3-68. This procedure provided the title compound as pale 
yellow oil (27% yield, 6:1 dr). Rf 0.43 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, 
CDCl3)  5.15 (t, J = 6.6 Hz, 1H), 4.28-4.24 (m, 1H), 3.64 (dd, J = 17.8, 2.5 Hz, 1H), 
3.51 (dd, J = 11.5, 8.0 Hz, 1H), 3.15 (dd, J = 17.6, 9.4 Hz, 1H), 3.02 (d, J = 11.7 Hz, 1H), 
2.92 (bs, 1H), 2.39−2.30 (m, 3H), 1.95 (t, J = 2.5 Hz, 1H), 1.80−1.66 (m, 2H), 1.05 (d, J 
= 7.0 Hz, 3H), 0.97 (d, J = 7.0 Hz, 1H);
 13
C NMR (100 MHz, CDCl3)  202.9, 172.8, 
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83.8, 71.3, 68.9, 68.2, 66.6, 45.3, 34.7, 30.8, 30.6, 14.8. HRMS [m/z+H
+
] 286.0934 (calcd 
for C13H19NO2S2, 285.0857). 
 
5-(Trimethylsilyl)pent-4-yn-1-ol (3-76a) 
4-Pentyn-1-ol (5.20 g, 56.0 mmol) dissolved in 200 mL THF at 0 °C 
was added nBuLi (56.0 mL, 123 mmol, 2.19 M in hexanes) over 30 min. The solution 
was allowed to stir for 3 h at 0 °C, and then TMSCl (15.7 mL, 123 mmol) was added to 
the reaction mixture dropwise. After stirring for 16 h at RT, 1 M HCl (200 mL, 200 
mmol) was added and the solution was allowed to stir at RT for another 16 h. The 
aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined organic 
layers were washed with 5 % NaHCO3, brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure which provided the title compound as colorless oil 
(100% yield, 8.75 g). 
1
H NMR (400 MHz, CDCl3)  3.79−3.73 (m, 2H), 2.34 (t, J = 6.8 
Hz, 2H), 1.81−1.73 (m, 2H), 1.55 (bs, 1H), 0.14 (s, 9H); 13C NMR (100 MHz, CDCl3)  
106.6, 85.3, 63.3, 61.9, 31.2, 16.6, 0.1 
 
5-(Trimethylsilyl)pent-4-ynal (3-76) 
Alcohol 3-76a (5.00 g, 32.0 mmol) in 200 mL EtOAc was added IBX 
(17.9 g, 64.0 mmol) and heated to reflux for 3 h. After allowing the 
solution to cool to room temperature, the solution was filtered through Celite and 
concentrated under reduced pressure, which provided the title compound as colorless oil 
(92% yield, 4.50 g). Rf 0.76 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.78 
(s, 1H) 2.69−2.65 (m, 2H), 2.55−2.51 (m, 2H), 0.13 (s, 9H); 13C NMR (100 MHz, 
CDCl3)  200.4, 104.7, 42.5, 13.1, 0.0, −3.5.  
 
(R)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-
yl)-7-(trimethylsilyl)hept-6-yn-1-one (3-77) 
The title compound was obtained from auxilliary 3-64 and 
aldehyde 3-76 using the aldol reaction conditions described 
above in the procedure to obtain compound 3-68. This procedure provided the title 
compound as pale yellow oil (85% yield, 6:1 dr). Rf 0.47 (50% EtOAc/hexanes). 
1
H 
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NMR (400 MHz, CDCl3)  5.13−5.10 (m, 1H), 4.22−4.18 (m, 1H), 3.58 (dd, J = 17.8, 2.5 
Hz, 1H), 3.49 (dd, J = 11.5, 8.0 Hz, 1H), 3.11 (dd, J = 17.8, 9.2 Hz, 1H), 2.99 (d, J = 11.7 
Hz, 1H), 2.96 (bs, 1H), 2.37−2.27 (m, 3H), 1.75−1.62 (m, 2H), 1.02 (d, J = 6.6 Hz, 3H), 
0.94 (d, J = 7.0 Hz, 3H), 0.09 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  202.8, 172.6, 
106.5, 71.2, 66.8, 45.3, 34.9, 30.7, 30.5, 19.0, 17.7, 16.2, 0.0. HRMS m/z 357.1246 (calcd 
for C16H27NO2S2Si, 357.1252). 
 
(R)-1-((S)-4-tert-Butyl-2-thioxothiazolidin-3-yl)-3-
hydroxy-7-(trimethylsilyl)hept-6-yn-1-one (3-78) 
The title compound was obtained from auxilliary 3-65 and 
aldehyde 3-76 using the aldol reaction conditions described above in the procedure to 
obtain compound 3-68. This procedure provided the title compound as pale yellow oil 
(86% yield, 10:1 dr). Rf 0.50 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.31 
(d, J = 8.2 Hz, 1H), 4.23−4.21 (m, 1H), 3.62 (dd, J = 17.6, 2.3 Hz, 1H), 3.54 (dd, J = 
11.7, 8.2 Hz, 1H), 3.15 (dd, J = 17.6, 8.9 Hz, 1H), 3.11 (d, J = 11.7 Hz, 1H), 2.97 (d, J = 
3.5 Hz, 1H), 2.39 (td, J = 7.2, 2.3 Hz, 1H), 1.76−1.69 (m, 2H), 1.03 (s, 9H), 0.13 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  205.1, 172.4, 106.6, 85.1, 72.1, 67.2, 45.0, 37.9, 35.0, 
30.6, 26.9, 16.4, 0.1. HRMS m/z 371.1410 (calcd for C17H29NO2S2Si, 371.1409). 
 
(R)-3-Hydroxy-1-((R)-4-mesityl-2-thioxothiazolidin-3-yl)-
7-(trimethylsilyl)hept-6-yn-1-one (3-79) 
The title compound was obtained from auxilliary 3-63 and 
aldehyde 3-76 using the aldol reaction conditions described 
above in the procedure to obtain compound 3-68. This procedure provided the title 
compound as pale yellow oil (52% yield, 5:1 dr). Rf 0.69 (50% EtOAc/hexanes). 
1
H 
NMR (400 MHz, CDCl3)  6.90−6.84 (m, 2H), 6.36 (t, J = 9.9 Hz, 1H), 4.00−3.94 (m, 
1H), 3.60−3.51 (m, 2H), 3.32 (dd, J = 11.1, 9.6 Hz, 1H), 3.19 (dd, J = 17.4, 2.54 Hz, 1H), 
2.94 (bs, 1H), 2.39−2.25 (m, 8H), 2.24 (s, 3H), 1.70−1.59 (m, 2H), 0.11 (s, 9H). 
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(S)-1,1,2-Triphenylethane-1,2-diol (3-81) 
(S)-Mandelate (37.0 g, 220 mmol) in 200 mL Et2O is added dropwise to a 
0 °C solution of phenylmagnesium bromide (300 mL, 880 mmol, 2.93 M 
in Et2O), such that the temperature stayed below 10 °C. The solution was 
stirred for 2 h at 0 °C and then brought to reflux for 3 h. After allowing to 
stand for 16 h at RT, the solution was poured onto 400 g of ice. Concentrated HCl was 
then added until the solution reached pH 4 and then stirred at RT for 1 h. The aqueous 
layers were then extracted with CH2Cl2 (3 x 200 mL), and the combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. The yellow solid was then recrystallized from MeOH to give the title 
compound as a white solid (62% yield, 39.6 g, mp 125 °C). Rf 0.13 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.69-7.67 (m, 2H), 7.42−7.38 (m, 2H), 
7.32−7.29 (m, 1H), 7.18−7.04 (m, 10H), 5.61 (d, J = 2.34 Hz, 1H), 3.15 (s, 1H), 2.47 (d, 
J = 3.1 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  145.1, 143.3, 138.8, 128.4, 128.1, 127.7, 
127.6, 127.5, 127.4, 126.9, 126.7, 126.2, 80.8, 78.0.  
 
(S)-2-hydroxy-1,2,2-triphenylethyl acetate (3-82)  
Diol 3-81 (12.7 g, 43.7 mmol) in 170 mL MeCN was added acetic 
anhydride (6.69 g, 65.6 mmol) followed by a solution of Sc(OTf)3 (430 
mg, 0.87 mmol) in 40 mL MeCN over 30 min. After 4 h of stirring at 
RT, the precipitate was filtered, washed with 50.0 mL cold MeCN, and 
dried under reduced pressure to give the title compound as a white solid (77% yield, 11.2 
g). Rf 0.45 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.56-7.54 (m, 2H), 
7.37−7.33 (m, 2H), 7.29−7.27 (m, 1H), 7.17−7.03 (m, 10H), 6.67 (s, 1H), 2.81 (s, 1H), 
1.98 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  169.7, 144.8, 142.7, 135.8, 128.4, 128.3, 
127.9, 127.8, 127.5, 127.3, 127.0, 126.3, 126.2, 80.3, 78.5, 21.1.  
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(R)-((S)-2-Hydroxy-1,2,2-triphenylethyl)-3-
hydroxy-7-(trimethylsilyl)hept-6-ynoate (3-84) 
LDA (prepared by adding nBuLi (1.09 mL, 2.29 M in 
hexanes, 2.50 mmol), dropwise to a solution of 
iPr2NH (367 μL, 2.60 mmol) in 5.00 mL THF at −78 
°C and allowing the solution to warm to 0 °C) was added to a stirring suspension of 
auxiliary 3-82 (331 mg, 1.00 mmol) in 9.00 mL THF −78 °C. The reaction mixture was 
allowed to warm to 0 °C to give a clear solution, which was added to a solution of 
MgBr2·OEt2 (516 mg, 2.00 mmol) in 15.0 mL Et2O at −78 °C. After 1 h, the reaction 
mixture was cooled to −115 °C using a EtOH/liquid N2 bath, and aldehyde 3-76 (247 mg, 
1.60 mmol) was slowly added as a solution in 2.00 mL THF. After stirring at −115 °C for 
40 min, the reaction was quenched with 30.0 mL half saturated aqueous NH4Cl solution. 
The solution was allowed to warm to RT and the aqueous layer was then extracted with 
EtOAc (3 x 20.0 mL), and the combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (53% yield, >20:1 dr, 150 mg). Rf 0.61 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.59−7.56 (m, 2H), 7.39−7.35 (m, 2H), 7.30−7.26 (m, 
1H), 7.20−7.06 (m, 10H), 6.73 (s, 1H), 3.99−3.96 (m, 1H), 2.87 (bs, 1H), 2.44−2.39 (m, 
2H), 2.27 (t, J = 7.0 Hz, 2H), 1.55−1.49 (m, 2H), 0.15 (s, 9H); 13C NMR (100 MHz, 
CDCl3)  171.0, 144.5, 142.4, 135.4, 128.4, 128.4, 128.1, 127.8, 127.6, 127.5, 127.1, 
126.2, 126.1, 106.4, 85.3, 80.2, 79.0, 67.0, 41.6, 34.7, 16.2, 0.1. 
 
(S)- and (R)-4-Benzyloxazolidin-2-one (3-86) 
(S)-4-Benzyloxazolidin-2-one was obtained from (S)-phenylalanine 
using the procedure described by Evans (70% yield).
8
 (R)-4-
Benzyloxazolidin-2-one was prepared in the same fashion, but starting from (R)-
phenylalanine (72% yield). Rf 0.15 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  
7.35−7.16 (m, 5H), 5.01 (bs, 1H), 4.48 (t, J = 8.4, 1H), 4.17−4.06 (m, 2H), 2.92−2.81 (m, 
2H); 
13
C NMR (100 MHz, CDCl3)  159.4, 136.0, 129.0, 129.0, 127.2, 69.6, 53.8, 41.4. 
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(S)- and (R)-4-Benzyl-3-(2-chloroacetyl)oxazolidin-
2-one (3-87) 
Oxazolidine-2-one 3-86 (3.54 g, 20.0 mmol) in 300 mL 
THF at −78 °C was added nBuLi (9.09 mL, 20.0 mmol, 2.20 M in hexanes) and allowed 
to stir for 15 min. The solution was then allowed to warm to RT and stirred for 2.5 h. 
After cooling the reaction mixture to −78 °C, chloroacetyl chloride (1.59 mL, 22.0 mmol) 
was added dropwise, allowed to stir for 15 min and then warmed to RT for 30 min. The 
reaction mixture was then quenched with 10.0 mL half saturated aqueous NH4Cl solution. 
The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as a white solid (90-95% 
yield, 4.71 g). Rf 0.34 (30% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.36−7.19 
(m, 5H), 4.74 (s, 2H), 4.72−4.67 (m, 1H), 4.31−4.23 (m, 2H), 3.34 (dd, J = 13.3, 3.1, 
1H), 2.81 (dd, J = 13.3, 9.4, 1H); 
13
C NMR (100 MHz, CDCl3)  166.1, 153.2, 134.7, 
129.4, 129.1, 127.6, 67.0, 55.4, 43.8, 37.6.  
 
(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-7-
(trimethylsilyl)hept-6-ynoyl)oxazolidin-2-one (3-88) 
EtN(iPr)2 (776 μL, 4.44 mmol) and Bu2BOTf (3.99 mL, 3.99 
mmol, 1.00 M in CH2Cl2) were added sequentially to a stirring solution of auxiliary (S)-
3-87 (845 mg, 3.33 mmol) in 11.0 mL CH2Cl2 (dried and degassed) at −78 °C. After the 
solution was allowed to stir at RT for 1.5 h, it was cooled to −78 °C, and aldehyde 3-76 
(342 mg, 2.22 mmol) was added dropwise as a solution in 2.00 mL CH2Cl2. The solution 
was then allowed to stir for 30 min at −78 °C followed by 2 h at 0 °C. The solution was 
then washed with 1.00 M NaHSO4 (4.00 mL, 4.00 mmol) and concentrated under 
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum). The 
resulting residue was dissolved in 25.0 mL MeOH, cooled to 0 °C, and 2.00 mL 30% 
H2O2 aqueous solution was added and allowed to stir for 1 h. After adding 15.0 mL H2O 
and 15.0 mL EtOAc, the aqueous layer was then extracted with EtOAc (3 x 15.0 mL), 
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and the combined organic layers were washed with brine, dried (MgSO4), filtered through 
Celite and concentrated under reduced pressure. Purification by flash chromatography on 
silica gel using EtOAc-hexanes for elution provided the title compound as pale yellow oil 
(78% yield, >20:1 dr, 705 mg). Rf 0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, 
CDCl3)  7.35−7.29 (m, 3H), 7.21 (d, J = 7.0 Hz, 2H), 5.67 (d, J = 2.9 Hz, 1H), 
4.74−4.70 (m, 1H), 4.28−4.23 (m, 3H), 3.31 (dd, J = 13.5, 3.5 Hz, 1H), 2.86−2.81 (m, 
2H), 2.44−2.41 (m, 2H), 1.94−1.88 (m, 1H), 1.81−1.78 (m, 1H), 1.53 (bs, 1H), 0.13 (s, 
9H); 
13
C NMR (100 MHz, CDCl3)  168.2, 152.5, 134.6, 129.4, 129.0, 127.5, 105.8, 
85.5, 70.2, 66.5, 59.4, 55.4, 37.2, 32.7, 16.2, 0.0. HRMS m/z 407.1305 (calcd for 
C20H26ClNO4Si, 407.1320). 
 
(S)-4-Benzyl-3-((R)-3-hydroxy-7-(trimethylsilyl)hept-6-
ynoyl)oxazolidin-2-one (3-89) 
Alcohol 3-88 (1.62 g, 3.98 mmol) in 35.0 mL reagent grade 
MeOH was added Zn powder (1.04 g, 15.9 mmol) and solid NH4Cl (850 mg, 15.9 mmol). 
After 5 min of stirring at RT, the solution was filtered through Celite and concentrated 
under reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (96% yield, 1.42 g). Rf 
0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.35−7.19 (m, 5H), 
4.73−4.67 (m, 1H), 4.26−4.16 (m, 4H), 3.27 (dd, J = 13.3, 3.5 Hz, 1H), 3.13−3.09 (m, 
2H), 2.80 (dd, J = 13.7, 9.4 Hz, 1H), 2.41 (t, J = 7.0 Hz, 2H), 1.83−1.69 (m, 2H), 0.14 (s, 
9H); 
13
C NMR (100 MHz, CDCl3)  172.4, 153.3, 134.9, 129.3, 129.0, 127.3, 106.5, 
85.0, 66.6, 66.3, 54.9, 42.5, 37.7, 35.1, 16.2, 0.0. HRMS [m/z+H
+
] 374.1775 (calcd for 
C20H27NO4Si, 373.1709). 
 
(R)-3-Hydroxy-N-methoxy-N-methyl-7-
(trimethylsilyl)hept-6-ynamide (3-90) 
N,O-Dimethylhydroxylamine hydrochloride salt (725 mg, 
7.43 mmol) in 40.0 mL THF at 0 °C was added Me3Al (3.71 mL, 7.43 mmol, 2.00 M in 
hexanes). After 30 min at 0 °C, the solution was stirred at RT for another 20 min. The 
mixture was cooled to −15 °C and alcohol 3-89 (923 mg, 2.47 mmol) in 15.0 mL THF 
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was added dropwise and stirred for 4 h at 0 °C. The reaction mixture was then quenched 
with 50.0 mL 0.50 M HCl. The aqueous layer was then extracted with EtOAc (3 x 25.0 
mL), and the combined organic layers were washed with brine, dried (MgSO4), filtered 
through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (80% yield, 508 mg). Rf 0.28 (40% EtOAc/hexanes). 
l
H NMR 
(400 MHz, CDCl3)  4.15−4.09 (m, 1H), 3.82 (d, J = 3.1 Hz, 1H), 3.68 (s, 3H), 3.19 (s, 
3H), 2.70−2.68 (m, 1H), 2.51−2.47 (m, 1H), 2.39 (td, J = 7.1, 3.3 Hz, 1H), 1.79−1.63 (m, 
2H), 0.13 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  173.5, 106.8, 84.7, 66.7, 61.2, 38.0, 
35.2, 31.8, 16.2, 0.1. HRMS [m/z+H
+
] 258.1535 (calcd for C12H23NO3Si, 257.1447). All 
of the auxiliary ((S)-3-86) was also recovered from the reaction mixture. 
 
(R)-5-Hydroxy-9-(trimethylsilyl)non-1-en-8-yn-3-one (3-91) 
The title compound was obtained from amide 3-90 using the 
Grignard addition conditions, as described above in the 
procedure to obtain compound 3-70. This procedure provided the title compound as 
colorless oil (78% yield). Rf 0.43 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  
6.36 (dd, J = 16.0, 10.2 Hz, 1H), 6.21 (dd, J = 17.6, 1.2 Hz, 1H), 5.89 (dd, J = 10.2, 1.2 
Hz, 1H), 4.23−4.18 (m, 1H), 3.17−3.16 (m, 1H), 2.84−2.68 (m, 2H), 2.40−2.36 (m, 2H), 
1.76−1.65 (m, 2H), 0.12 (s, 9H); 13C NMR (100 MHz, CDCl3)  200.9, 136.7, 129.2, 
129.2, 106.7, 85.1, 66.6, 45.6, 35.0, 16.2, 0.1. HRMS [m/z+H
+
] 225.1305 (calcd for 
C12H20O2Si, 224.1233). 
 
(3R,5R)-9-(Trimethylsilyl)non-1-en-8-yne-3,5-diol (3-92) 
The title compound was obtained from ketone 3-91 using the 
Prasad reduction reaction conditions, as described above in the 
procedure to obtain compound 3-72. This procedure provided the title compound as a 
white solid (87% yield). Rf 0.35 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  
5.86 (ddd, J = 16.9, 10.5, 5.9 Hz, 1H), 5.24 (dt, J = 17.2, 1.4 Hz, 1H), 5.09 (dt, J = 10.5, 
1.2 Hz, 1H), 4.40−4.35 (m, 1H), 4.04−3.98 (m, 1H), 3.33 (bs, 1H), 3.07 (bs, 1H), 2.34 (t, 
J = 4.0 Hz, 2H), 1.71−1.56 (m, 4H), 0.13 (s, 9H); 13C NMR (100 MHz, CDCl3)  140.6, 
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114.6, 106.8, 85.5, 73.6, 71.5, 42.8, 36.2, 16.2, 0.1. HRMS [m/z+H
+
] 227.1469 (calcd for 
C12H22O2Si, 226.1389). 
 
(2R,3R,5R)-2-(Hydroxymethyl)-5-(4-(trimethylsilyl)but-3-
ynyl)tetrahydrofuran-3-ol (3-93) 
Diol 3-92 (67.0 mg, 0.29 mmol) was added as a solution in 3.40 mL 
iPrOH to a flask charged with Co(nmp)2 (25.0 mg, 0.04 mmol) under 1 
atm of O2 (balloon). At room temperature, tert-butyl hydroperoxide (8.00 μL, 0.04 mmol, 
5.33 M is isooctane) was added in one portion, and the resulting solution was heated at 55 
°C for 16 h. The solution was cooled to RT, and the solvent was removed completely 
under reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum 
while stirring). The resulting residue was then dissolved in 5.00 mL EtOAc and filtered 
through a pad of Celite and washed with 10.0 mL EtOAc. Solvent removal under reduced 
pressure provided the title compound as pale yellow oil (91% yield, 63.9 mg). Rf 0.13 
(50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  4.50 (bs, 1H), 4.37−4.30 (m, 1H), 
3.93−3.89 (m, 3H), 3.36 (bs, 1H), 2.66 (bs, 1H), 2.37−2.26 (m, 2H), 2.11 (dd, J = 13.5, 
5.9 Hz, 1H), 1.82−1.64 (m, 3H), 0.11 (s, 9H); 13C NMR (100 MHz, CDCl3)  106.6, 
84.7, 80.2, 77.1, 74.3, 61.8, 41.8, 34.8, 16.7, 0.1. HRMS [m/z+H
+
] 243.8411 (calcd for 
C12H22O3Si, 242.1338). 
 
(4-((4aR,6R,7aR)-2-(4-Methoxyphenyl)tetrahydro-4H-
furo[3,2-d][1,3]dioxin-6-yl)but-1-ynyl)trimethylsilane (3-94) 
Diol 3-93 (50.0 mg, 0.21 mmol) in 3.00 mL CH2Cl2 was added 
p-methoxybenzaldehyde diethylacetal (45.0 μL, 0.23 mmol) 
followed by 10-CSA (5.00 mg, 0.02 mmol). After stirring at 
room temperature for 3 h, the solution was quenched with 5.00 mL H2O and 5.00 mL 
CH2Cl2. The mixture was separated and the aqueous layer was extracted with CH2Cl2 (3 
x 5.00 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc−hexanes for elution provided the title 
compound as colorless oil (93% yield, 69.0 mg). Rf 0.64 (50% EtOAc/hexanes). 
1
H NMR 
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(400 MHz, CDCl3)  7.41 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 5.40 (s, 1H), 
4.55−4.51 (m, 2H), 4.36 (d, J = 12.9 Hz, 1H), 4.06 (dd, J = 13.1, 2.2 Hz, 1H), 3.79 (s, 
4H), 2.40−2.28 (m, 3H), 1.90−1.81 (m, 1H), 1.79−1.71 (m, 2H), 0.13 (s, 9H); 13C NMR 
(100 MHz, CDCl3)  160.0, 130.6, 127.5, 113.6, 106.8, 99.3, 84.6, 78.3, 77.3, 73.4, 67.9, 
55.2, 39.8, 35.3, 16.8, 0.1. HRMS m/z 360.1878 (calcd for C20H28O4Si, 360.1757). 
 
(4aR,6R,7aR)-6-(But-3-ynyl)-2-(4-
methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine (3-95) 
Alkyne 3-94 (262 mg, 0.72 mmol) in 6.00 mL MeOH was 
added K2CO3 (110 mg, 0.80 mmol) and the solution was 
allowed to stir at RT for 6 h. The reaction was quenched by the 
addition of 6.00 mL half saturated aqueous NH4Cl, followed by 6.00 mL EtOAc. The 
aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and the combined organic 
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated 
under reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (98% yield, 207 mg). Rf 
0.43 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.40 (d, J = 8.8 Hz, 2H), 6.86 
(d, J = 8.8 Hz, 2H), 5.38 (s, 1H), 4.54−4.49 (m, 1H), 4.47−4.46 (m, 1H), 4.33 (d, J = 13.5 
Hz, 1H), 4.03 (dd, J = 13.2, 2.1 Hz, 1H), 3.76 (s, 4H), 2.38−2.33 (m, 1H), 2.30−2.24 (m, 
2H), 1.94 (t, J = 12.9 Hz, 1H), 1.86−1.80 (m, 1H), 1.78−1.69 (m, 2H); 13C NMR (100 
MHz, CDCl3)  159.9, 130.6, 127.4, 113.5, 99.2, 83.9, 78.0, 77.2, 73.3, 68.4, 67.7, 55.1, 
39.7, 35.1, 15.3. HRMS m/z 288.1361 (calcd for C17H20O4, 288.1362). 
 
(4aR,6R,7aR)-6-((Z)-3-Chlorohepta-3,6-dienyl)-2-(4-
methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine  
(3-96) 
A solution of PdCl2 (7.70 mg, 0.04 mmol) and LiCl (12.8 
mg, 0.30 mmol) in 4.86 mL acetone:acetic acid (4:1) was 
cooled to −78 °C. Alkyne 3-95 (42.0 mg, 0.15 mmol) and then allyl chloride (118 μL, 
1.46 mmol) were added neat, allowed to stir for 30 min, then allowed to warm to RT and 
stirred for 16 h. The reaction was quenched at the addition of 5.00 mL H2O, and the 
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aqueous layer was extracted with EtOAc (3 x 5.00 mL), and the combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (83% yield, 44.0 mg). Rf 
0.70 (50% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.41 (d, J = 8.8 Hz, 2H), 6.87 
(d, J = 8.8 Hz, 2H), 5.82−5.75 (m, 1H), 5.54 (t, J = 7.0 Hz, 1H), 5.40 (s, 1H), 5.06 (dq, J 
= 17.5, 1.6 Hz, 1H), 4.99 (dq, J = 10.2, 1.5 Hz, 1H), 4.51−4.44 (m, 2H), 4.36 (d, J = 12.9 
Hz, 1H), 4.06 (dd, J = 12.9, 2.2 Hz, 1H), 3.82−3.80 (m, 1H), 3.79 (s, 3H), 2.92 (t, J = 6.7 
Hz, 2H), 2.53 (ddd, J = 14.6, 9.4, 5.9 Hz, 1H), 2.40 (ddd, J = 14.8, 8.6, 6.4 Hz, 1H), 2.27 
(dd, J = 13.5, 5.9 Hz, 1H), 1.86−1.79 (m, 2H), 1.73 (ddd, J = 13.5, 9.7, 3.8 Hz, 1H); 13C 
NMR (100 MHz, CDCl3)  160.0, 135.2, 130.7, 127.5, 122.9, 115.3, 113.6, 99.3, 78.4, 
77.3, 73.4, 68.0, 55.3, 40.0, 36.3, 34.3, 32.8.  
 
(4aR,6R,7aR)-6-((3Z)-3-Chloroocta-3,6-dienyl)-2-(4-
methoxyphenyl)tetrahydro-4H-furo[3,2-d][1,3]dioxine  
(3-98) 
The title compound was obtained from alkyne 3-95 using the 
chloropalladation reaction conditions described above in the 
procedure to obtain compound 3-96, except 3-chlorobut-1-ene was used instead of allyl 
chloride. This procedure provided the title compound as colorless oil (46% yield). Rf 0.18 
(20% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.41 (d, J = 8.8 Hz, 2H), 6.87 (d, J 
= 8.8 Hz, 2H), 5.52−5.47 (m, 2H), 5.40 (s, 1H), 5.40−5.35 (m, 1H), 4.51−.4.49 (m, 1H), 
4.47−4.44 (m, 1H), 4.36 (d, J = 13.5 Hz, 1H), 4.06 (d, J = 12.9 Hz, 1H), 3.81−3.80 (m, 
1H), 3.78 (s, 3H), 2.91 (t, J = 7.0 Hz, 1H), 2.83 (t, J = 6.4 Hz, 1H), 2.52−2.48 (m, 1H), 
2.40−2.34 (m, 1H), 2.27 (dd, J = 13.2, 5.6 Hz, 1H), 1.85−1.78 (m, 2H), 1.72 (ddd, J = 
13.2, 9.7, 4.1 Hz, 1H), 1.67−1.61 (m, 3H); 13C NMR (100 MHz, CDCl3)  160.0, 134.4, 
134.3, 130.7, 127.7, 127.4, 126.9, 126.0, 125.1, 123.9, 123.8, 113.5, 99.3, 78.4, 77.3, 
73.4, 67.9, 55.2, 40.0, 36.2, 36.2, 34.4, 34.3, 31.7, 26.6, 17.8. HRMS m/z 378.1605 (calcd 
for C21H27ClO4, 378.1598).  
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Methyl 2-(hydroxymethyl)acrylate (3-101) 
Formaldehyde (5.00 g, 166 mmol) and methyl acrylate (44.0 mL, 498 
mmol) in 20.0 mL 1,4-dioxane:H2O (1:1 ratio), was added DABCO 
(18.6 g, 166 mol) and the solution was allowed to stir for 16 h at RT. EtOAc (20.0 mL) 
and H2O (20.0 mL) were then added and the aqueous layer was extracted with EtOAc (3 
x 20.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (89% yield, 17.1 g). Rf 0.27 (40% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)  6.26 (d, J = 1.2 Hz, 1H), 5.83 (d, J = 1.2 Hz, 1H), 4.33 (d, J = 5.9 
Hz, 2H), 3.79 (s, 3H), 2.18 (t, J = 6.6 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  166.8, 
139.2, 125.9, 62.5, 51.9. 
 
Methyl 2-((tert-butyldimethylsilyloxy)methyl)acrylate (3-102) 
The title compound was obtained from alcohol 3-101 using the 
standard TBS protection reaction conditions described above in the 
procedure to obtain compound 3-67a. This procedure provided the title compound as 
colorless oil (100% yield). Rf 0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  
6.24 (q, J = 1.9 Hz, 1H), 5.89 (d, J = 2.1 Hz, 1H), 4.35 (t, J =2.2 Hz, 2H), 3.74 (s, 3H), 
0.90 (s, 9H), 0.07 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  166.4, 139.6, 123.9, 61.5, 51.6, 
25.9, 18.3, −5.5. 
 
2-((tert-Butyldimethylsilyloxy)methyl)prop-2-en-1-ol (3-103) 
Ester 3-102 (9.02 g, 39.4 mmol) in 80.0 mL THF at −78 °C was added 
DIBAL (84.7 mL, 84.7 mmol, 1.00 M in Et2O) dropwise. After stirring for 1 h at 0 °C, 
the solution was slowly poured into 80.0 mL half saturated aqueous solution of 
Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the 
aqueous layer was extracted with EtOAc (3 x 60.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (93% yield, 7.35 g). Rf 
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0.74 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.07 (d, J = 6.6 Hz, 2H), 4.23 
(s, 2H), 4.16 (d, J = 5.5 Hz, 2H), 2.00 (t, J = 5.9 Hz, 1H), 0.90 (s, 9H), 0.07 (s, 6H); 
13
C 
NMR (100 MHz, CDCl3)  147.5, 111.1, 65.1, 64.7, 25.9, 18.3, −5.4. 
 
2-((tert-Butyldimethylsilyloxy)methyl)acrylaldehyde (3-104) 
The title compound was obtained from alcohol 3-103 after a standard 
Swern oxidation, as described above in the procedure to obtain compound 
3-67. This procedure provided the title compound as pale yellow oil (96% yield). Rf 0.74 
(50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.60 (s, 1H), 6.51 (d, J = 1.6 Hz, 
1H), 6.09 (d, J = 1.2 Hz, 1H), 4.38 (t, J = 2.2 Hz, 2H),  0.91 (s, 9H), 0.07 (s, 6H); 
13
C 
NMR (100 MHz, CDCl3)  193.6, 149.5, 132.8, 59.6, 25.8, 18.3, −5.5. 
 
Ethyl 4-((tert-butyldimethylsilyloxy)methyl)-3-hydroxypent-4-
enoate (rac-3-105) 
To iPr2NH (885 μL, 6.26 mmol) in 10.0 mL THF at 0 °C was 
added nBuLi (2.18 mL, 5.48 mmol, 2.51 M in hexanes) dropwise. After 15 min at 0 °C, 
the solution was cooled to −60 °C and EtOAc (539 μL, 5.48 mmol) was added dropwise. 
The solution was allowed to stir for 30 min at −60 °C and then a solution of aldehyde 3-
104 (980 mg, 4.89 mmol) in 1.00 mL THF was added slowly. The solution was stirred at 
−40 °C for 1 h and then the reaction mixture was quenched by 10.0 mL half saturated 
NH4Cl. The aqueous layers were then extracted with EtOAc (3 x 10.0 mL), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (83% 
yield, 1.17 g). Rf 0.71 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.13 (s, 2H), 
4.63−4.59 (m, 1H), 4.29−4.20 (m, 2H), 4.16 (q, J = 7.2 Hz, 2H), 3.27 (d, J = 5.1 Hz, 1H), 
2.66 (s, 1H), 2.64 (d, J = 2.3 Hz, 1H), 1.26 (t, J = 7.0 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  172.3, 148.1, 111.3, 69.6, 64.4, 60.7, 40.7, 25.9, 18.3, 
14.2, −5.5. 
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(R)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-3-
hydroxypent-4-enoate ((R)-3-105) 
To a mixture of 4Ǻ molecular sieves (400 mg), and Ti(OiPr)2 (162 
μL, 0.55 mmol) in 5.00 mL CH2Cl2 was added (+)-diethyl tartrate (113 μL, 0.66 mmol) 
dropwise at −20 °C. The mixture was stirred at −20 °C for 20 min and then allylic alcohol 
rac-3-105 (400 mg, 1.38 mmol) in 1.00 mL CH2Cl2 was added. After 20 min at −20 °C, 
the solution was cooled to −40 °C and a solution of tert-butyl hydroperoxide (259 μL, 
1.38 mmol, 5.33 M in isooctane) was added dropwise and the resulting solution was 
allowed to stir for 24 h at −20 °C. Me2S (101 μL, 1.38 mmol) was added slowly and the 
solution was allowed to stir at −20 °C for 30 min before adding tartaric acid (207 mg, 
1.38 mmol). The solution was then filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (42% yield, 190 mg, 60% 
ee). All characterization data is the same as the racemic mixture above. The enantiomeric 
excess was determined by NMR with the use of chiral shift reagent Eu(hfc)3 
(Europium(III)tris[3-hepafluoropropylhydroxymethylene]-d-camphorate). 
 
Ethyl 3-(tert-butyldimethylsilyloxy)-4-((tert-
butyldimethylsilyloxy)methyl)pent-4-enoate (3-106) 
The title compound was obtained from alcohol (R)-3-105 using the 
standard TBS protection reaction conditions described above in the procedure to obtain 
compound 3-67a. This procedure provided the title compound as colorless oil (95% 
yield). Rf 0.75 (25% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.11 (s, 2H), 4.67 
(dd, J = 8.2, 4.7 Hz, 1H), 4.18 (s, 2H), 4.14-4.06 (m, 2H), 2.57-2.46 (m, 2H), 1.24 (t, J = 
7.2 Hz, 1H), 0.90 (s, 9H), 0.85 (s, 9H), 0.06 (s, 6H), 0.02 (s, 3H), 0.00 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3)  171.3, 149.9, 110.3, 71.4, 62.5, 60.4, 43.4, 25.9, 25.7, 18.4, 18.0, 
14.2, −4.7, −5.4. 
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3-(tert-Butyldimethylsilyloxy)-4-((tert-
butyldimethylsilyloxy)methyl)pent-4-enoic acid (3-107) 
An aqueous solution of KOH (202 mg, 3.60 mmol, 10.0 M) was 
added to a solution of ester 3-106 in 3.00 mL EtOH and allowed to stir for 16 h. After 
addition of 1.00 M HCl solution until the solution was pH 4, EtOAc (10.0 mL) was 
added. The aqueous layer was then extracted with EtOAc (3 x 10.0 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure provided the title compound as a white solid (96% 
yield, 130 mg). Rf 0.07 (25% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.18-5.15 
(m, 2H), 4.73-4.66 (m, 1H), 4.23-4.14 (m, 2H), 2.73-2.63 (m, 2H), 0.90 (s, 9H), 0.88 (s, 
9H), 0.09 (s, 3H), 0.07 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H). 
 
Methyl 3-hydroxy-2-methyleneoct-7-enoate (3-110) 
To a stirred solution of hex-5-enal (1.00 g, 10.2 mmol) and methyl 
acrylate (919 μL, 10.2 mmol) at room temperature was added DABCO (1.14 g, 10.2 
mmol), Sc(OTf)3 (251 mg, 0.51 mmol), and (+)-diethyltartrate (873 μL, 5.10 mmol). 
After stirring for 7 days, the thick and homogeneous mixture was diluted with 100 mL 
Et2O and washed with 20.0 mL 2% HCl aqueous solution, followed by 20.0 mL H2O. 
The organic layer were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as colorless oil (49% yield, 
920 mg). Rf 0.60 (50% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)   6.22 (s, 1H), 
5.84−5.74 (m, 2H), 5.02−4.93 (m, 2H), 4.40−4.37 (m, 1H), 3.77 (s, 3H), 2.20 (bs, 1H), 
2.10−2.05 (m, 2H), 1.69−1.62 (m, 2H), 1.61−1.52 (m, 1H), 1.48−1.39 (m, 1H); 13C NMR 
(100 MHz, CDCl3)  167.0, 142.3, 138.5, 125.1, 114.7, 110.0, 71.7, 51.9, 35.6, 33.4, 
25.1. HRMS [m/z+H
+
] 185.1176 (calcd for C10H16O3, 184.1099). 
 
(E)-2-(Methoxycarbonyl)octa-2,7-dienyl 4-nitrobenzoate (3-111) 
To a solution of allylic alcohol 3-110 (195 mg, 1.06 mmol) in 10.0 
mL THF was added triphenyl phosphine (359 mg, 1.37 mmol) and p-nitrobenzoic acid 
(229 mg, 1.37 mmol). The solution was cooled to −40 °C and DIAD (271 μL, 1.37 
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mmol) over 10 min. The solution was allowed to warm to −30 °C over 1 h and kept at 
that temperature for 3 h. After slowly warming to 0 °C for 15 min, the solution was 
concentrated under reduced pressure. The residue was dissolved in 20.0 mL EtOAc and 
washed with 20.0 mL H2O followed by 10.0 mL 1.00 M aqueous NaOH solution. The 
aqueous layers were then extracted with EtOAc (3 x 20.0 mL), and the combined organic 
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated 
under reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as pale yellow oil (93% yield, 328 mg). 
Rf 0.64 (50% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  8.26 (d, J = 8.8 Hz, 2H), 
8.16 (d, J = 8.8 Hz, 2H), 7.14 (t, J = 7.6 Hz, 1H), 5.79−5.72 (m, 1H), 5.13 (s, 2H), 
5.01−4.96 (m, 2H), 3.79 (s, 3H), 2.39 (q, J = 17.9, 11.9 Hz, 1H), 2.09 (q, J = 7.0 Hz, 1H), 
1.59 (p, J = 7.5 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  166.7, 164.4, 150.5, 150.1, 
137.6, 135.4, 130.8, 126.7, 123.5, 115.4, 59.4, 52.1, 33.2, 28.2, 27.7. HRMS m/z 
333.1209 (calcd for C17H19NO6, 333.1212). 
 
(E)-Methyl 2-(hydroxymethyl)octa-2,7-dienoate (3-112) 
A solution of ester 3-111 (220 mg, 0.66 mmol) in 14.0 mL MeOH 
and 4.20 mL THF was cooled to 0 °C and K2CO3 (91.0 mg, 0.66 mmol) was added. After 
stirring for 2 h at 0 °C, the solvent was removed under reduced pressure and the residue 
dissolved in 20.0 mL half saturated brine and 20.0 mL EtOAc. The aqueous layers were 
then extracted with EtOAc (3 x 10.0 mL), and the combined organic layers were washed 
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced 
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for 
elution provided the title compound as colorless oil (78% yield, 95.0 mg). Rf 0.54 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.87 (t, J = 7.8 Hz, 1H), 5.82−5.71 (m, 
1H), 5.03−4.91 (m, 2H), 4.31 (s, 2H), 3.77 (s, 3H), 2.30−2.25 (m, 3H), 2.07 (q, J = 7.0 
Hz, 2H), 1.55 (p, J = 7.4 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  168.0, 145.5, 137.8, 
131.0, 115.2, 57.3, 51.9, 33.1, 27.8, 27.6. HRMS [m/z+H
+
] 185.1175 (calcd for C10H16O3, 
184.1099). 
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(E)-Methyl-2-((4-methoxybenzyloxy)methyl)octa-2,7-dienoate 
(3-113) 
To a solution of alcohol 3-112 (150 mg, 0.81 mmol) and 4-methoxybenzyl-2,2,2-
trichloroacetimidate (461 mg, 1.63 mmol) in 3.00 mL CH2Cl2, was added 10-CSA (19.0 
mg, 0.08 mmol) at RT. The solution was allowed to stir for 16 h and quenched by 10.0 
mL half saturated NaHCO3 and 10.0 mL CH2Cl2. The aqueous layers were then extracted 
with CH2Cl2 (3 x 10.0 mL), and the combined organic layers were washed with brine, 
dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the title compound as colorless oil (87% yield, 216 mg). Rf 0.70 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.26 (d, J = 8.6 Hz, 2H), 6.99 (t, J = 7.8 
Hz, 1H), 6.87 (d, J = 8.6 Hz, 2H), 5.76 (ddt, J = 17.0, 10.4, 6.6 Hz, 1H), 5.08−4.95 (m, 
2H), 4.45 (s, 2H), 4.20 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H), 2.24 (q, J = 7.7 Hz, 2H), 2.05 
(q, J = 7.0 Hz, 2H), 1.56−1.49 (m, 2H); 13C NMR (100 MHz, CDCl3)  167.6, 159.2, 
148.2, 138.0, 130.4, 129.4, 129.2, 115.1, 113.7, 72.1, 63.1, 55.3, 51.8, 33.3, 28.1, 27.8. 
HRMS m/z 304.8147 (calcd for C18H24O4, 304.1675). 
 
(E)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dienal (3-114) 
The title compound was obtained from alcohol (Z)-3-125 after a 
standard Swern oxidation, as described above in the procedure to 
obtain compound 3-67. This procedure provided the title compound as colorless oil (95% 
yield). Rf 0.51 (30% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  9.42 (s, 1H), 7.23 
(d, J = 9.4 Hz, 2H), 7.23 (d, J = 9.4 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 6.68 (t, J = 7.6 Hz, 
1H), 5.79-5.72 (m, 1H), 5.01−4.96 (m, 2H), 4.41 (s, 2H), 4.16 (s, 2H), 3.78 (s, 3H), 2.43 
(q, J = 7.6 Hz, 2H), 2.07 (q, J = 7.0 Hz, 2H), 1.59 (p, J = 7.5 Hz, 2H); 
13
C NMR (100 
MHz, CDCl3)  193.8, 159.2, 139.8, 137.7, 130.2, 129.5, 115.3, 113.7, 72.5, 60.6, 55.2, 
33.3, 28.6, 27.7.  
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Methyl 2-((4-methoxybenzyloxy)methyl)acrylate (3-115) 
To a solution of alcohol 3-101 (560 mg, 4.82 mmol) and 4-
methoxybenzyl-2,2,2-trichloroacetimidate (2.72 g, 9.64 mmol) in 30.0 
mL CH2Cl2, was added 10-CSA (111 mg, 0.48 mmol) at RT. The solution was allowed to 
stir for 16 h and quenched by 30.0 mL half saturated NaHCO3 and 30.0 mL CH2Cl2. The 
aqueous layers were then extracted with CH2Cl2 (3 x 20.0 mL), and the combined organic 
layers were washed with brine, dried (MgSO4), filtered through Celite and concentrated 
under reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (82% yield, 932 mg). Rf 
0.63 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.28−7.25 (m, 2H), 
6.89−6.86 (m, 2H), 6.30 (q, J = 1.4 Hz, 1H), 5.91 (q, J = 1.8 Hz, 1H), 4.50 (s, 2H), 4.19 
(t, J = 1.6 Hz, 2H), 3.80 (s, 3H), 3.75 (s, 3H). HRMS m/z 236.1050 (calcd for C13H16O4, 
236.1049). 
 
2-((4-Methoxybenzyloxy)methyl)prop-2-en-1-ol (3-115b) 
The title compound was obtained from ester 3-115 after a DIBAL 
reduction, as described above in the procedure to obtain compound (Z)-3-125. This 
procedure provided the title compound as colorless oil (86% yield). Rf 0.29 (40% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.26−7.24 (m, 1H), 6.89−6.86 (m, 2H), 
5.19−5.18 (m, 1H), 5.14−5.12 (m, 1H), 4.45 (s, 2H), 4.18 (d, J = 5.9 Hz, 2H), 4.06 (s, 
2H), 3.80 (s, 3H), 1.89 (t, J = 6.1 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  159.3, 145.1, 
130.0, 129.4, 113.8, 113.5, 72.0, 71.5, 64.6, 55.3. HRMS m/z 208.1098 (calcd for 
C12H16O3, 208.1099). 
 
2-((4-Methoxybenzyloxy)methyl)acrylaldehyde (3-116) 
The title compound was obtained from alcohol 3-115b after a standard 
Swern oxidation, as described above in the procedure to obtain 
compound 3-67. This procedure provided the title compound as pale yellow oil (98% 
yield). Rf 0.71 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.58 (s, 1H), 7.24 
(d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 6.52 (d, J = 1.2 Hz, 1H), 6.11 (d, J = 1.2 Hz, 
1H), 4.50 (s, 2H), 4.19 (t, J = 1.8 Hz, 2H), 3.80 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  
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193.3, 159.2, 146.7, 133.9, 129.8, 129.2, 113.7, 72.7, 65.5, 55.1. HRMS m/z 206.0937 
(calcd for C12H14O3, 206.0943). 
 
2-((4-Methoxybenzyloxy)methyl)octa-1,7-dien-3-ol (3-117) 
Aldehyde 3-116 (100 mg, 0.48 mmol) in 6.00 mL Et2O at 0 °C was 
added a solution of pent-4-enylmagnesium bromide (10.0 mL, 0.96 mmol, 0.10 M in 
Et2O). After 2 h at RT, the reaction was quenched with 10.0 mL half saturated aqueous 
NH4Cl solution.  The aqueous layer was then extracted with EtOAc (3 x 10.0 mL), and 
the combined organic layers were washed with brine, dried (MgSO4), filtered through 
Celite and concentrated under reduced pressure. Purification by flash chromatography on 
silica gel using EtOAc-hexanes for elution provided the title compound as colorless oil 
(75% yield, 100 mg). Rf 0.53 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.24 
(d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 5.77 (ddt, J = 17.1, 10.3, 6.5 Hz, 1H), 5.13 
(d, J = 16.9 Hz, 2H), 4.98 (d, J = 16.9 Hz, 1H), 4.92 (d, J = 9.9 Hz, 1H), 4.44 (s, 2H), 
4.18−4.14 (m, 1H), 4.09 (d, J = 11.7 Hz, 1H), 4.00 (d, J = 12.3 Hz, 1H), 3.79 (s, 3H), 
2.39 (bs, 1H), 2.05 (q, J = 7.4 Hz, 2H), 1.58 (q, J = 12.0, 6.0 Hz, 2H), 1.54−1.48 (m, 1H), 
1.41−1.35 (m, 1H); 13C NMR (100 MHz, CDCl3)  159.3, 147.3, 138.6, 129.9, 129.4, 
114.6, 113.8, 113.8, 113.7, 72.1, 71.0, 55.2, 35.1, 33.5, 25.0. HRMS m/z 276.1737 (calcd 
for C17H24O3, 276.1725). 
 
2-((4-Methoxybenzyloxy)methyl)octa-1,7-dien-3-yl-4-
nitrobenzoate (3-119) 
The title compound was obtained from alcohol 3-117 using the Mitsunobu reaction 
conditions described above in the procedure to obtain compound 3-111. This procedure 
provided the title compound as colorless oil (73% yield). Rf 0.75 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  8.24 (d, J = 9.3 Hz, 2H), 8.16 (d, J = 9.4 Hz, 2H), 7.23 (d, 
J = 8.8 Hz, 2H), 6.84 (d, J = 8.2 Hz, 2H), 5.76 (ddt, J = 16.9, 10.3, 6.9 Hz, 1H), 5.59 (t, J 
= 6.4 Hz, 1H), 5.27 (d, J = 3.5 Hz, 2H), 4.99 (dq, J = 17.4, 1.4 Hz, 1H), 4.96-4.94 (m, 
1H), 4.47 (d, J = 11.1 Hz, 1H), 4.40 (d, J = 11.0 Hz, 1H), 4.08 (d, J = 11.9 Hz, 1H), 4.05 
(d, J = 11.9 Hz, 1H), 3.79 (s, 3H), 2.10−2.07 (m, 2H), 1.87−1.83 (m, 2H), 1.52−1.46 (m, 
2H); 
13
C NMR (100 MHz, CDCl3)  163.9, 159.2, 150.5, 143.6, 138.1, 135.8, 130.7, 
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130.0, 129.4, 123.5, 115.1, 113.7, 76.5, 71.9, 70.1, 55.3, 33.3, 32.7, 24.7. HRMS m/z 
425.1823 (calcd for C24H27NO6, 425.1838). 
 
Hex-5-enyltriphenylphosphonium iodide (3-121) 
6-Iodohex-1-ene (9.46 g, 45.0 mmol) and triphenylphosphine 
(17.7 g, 67.5 mmol) were dissolved in 220 mL MeCN and the solution was heated to 90 
°C for 48 h. The solution was cooled to room temperature and the concentrated under 
reduced pressure. Residue triturated with Et2O (2 x 50.0 mL) and minor amounts of 
solvent removed under reduced pressure to provide the title compound as white solid 
(94% yield, 20.2 g). 
1
H NMR (600 MHz, CDCl3)  7.84−7.78 (m, 10H), 7.71−7.68 (m, 
6H), 5.67 (ddt, J = 17.1, 10.2, 6.9 Hz, 1H), 4.92 (dq, J = 17.1, 1.7 Hz, 1H), 4.88 (dd, J = 
9.7, 1.5 Hz, 1H), 3.77−3.72 (m, 2H), 2.08 (q, J = 7.0 Hz, 2H), 1.78 (quin, J = 7.5 Hz, 
2H), 1.66−1.60 (m, 2H); 13C NMR (100 MHz, CDCl3)  135.0, 133.8, 130.5, 130.4, 
115.4, 110.0, 32.9, 29.2, 23.2, 21.8. 
 
5-(hex-5-enylidene)-2,2-dimethyl-1,3-dioxane (3-122) 
To a solution of hexenyltriphenylphosphonium iodide 3-121 (20.0 g, 
42.4 mmol) in 220 mL THF at −78 °C was added nBuLi (18.6 mL, 35.8 
mmol, 1.92 M in hexanes) dropwise. After 1 h at −78 °C, 2,2-dimethyl-
1,3-dioxan-5-one 3-120 (3.67 g, 28.2 mmol) in 30.0 mL THF was added slowly and 
stirred at −78 °C for 2 h followed by 30 min at 0 °C. Solution cooled to −78 °C, and 
quenched by the addition of 200 mL half saturated aqueous NH4Cl, followed by 100 mL 
THF. The mixture was allowed to stir until warmed to room temperature, the layers 
separated, and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as colorless oil (95% yield, 
5.23 g). Rf 0.50 (20% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.77 (ddt, J = 
16.9, 10.4, 6.5 Hz, 1H), 5.22 (t, J = 7.4 Hz, 1H), 4.98 (m, 2H), 4.38 (s, 2H), 4.22 (s, 2H), 
2.04 (q, J = 6.6 Hz, 2H), 1.96 (q, J = 7.4 Hz, 2H), 1.42 (s, 8H); 
13
C NMR (100 MHz, 
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CDCl3)  138.4, 131.9, 123.3, 114.8, 99.0, 64.6, 59.9, 41.9, 33.2, 28.5, 26.0, 24.1. HRMS 
m/z 196.1485 (calcd for C12H20O2, 196.1463). 
 
2-(Hex-5-enylidene)propane-1,3-diol (3-123) 
Acetal 3-122 (1.00 g, 5.09 mmol) in 150 mL MeOH (reagent grade) was 
added PPTS (25.0 mg, 0.10 mmol). After 2 h of stirring, NaHCO3 (8.00 
mg, 0.10 mmol) was added and the solution was concentrated under reduced pressure. 
Purification of the residue by flash chromatography on silica gel using EtOAc-hexanes 
for elution provided the title compound as colorless oil (97% yield, 771 mg). Rf 0.15 
(40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.83−5.73 (m, 1H), 5.54 (t, J = 7.8 
Hz, 1H), 5.02−4.94 (m, 2H), 4.30 (s, 2H), 4.21 (s, 2H), 2.12−2.01 (m, 6H), 1.47 (quin, J 
= 7.5 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  138.4, 137.2, 130.9, 114.8, 67.7, 60.1, 
33.2, 28.7, 26.7. HRMS [m/z+H
+
] 157.1031 (calcd for C9H16O2, 156.1150). 
 
5-(Hex-5-enylidene)-2-(4-methoxyphenyl)-1,3-dioxane (3-123b) 
Diol 3-123 (250 mg, 1.60 mmol) in 15.0 mL CH2Cl2 was added p-
methoxybenzaldehyde diethylacetal (350 μL, 1.76 mmol) followed by 
10-CSA (37.0 mg, 0.16 mmol). After stirring at room temperature for 16 
h, the solution was quenched with 20.0 mL H2O. The mixture was 
separated and the aqueous layer was extracted with CH2Cl2 (3 x 10.0 
mL). The combined organic layers were washed with brine, dried (MgSO4), filtered 
through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (89% yield, 390 mg). Rf 0.67 (40% EtOAc/hexanes). 
1
H NMR 
(600 MHz, CDCl3)  7.43−7.40 (m, 2H), 6.90−6.87 (m, 2H), 5.79 (ddt, J = 17.1, 10.3, 6.6 
Hz, 1H), 5.58 (s, 1H), 5.39 (t, J = 7.6 Hz, 1H), 5.03 (dq, J = 17.2, 1.7 Hz, 1H), 4.99−4.96 
(m, 1H), 4.83 (d, J = 12.9 Hz, 1H), 4.50 (d, J = 12.0 Hz, 1H), 4.39−4.32 (m, 2H), 3.78 
(m, 3H), 2.15−1.98 (m, 4H), 1.53−1.43 (m, 2H); 13C NMR (100 MHz, CDCl3)  159.9, 
138.2, 130.7, 129.3, 127.3, 126.0, 114.8, 113.5, 101.4, 72.4, 66.2, 55.2, 41.8, 33.0, 28.5, 
25.9. HRMS m/z 274.1639 (calcd for C17H22O3, 274,1569). 
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2-((tert-Butyldimethylsilyloxy)methyl)octa-2,7-dien-1-ol (3-124) 
Diol 3-123 (1.54 g, 9.86 mmol) in 80.0 mL CH2Cl2 was added 
imidazole (778 mg, 11.4 mmol) followed by TBSCl (1.56 g, 10.4 mmol). After stirring 
for 16 h, 50.0 mL of H2O was added. The mixture was separated and the aqueous layer 
was extracted with CH2Cl2 (3 x 30.0 mL). The combined organic layers were washed 
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced 
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for 
elution provided the title compound as colorless oil (75% yield brsm (3:1 ratio of E:Z), 
1.59 g). Rf  0.66 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  5.83−5.73 (m, 
1H), 5.47 (t, J = 7.4 Hz, 1H), 5.02−4.93 (m, 2H), 4.33−4.13 (m, 4H), 2.17 (bs, 1H), 
2.13−2.02 (m, 4H), 1.46 (quin, J = 7.5 Hz, 2H), 0.90 (s, 9H), 0.08 (s, 6H); 13C NMR (100 
MHz, CDCl3)  138.5, 137.0, 129.3, 129.0, 114.7, 68.3, 67.3, 61.1, 60.0, 33.2, 28.8, 28.6, 
26.8, 26.7, 25.9, 18.3, −5.4, −5.5. HRMS [m/z+H+] 271.2083 (calcd for C15H30O2Si, 
270.2015). 
 
(Z)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol             
((Z)-3-125) 
To a solution of ester 3-113 (5.26 g, 17.3 mmol) in 100 mL THF at −78 °C was added 
DIBAL (36.3 mL, 36.3 mmol, 1.00 M in Et2O). After 1 h at −78 °C, the reaction mixture 
slowly poured into 150 mL half saturated aqueous solution of Rochelle’s salt 
(Na·K·tartrate) and stirred for 30 min. The mixture was separated and the aqueous layer 
was extracted with EtOAc (3 x 40.0 mL). The combined organic layers were washed with 
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the title compound as colorless oil (76% yield, 3.63 g). Rf 0.49 (50% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.25 (d, J = 8.2 Hz, 2H), 6.87 (d, J = 8.6 
Hz, 2H), 5.82−5.72 (m, 1H), 5.61 (t, J = 7.4 Hz, 1H), 5.02−4.93 (m, 2H), 4.44 (s, 2H), 
4.13 (s, 2H), 4.12 (s, 2H), 3.80 (s, 3H), 2.07−2.00 (m, 4H), 1.75 (bs, 1H), 1.45 (p, J = 7.5 
Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  159.2, 138.4, 135.3, 131.2, 130.0, 129.3, 114.7, 
113.8, 72.2, 66.9, 66.5, 55.2, 33.2, 28.6, 26.9. HRMS m/z 275.1638 (calcd for C17H24O3, 
276.1725). 
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(Z)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol  
((Z)-3-125) 
(E)-2-((4-Methoxybenzyloxy)methyl)octa-2,7-dien-1-ol  
((E)-3-125) 
Acetal 3-123b (337 mg, 1.23 mmol) was dissolved in 6.00 mL Et2O at 0 °C, and DIBAL 
(1.00 M in Et2O, 2.70 mL, 2.70 mmol) was added dropwise. After stirring for 3 h at 0 °C, 
the solution was slowly poured into 50 mL half saturated aqueous solution of Rochelle’s 
salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the aqueous 
layer was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed 
with brine, dried (MgSO4), filtered through Celite and concentrated under reduced 
pressure. Purification by flash chromatography on silica gel using EtOAc-hexanes for 
elution provided the separable isomers as colorless oils (92% yield, 2:1 dr, 208 mg (E-
isomer), 104 mg (Z-isomer). The characterization data for the (Z)-isomer is reported 
above, whereas the (E)-isomer data is reported here: Rf 0.46 (40% EtOAc/hexanes). 
1
H 
NMR (400 MHz, CDCl3)  7.27−7.23 (m, 2H), 6.89−6.85 (m, 2H), 5.78 (ddt, J = 17.0, 
10.4, 6.6 Hz, 1H), 5.54 (t, J = 7.4 Hz, 1H), 5.03−4.93 (m, 2H), 4.44 (s, 2H), 4.23 (s, 2H), 
4.05 (s, 2H), 3.80 (s, 3H), 2.12 (q, J = 7.4 Hz, 2H), 2.08−2.03 (m, 2H), 1.47 (quin, J = 7.5 
Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  159.3, 138.4, 134.9, 132.1, 130.0, 129.4, 114.7, 
113.8, 74.7, 71.9, 60.0, 55.2, 33.2, 28.6, 26.8. HRMS m/z 276.1715 (calcd for C17H24O3, 
276.1725). 
 
(R,E)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-
yl)-4-((4-methoxybenzyloxy)methyl)deca-4,9-dien-1-one 
(3-126) 
TiCl4 (74.0 μL, 0.68 mmol) and NEt(iPr)2 (117 μL, 0.67 
mmol) are added sequentially to a solution of auxilliary 3-64 (127 mg, 0.63 mmol) in 
2.50 mL CH2Cl2 at −40 °C. After 1.5 h at −40 °C, the solution was cooled to −78 °C, and 
the aldehyde 3-114 (104 mg, 0.38 mmol) is added slowly dropwise. After 10 min at −78 
°C, the reaction is quenched with the addition of 2.50 mL 1.00 M NaH2PO4·H2O and the 
solution was allowed to warm to RT. The aqueous layer was then extracted with CH2Cl2 
(3 x 10.0 mL), and the combined organic layers were washed with brine, dried (MgSO4), 
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filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as pale yellow oil (63% yield, 5:1 dr, 144 mg). Rf 0.54 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.25 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 
5.81−5.70 (m, 2H), 5.14−5.11 (m, 1H), 5.00−4.92 (m, 2H), 4.62 (dd, J = 8.8, 3.3 Hz, 
2H), 4.42 (s, 2H), 4.12−4.05 (m, 2H), 3.79 (s, 3H), 3.69−3.63 (m, 1H), 3.52−3.43 (m, 
3H), 2.99 (d, J = 12.5 Hz, 1H), 2.35 (dq, J = 13.5, 6.7 Hz, 1H), 2.09−1.99 (m, 4H), 1.45 
(q, J = 7.5 Hz, 2H), 1.04 (d, J = 7.0 Hz, 1H), 0.96 (d, J = 7.0 Hz, 1H); 
13
C NMR (100 
MHz, CDCl3)  202.8, 173.0, 159.2, 138.4, 135.9, 131.8, 130.1, 129.5, 114.7, 113.8, 
72.2, 71.9, 71.5, 65.3, 55.3, 44.4, 33.2, 30.7, 30.4, 28.6, 26.9, 19.1, 17.7. HRMS m/z 
477.2001 (calcd for C25H35NO4S2, 477.2007).  
 
(R,E)-1-((S)-4-tert-Butyl-2-thioxothiazolidin-3-yl)-3-
hydroxy-4-((4-methoxybenzyloxy)methyl)deca-4,9-dien-1-
one (3-127) 
The title compound was obtained from auxilliary 3-65 and 
aldehyde 3-114 using the aldol reaction conditions described above in the procedure to 
obtain compound 3-126. This procedure provided the title compounds as pale yellow oils 
(64% yield, 7:1 dr). Rf 0.49 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.25 
(d, J = 8.2 Hz, 2H), 6.85 (d, J = 8.2 Hz, 2H), 5.79−5.70 (m, 2H), 5.27 (d, J = 8.6 Hz, 1H), 
5.00−4.92 (m, 2H), 4.70−4.66 (m, 1H), 4.42 (s, 2H), 4.11 (d, J = 17.9 Hz, 1H), 4.04 (d, J 
= 11.9 Hz, 1H), 3.79 (s, 3H), 3.55 (d, J = 5.9 Hz, 2H), 3.49 (dd, J = 11.7, 8.2 Hz, 2H), 
3.24 (d, J = 5.1 Hz, 1H), 3.07 (d, J = 11.7 Hz, 1H), 2.08−1.99 (m, 4H), 1.44 (p, J = 7.5 
Hz, 2H), 1.01 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  205.1, 171.9, 159.2, 138.4, 135.8, 
131.6, 129.9, 129.4, 114.7, 113.7, 72.3, 72.2, 71.7, 65.4, 55.2, 43.9, 37.8, 33.2, 30.6, 28.6, 
26.9, 26.8. HRMS m/z 491.2180 (calcd for C26H37NO4S2, 491.2164). 
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(S,E)-((S)-2-Hydroxy-1,2,2-triphenylethyl)-3-
hydroxy-4-((4-methoxybenzyloxy)methyl)deca-4,9-
dienoate (3-128) 
The title compound was obtained from auxilliary 3-82 
and aldehyde 3-114 using the aldol reaction conditions 
described above in the procedure to obtain compound 3-84. This procedure provided the 
title compound as colorless oil (46% yield, >20:1 dr). Rf 0.29 (30% EtOAc/hexanes). 
1
H 
NMR (400 MHz, CDCl3)  7.54 (m, 2H), 7.35−7.31 (m, 2H), 7.27−7.23 (m, 1H), 
7.20−7.07 (m, 10H), 7.02−7.00 (m, 2H), 6.86−6.82 (m, 2H), 6.66 (s, 1H), 5.78−5.70 (m, 
1H), 5.55−5.47 (m, 1H), 4.98−4.92 (m, 2H), 4.38−4.32 (m, 3H), 4.00−3.89 (m, 2H), 3.79 
(s, 3H), 3.03−2.87 (m, 2H), 2.60−2.48 (m, 2H), 1.99−1.88 (m, 4H), 1.39−1.29 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  170.7, 170.6, 159.3, 144.7, 142.5, 138.3, 135.6, 135.5, 
131.8, 131.7, 129.8, 129.8, 129.5, 128.4, 128.3, 127.9, 127.7, 127.4, 127.3, 126.9, 126.9, 
126.4, 126.4, 126.2, 114.7, 113.8, 80.2, 78.8, 72.3, 71.7, 71.7, 65.1, 55.2, 41.0, 40.9, 33.2, 
28.5, 28.4, 26.8.  
 
 2-((tert-Butyldimethylsilyloxy)methyl)octa-2,7-dienal (3-129) 
Alcohol 3-124 (800 mg, 2.96 mmol) in 20.0 mL EtOAc was added 
IBX (1.66 g, 5.92 mmol) and heated to reflux for 3 h. After allowing 
the solution to cool to room temperature, the solution was filtered through Celite and 
concentrated under reduced pressure, which provided the title compound as colorless oil 
as a 3:1 ratio of E:Z inseparable isomers (89% yield, 390 mg). Rf 0.73 (40% 
EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  10.10 (s, 0.75 H), 9.38 (s, 0.25H), 6.74 
(t, J = 8.5 Hz, 0.75H), 6.60 (t, J = 7.6 Hz, 0.25H), 5.82−5.72 (m, 1H), 5.04−4.98 (m, 2H), 
4.35 (s, 0.50H), 4.31 (s, 1.50H), 2.60 (q, J = 7.4 Hz, 1.50H), 2.52 (q, J = 7.4 Hz, 0.50H), 
2.12 (q, J = 7.0 Hz, 2H), 1.61 (quin, J = 7.5 Hz, 2H), 0.91 (s, 9H), 0.07 (s, 6H); 
13
C NMR 
(100 MHz, CDCl3)  190.3, 147.7, 138.7, 137.8, 115.4, 60.2, 54.8, 33.0, 28.6, 25.9, 18.4, 
−5.4. 
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(R)-4-Benzyl-3-((2R,3S,E)-2-chloro-3-hydroxy-4-((4-
methoxybenzyloxy)methyl)deca-4,9-dienoyl)oxazolidin-2-
one (3-131) 
The title compound was obtained from auxilliary (R)-3-87 and aldehyde 3-114 using the 
aldol reaction conditions described above in the procedure to obtain compound 3-88. This 
procedure provided the title compound as colorless oil (75% yield, >20:1 dr). Rf 0.38 
(40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.33−7.17 (m, 7H), 6.83 (d, J = 
8.2 Hz, 2H), 5.88−5.84 (m, 2H), 5.76 (ddt, J = 16.9, 10.3, 6.9 Hz, 1H), 4.98 (dq, J = 16.9, 
1.8 Hz, 1H), 4.93 (dd, J = 10.8, 1.5 Hz, 1H), 4.74−4.61 (m, 1H), 4.47−4.44 (m, 1H), 
4.41−4.36 (m, 2H), 4.07−4.01 (m, 3H), 3.80−3.74 (m, 1H), 3.77 (s, 3H), 3.21 (dd, J = 
13.8, 3.2 Hz, 1H), 3.01 (d, J = 3.5 Hz, 1H), 2.76 (dd, J = 13.5, 9.4 Hz, 1H), 2.09 (q, J = 
7.6 Hz, 2H), 2.02 (q, J = 7.0 Hz, 2H), 1.47 (quin, J = 7.5 Hz, 2H); 
13
C NMR (100 MHz, 
CDCl3)  167.5, 159.1, 152.2, 138.2, 136.9, 134.7, 132.4, 129.9, 129.4, 128.9, 128.8, 
127.3, 114.7, 113.6, 75.7, 72.3, 65.9, 64.2, 57.7, 55.1, 55.1, 37.0, 33.0, 28.4, 27.0.  
 
(R)-4-Benzyl-3-((R,E)-3-hydroxy-4-((4-
methoxybenzyloxy)methyl)deca-4,9-dienoyl)oxazolidin-2-
one (3-132) 
The title compound was obtained from alcohol 3-131 using the chloride cleavage reaction 
conditions described above in the procedure to obtain compound 3-89. This procedure 
provided the title compound as colorless oil (86% yield, 3:1 ratio of products 3-132:3-
133). Rf 0.34 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3) 7.31−7.22 (m, 5H), 
7.18−7.16 (m, 2H), 6.87−6.83 (m, 2H), 5.80−5.70 (m, 2H), 5.00−4.91 (m, 2H), 4.69−4.65 
(m, 1H), 4.64−4.60 (m, 1H), 4.46−4.39 (m, 2H), 4.14−4.07 (m, 4H), 3.77 (s, 3H), 3.36 
(dd, J = 16.4, 8.9 Hz, 1H), 3.24 (dd, J = 13.3, 3.1 Hz, 1H), 3.16 (dd, J = 16.4, 3.9 Hz, 
1H), 2.69 (dd, J = 13.5, 9.6 Hz, 1H), 2.10−1.99 (m, 4H), 1.45 (quin, J = 7.5 Hz, 2H); 13C 
NMR (150 MHz, CDCl3)  171.9, 159.1, 153.3, 138.3, 136.0, 135.1, 131.5, 129.9, 129.4, 
129.3, 128.8, 127.2, 114.6, 113.7, 72.2, 71.5, 66.0, 65.2, 55.1, 55.0, 41.7, 37.6, 33.1, 28.5, 
26.8. HRMS [m/z+H
+
] 494.2534 (calcd for C29H35NO6, 493.2464). 
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(R,Z)-4-Benzyl-3-(4-((4-methoxybenzyloxy)methyl)deca-
4,9-dien-2-ynoyl)oxazolidin-2-one (3-133) 
*Note: The title compound was not confirmed but was only 
suspected using the following procedure.*  
The suspected title compound was obtained from alcohol 3-131 using the chloride 
cleavage reaction conditions described above in the procedure to obtain compound 3-89. 
This procedure provided the suspected title compound as colorless oil (86% yield, 3:1 
ratio of products 3-132:3-133). Rf 0.54 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, 
CDCl3)  7.09−6.96 (m, 7H), 6.63−6.61 (m, 2H), 5.93 (t, J = 7.8 Hz, 1H), 5.52 (ddt, J = 
17.1, 10.3, 6.6 Hz, 1H), 4.78−4.70 (m, 2H), 4.78−4.70 (m, 2H), 4.52−4.46 (m, 1H), 4.25 
(s, 2H), 3.96 (s, 2H), 3.94−3.89 (m, 2H), 3.54 (s, 3H), 3.09 (dd, J = 13.3, 3.1 Hz, 1H), 
2.54 (dd, J = 13.5, 9.6 Hz, 1H), 1.99 (q, J = 7.8 Hz, 2H), 1.80 (q, J = 7.0 Hz, 2H), 1.27 
(quin, J = 7.4 Hz, 2H); 
13
C NMR (150 MHz, CDCl3)  165.6, 159.2, 153.3, 148.9, 146.9, 
138.0, 135.4, 134.6, 130.1, 129.6, 129.4, 128.9, 127.2, 115.8, 115.0, 113.7, 72.4, 66.0, 
64.9, 63.7, 55.4, 55.2, 37.9, 33.2, 28.2.  
 
(R,Z)-4-Benzyl-3-(4-(hydroxymethyl)deca-4,9-dien-2-
ynoyl)oxazolidin-2-one (3-133b) 
*Note: The title compound was not confirmed but was only 
suspected using the following procedure.*  
Suspected ene-yne 3-133 (160 mg, 0.35 mmol) in 8.00 mL CH2Cl2 and 0.80 mL H2O was 
added DDQ (157 mg, 0.69 mmol) at RT. After stirring for 2 h at RT, 10.0 mL CH2Cl2 
and 10.0 mL H2O was added to the reaction solution. The aqueous layers were then 
extracted with CH2Cl2 (3 x 10.0 mL), and the combined organic layers were washed with 
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the suspected title compound as colorless oil (65% yield, 79.5 mg). Rf 0.33 
(40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.49−7.43 (m, 2H), 7.34−7.31 (m, 
2H), 7.27 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6 Hz, 2H), 6.15 (t, J = 7.6 Hz, 1H), 5.79 (ddt, 
J = 17.1, 10.3, 6.5 Hz, 1H), 5.02 (d, J = 17.6 Hz, 1H), 4.98 (d, J = 10.5 Hz, 1H), 
4.76−4.72 (m, 1H), 4.43 (m, 2H), 4.22−4.15 (m, 2H), 3.35 (dd, J = 13.5, 3.4 Hz, 1H), 
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2.78 (dd, J = 13.2, 9.7 Hz, 1H), 2.34 (q, J = 7.6 Hz, 2H), 2.09 (q, J = 7.2 Hz, 2H), 1.68 
(bs, 1H), 1.56 (quin, J = 7.5 Hz, 2H); 
13
C NMR (150 MHz, CDCl3)  165.5, 153.5, 148.4, 
146.2, 138.0, 136.7, 135.4, 129.4, 128.9, 127.3, 115.7, 115.2, 66.1, 56.9, 55.4, 38.0, 33.2, 
28.3, 28.1. HRMS [m/z+H
+
] 354.7795 (calcd for C21H23NO4, 353.1627).  
 
3-(4-Methoxybenzyloxy)propan-1-ol (3-151b) 
The title compound was obtained from 1,3-propanediol using the standard PMB 
protection reaction conditions described in the procedure to obtain compound 3-170c. 
This procedure provided the title compound as colorless oil (90% yield). Rf 0.36 (40% 
EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.25 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.8 
Hz, 2H), 4.44 (s, 2H), 3.80 (s, 3H), 3.76 (q, J = 5.7 Hz, 2H), 3.63 (t, J = 5.9 Hz, 2H), 2.25 
(t, J = 5.6 Hz, 2H), 1.84 (quin, J = 5.7 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  159.3, 
130.2, 129.3, 113.8, 72.9, 69.2, 62.1, 55.3, 32.1. 
 
3-(tert-Butyldiphenylsilyloxy)propan-1-ol (3-151c) 
The title compound was obtained from 1,3-propanediol using the silyl protection strategy 
described above in the procedure to obtain compound 3-67a, except TBDPSCl was used. 
This procedure provided the title compound as a white solid (97% yield). Rf 0.41 (20% 
EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.89−7.66 (m, 4H), 7.45−7.37 (m, 6H), 
3.86−3.82 (m, 4H), 2.36 (d, J = 5.5 Hz, 1H), 1.80 (quin, J = 5.7 Hz, 2H), 1.04 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  135.5, 133.2, 129.8, 127.7, 63.3, 62.0, 34.2, 26.8, 19.1.  
 
3-(4-Methoxybenzyloxy)propanal (3-151) 
The title compound was obtained from alcohol 3-151b using the 
standard IBX oxidation reaction conditions described above in the procedure to obtain 
compound 3-76. This procedure provided the title compound as colorless oil (95% yield). 
Rf 0.55 (60% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.78 (t, J = 1.8 Hz, 1H), 
7.24 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 4.45 (s, 2H), 3.79 (s, 3H), 3.80−3.76 
(m, 2H), 2.67 (td, J = 6.2, 1.8 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  201.2, 159.3, 
129.9, 129.3, 113.8, 72.9, 63.5, 55.3, 43.9. 
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(Z)-Ethyl 2-iodo-5-(4-methoxybenzyloxy)pent-2-enoate (3-152) 
To a solution of phosphorane
41
 (388 mg, 2.00 mmol) in 10.0 mL 
CH2Cl2 at −20 °C was added NIS (495 mg, 2.20 mmol). After allowing the solution to 
stir for 20 min at −20 °C, K2CO3 (691 mg, 5.00 mmol) was added. The reaction mixture 
was heated to reflux and aldehyde 3-151 (388 mg, 2.00 mmol) in 1.00 mL CH2Cl2 was 
added dropwise. The reaction was held at reflux for 16 h and then cooled to RT. The 
reaction mixture was filtered through Celite and concentrated under reduced pressure. 
Purification by distillation provided the title compound as colorless oil (88% yield, 686 
mg). Rf 0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.31−7.24 (m, 3H), 
6.88−6.86 (m, 2H), 4.46 (s, 2H), 4.25 (q, J = 7.0 Hz, 2H), 3.80 (s, 3H), 3.58 (t, J = 6.5 
Hz, 2H), 2.58 (q, J = 6.5 Hz, 2H), 1.31 (t, J = 7.2 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) 
 162.7, 159.3, 150.0, 130.1, 129.3, 113.8, 96.8, 72.7, 67.1, 62.7, 55.3, 37.7, 14.2. HRMS 
m/z 390.0313 (calcd for C15H19IO4, 390.0328). 
 
(Z)-2-Iodo-5-(4-methoxybenzyloxy)pent-2-en-1-ol (3-152b) 
To a solution of ester 3-152 (471 mg, 1.25 mmol) in 15.0 mL THF at 
−78 °C was added DIBAL (3.80 mL, 3.80 mmol, 1.00 M in Et2O). After 4 h at −30 °C, 
the reaction mixture slowly poured into 20.0 mL half saturated aqueous solution of 
Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture was separated and the 
aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (94% yield, 390 g). Rf 
0.38 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.26−7.24 (m, 2H), 
6.89−6.86 (m, 2H), 6.00 (t, J = 6.5 Hz, 1H), 4.44 (s, 2H), 4.23 (d, J = 5.9 Hz, 2H), 3.80 
(s, 3H), 3.51 (t, J = 6.5 Hz, 1H), 2.46 (q, J = 6.5 Hz, 2H), 1.58 (t, J = 6.6 Hz, 1H); 
13
C 
NMR (100 MHz, CDCl3)  159.2, 133.1, 130.2, 129.3, 113.8, 109.7, 72.6, 71.6, 67.9, 
55.3, 36.3. HRMS m/z 348.0211 (calcd for C13H17IO3, 348.0222). 
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(Z)-tert-Butyl(2-iodo-5-(4-methoxybenzyloxy)pent-2-
enyloxy)dimethylsilane (3-153) 
The title compound was obtained from alcohol 3-152b using the standard TBS protection 
reaction conditions described above in the procedure to obtain compound 3-67a. This 
procedure provided the title compound as colorless oil (96% yield). Rf 0.58 (40% 
EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.25 (d, J = 6.4 Hz, 2H), 6.87 (d, J = 8.2 
Hz, 2H), 6.02 (t, J = 6.7 Hz, 1H), 4.44 (s, 2H), 4.25 (s, 2H), 3.80 (s, 3H), 3.50 (t, J = 6.4 
Hz, 2H), 2.47 (q, J = 6.4 Hz, 2H), 0.91 (s, 9H), 0.08 (s, 6H); 
13
C NMR (100 MHz, 
CDCl3)  159.2, 133.1, 130.2, 129.3, 113.8, 109.7, 72.6, 71.6, 67.9, 55.3, 36.3. HRMS 
m/z 462.0991 (calcd for C19H31IO3Si, 462.1087). 
 
(2Z,4E)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-7-(4-
methoxybenzyloxy)hepta-2,4-dienoate (3-149) 
Iodide 3-153 (694 mg, 1.50 mmol) and Pd(PPh3)4 (60.0 mg, 0.05 
mmol) in 5.00 mL toluene was added vinyl borane
43
 (678 mg, 3.00 mmol) in 2.50 mL 
toluene. A solution of NaOMe (3.75 mL, 1.88 mmol, 0.50 M) in MeOH was then added 
and the solution was heated to 68 °C for 12 h. The reaction mixture was cooled to RT and 
quenched with 10.0 mL half saturated aqueous NH4Cl. The mixture was separated and 
the aqueous layer was extracted with EtOAc (3 x 10.0 mL). The combined organic layers 
were washed with brine, dried (MgSO4), filtered through Celite and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel using EtOAc-
hexanes for elution provided the title compound as colorless oil (84% yield, 547 mg). Rf 
0.74 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.25−7.22 (m, 2H), 
6.87−6.84 (m, 2H), 6.57 (d, J = 12.5 Hz, 1H), 5.87 (d, J = 11.7 Hz, 1H), 5.70 (t, J = 7.0 
Hz, 1H), 4.41 (s, 2H), 4.26 (s, 2H), 4.12 (q, J = 7.0 Hz, 2H), 3.79 (s, 3H), 3.45 (t, J = 3.4 
Hz, 2H), 2.33 (q, J = 7.0 Hz, 2H), 1.31−1.22 (m, 3H), 0.88 (s, 9H), 0.04 (s, 6H); 13C 
NMR (100 MHz, CDCl3)  159.1, 140.6, 138.0, 137.2, 130.5, 129.2, 125.5, 122.0, 113.7, 
72.5, 69.2, 65.7, 60.1, 55.2, 29.3, 25.9, 14.2, −5.3. HRMS m/z 434.2483 (calcd for 
C24H38O5Si, 434.2489). 
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(E)-5-(3-(4-Methoxybenzyloxy)propylidene)-5,6-dihydro-2H-pyran-
2-one (3-161) 
Ester 3-160 (50.0 mg, 0.12 mmol) in 1.50 mL MeOH was added p-
toluenesulphonic acid monohydrate (2.00 mg, 0.01 mmol) and the 
reaction mixture was allowed to stir for 2 h. The reaction was quenched with 5.00 mL 
half saturated NaHCO3. The mixture was separated and the aqueous layer was extracted 
with EtOAc (3 x 5.00 mL). The combined organic layers were washed with brine, dried 
(MgSO4), filtered through Celite and concentrated under reduced pressure. Purification 
by flash chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (100% yield, 32.0 mg). Rf 0.34 (40% EtOAc/hexanes). 
1
H 
NMR (600 MHz, CDCl3)  7.31 (d, J = 10.0 Hz, 1H), 7.21 (d, J = 8.2 Hz, 2H), 6.87 (d, J 
= 8.2 Hz, 2H), 5.92 (d, J = 10.0 Hz, 1H), 5.82 (t, J = 7.6 Hz, 1H), 4.85 (s, 2H), 4.42 (s, 
2H), 3.79 (s, 3H), 3.50 (t, J = 6.4 Hz, 2H), 2.49 (q, J = 6.6 Hz, 2H); 
13
C NMR (100 MHz, 
CDCl3)  159.3, 138.9, 131.7, 130.0, 129.3, 127.5, 119.2, 113.8, 113.8, 72.8, 71.1, 68.3, 
55.3, 28.4. HRMS m/z 274.1211 (calcd for C16H18O4, 274.1205). 
 
(E)-5-(3-(4-Methoxybenzyloxy)propylidene)-5,6-dihydro-2H-pyran-
2-ol (3-161b) 
To a solution of lactone 3-161 (32.0 mg, 0.12 mmol) in 2.00 mL CH2Cl2 
at −78 °C was added DIBAL (0.15 mL, 0.15 mmol, 1.00 M in Et2O). 
After 45 min at −78 °C, the reaction mixture slowly poured into 10.0 mL half saturated 
aqueous solution of Rochelle’s salt (Na·K·tartrate) and stirred for 30 min. The mixture 
was separated and the aqueous layer was extracted with CH2Cl2 (3 x 10.0 mL). The 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as colorless oil (100% 
yield, 32.0 g). Rf 0.23 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.21 (d, J = 
8.9 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 6.58 (d, J = 10.2 Hz, 1H), 5.80 (dt, J = 10.2, 2.3 
Hz, 1H), 5.375.35 (m, 2H), 4.52 (d, J = 12.9 Hz, 1H), 4.40 (s, 2H), 4.01 (d, J = 13.3 Hz, 
1H), 3.77 (s, 3H), 3.44 (t, J = 6.8 Hz, 2H), 2.97 (d, J = 5.1 Hz, 1H), 2.45 (d, J = 7.6 Hz, 
1H), 2.41 (d, J = 7.6 Hz, 1H). 
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(E)-6-Methoxy-3-(3-(4-methoxybenzyloxy)propylidene)-3,6-dihydro-
2H-pyran (3-162) 
Lactol 3-161b (390 mg, 1.41 mmol) in 15.0 mL MeOH was added PPTS 
(35.0 mg, 0.14 mmol). The solution was allowed to stir for 16 h at RT. 
To the reaction mixture was added 1.00 mL NEt3 (7.21 mmol) and the solution was 
concentrated under reduced pressure to give the title compound as colorless oil (100% 
yield, 385 mg). Rf 0.55 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.24 (d, J 
= 8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.60 (d, J = 10.0 Hz, 1H), 5.78 (d, J = 11.7 Hz, 
1H), 5.38 (t, J = 7.6 Hz, 1H), 4.89 (d, J = 3.5 Hz, 1H), 4.48 (d, J = 12.9 Hz, 1H), 4.43 (s, 
2H), 3.98 (d, J = 12.9 Hz, 1H), 3.79 (s, 3H), 3.46 (t, J = 6.7 Hz, 2H), 3.44 (s, 3H), 2.45 
(q, J = 7.0 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  159.2, 130.5, 130.3, 129.2, 125.6, 
124.3, 123.9, 113.8, 95.6, 72.6, 69.2, 62.9, 55.3, 55.2, 27.3. HRMS m/z 290.1523 (calcd 
for C17H22O4, 290.1518). 
 
(E)-3-(6-Methoxy-2H-pyran-3(6H)-ylidene)propan-1-ol (3-163) 
Silyl ether 3-169c (250 mg, 0.61 mmol) was dissolved in 3.00 mL reagent 
grade THF and TBAF (1.00 M in THF, 0.92 mL, 0.92 mmol) was added 
dropwise. After stirring for 1 h at RT, the solution was diluted with 10.0 
mL H2O and 10.0 mL EtOAc. The mixture was separated and the aqueous layer was 
extracted with EtOAc (3 x 10.0 mL). The combined organic layers were washed with 
brine, dried (MgSO4), filtered through Celite and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel using EtOAc-hexanes for elution 
provided the title compound as colorless oil (94% yield, 97.0 mg). Rf 0.16 (40% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.60 (d, J = 10.2 Hz, 1H), 5.78 (ddd, J = 
10.3, 3.0, 1.6 Hz, 1H), 5.36 (t, J = 7.8 Hz, 1H), 4.88 (d, J = 3.1 Hz, 1H), 4.47 (d, J = 11.7 
Hz, 1H), 3.98 (d, J = 12.9 Hz, 1H), 3.63 (t, J = 6.3 Hz, 2H), 3.42 (s, 3H), 2.432.37 (m, 
2H), 1.98 (bs, 1H); 
13
C NMR (100 MHz, CDCl3)  131.5, 125.9, 124.2, 123.5, 95.5, 62.8, 
61.9, 55.3, 30.1. HRMS m/z 170.0910 (calcd for C9H14O3, 170.0943). 
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3-(tert-Butyldiphenylsilyloxy)propanal (3-165) 
The title compound was obtained from alcohol 3-151c using the 
standard Swern oxidation reaction conditions described above in the procedure to obtain 
compound 3-67. This procedure provided the title compound as pale yellow oil (99% 
yield). Rf 0.67 (20% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.81 (t, J = 2.2 Hz, 
1H), 7.66−7.64 (m, 4H), 7.43−7.37 (m,   6H), 4.01 (t, J = 6.1 Hz, 2H), 2.59 (td, J = 6.1, 
2.3 Hz, 2H), 1.03 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  201.9, 135.5, 133.2, 129.8, 
127.7, 58.3, 46.4, 26.7, 19.1. 
 
(Z)-Ethyl-5-(tert-butyldiphenylsilyloxy)-2-iodopent-2-enoate   
(3-166) 
The title compound was obtained from aldehyde 3-165 using the reaction conditions 
described above in the procedure to obtain compound 3-152. This procedure provided the 
title compound as pale yellow oil (80% yield). Rf 0.56 (10% EtOAc/hexanes). 
1
H NMR 
(400 MHz, CDCl3)  7.67−7.64 ( m, 4H), 7.43−7.35 (m, 7H), 4.27 (q, J = 7.2 Hz, 2H), 
3.79 (t, J = 6.5 Hz, 2H), 2.55 (q, J = 6.5 Hz, 2H), 1.32 (t, J = 7.0 Hz, 2H), 1.05 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  162.8, 150.2, 135.6, 133.4, 129.7, 127.7, 96.6, 62.6, 61.4, 
40.3, 26.8, 19.2, 14.2. HRMS m/z 508.0845 (calcd for C23H29IO3Si, 508.0931). 
 
(Z)-5-(tert-Butyldiphenylsilyloxy)-2-iodopent-2-en-1-ol (3-166b) 
The title compound was obtained from ester 3-166 using the 
reduction reaction conditions described above in the procedure to obtain compound 3-
152b. This procedure provided the title compound as colorless oil (92% yield). Rf 0.64 
(40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.68−7.66 (m, 4H), 7.45−7.37 (m, 
6H), 5.96 (t, J = 6.6 Hz, 1H), 4.20 (d, J = 6.6 Hz, 2H), 3.75 (t, J = 6.5 Hz, 2H), 2.44 (q, J 
= 6.6 Hz, 2H), 1.90 (t, J = 6.6 Hz, 1H), 1.06 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  
135.6, 133.7, 133.2, 129.6, 127.7, 109.6, 71.6, 62.1, 39.1, 26.8, 19.2. HRMS m/z 
466.8543 (calcd for C21H27IO2Si, 466.0825). 
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(Z)-6-Iodo-2,2,3,3,12,12-hexamethyl-11,11-diphenyl-4,10-
dioxa-3,11-disilatridec-6-ene (3-167) 
The title compound was obtained from alcohol 3-166b using the standard TBS protection 
reaction conditions described above in the procedure to obtain compound 3-67a. This 
procedure provided the title compound as colorless oil (97% yield). Rf 0.73 (10% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.67−7.65 (m, 4H), 7.43−7.35 (m, 6H), 
6.06 (tt, J = 6.8, 1.6 Hz, 1H), 4.24 (d, J = 1.6 Hz, 2H), 3.71 (t, J = 6.5 Hz, 2H), 2.44 (q, J 
= 6.5 Hz, 2H), 1.04 (s, 9H), 0.91 (s, 9H), 0.08 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  
135.6, 133.8, 130.6, 129.6, 127.6, 108.8, 71.5, 62.3, 38.9, 26.8, 25.9, 19.2, 18.4, -5.2  . 
HRMS m/z 580.7525 (calcd for C27H41IO2Si2, 580.6887). 
 
(2Z,4E)-Ethyl-4-((tert-butyldimethylsilyloxy)methyl)-7-(tert-
butyldiphenylsilyloxy)hepta-2,4-dienoate (3-168) 
The title compound was obtained from iodide 3-167 using the 
Suzuki reaction conditions described above in the procedure to obtain compound 3-160. 
This procedure provided the title compound as colorless oil (80% yield). Rf 0.23 (5% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.69−7.66 (m, 4H), 7.44−7.36 (m, 6H), 
6.53 (d, J = 12.1 Hz, 1H), 5.85 (d, J = 12.9 Hz, 1H), 5.77 (t, J = 7.2 Hz, 1H), 4.29 (s, 2H), 
4.12 (q, J = 7.2 Hz, 2H), 3.68 (t, J = 6.6 Hz, 2H), 2.32 (q, J = 6.6 Hz, 2H), 1.25 (t, J = 7.2 
Hz, 3H), 1.06 (s, 9H), 0.90 (s, 9H), 0.06 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  165.7, 
140.5, 137.1, 135.5, 133.9, 129.5, 127.6, 125.8, 121.8, 65.6, 63.1, 60.1, 32.1, 26.8, 25.9, 
19.1, 18.4, 14.1, −5.3. HRMS m/z 551.3039 (calcd for C32H48O4Si2, 552.3091). 
 
(E)-5-(3-(tert-Butyldiphenylsilyl)propylidene)-5,6-dihydro-2H-
pyran-2-one (3-169) 
The title compound was obtained from ester 3-168 using the 
cyclization reaction conditions described above in the procedure to 
obtain compound 3-161. This procedure provided the title compound as colorless oil 
(99% yield). Rf 0.60 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.647.62 
(m, 4H), 7.467.36 (m, 6H), 7.21 (d, J = 9.8 Hz, 1H), 5.90 (dd, J = 9.9, 1.8 Hz, 1H), 5.76 
(t, J = 7.8 Hz, 1H), 2.462.41 (m, 2H), 1.04 (s, 9H); 13C NMR (100 MHz, CDCl3)  
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168.0, 139.0, 135.5, 133.4, 131.7, 129.8, 127.7, 119.0, 71.0, 62.5, 31.0, 26.8, 19.1. 
HRMS m/z 392.7631 (calcd for C24H28O3Si, 392.1808). 
 
(E)-5-(3-(tert-Butyldiphenylsilyloxy)propylidene)-5,6-dihydro-2H-
pyran-2-ol (3-169b) 
The title compound was obtained from lactone 3-169 using the 
reduction reaction conditions described above in the procedure to 
obtain compound 3-161b. This procedure provided the title compound as colorless oil 
(99% yield). Rf 0.45 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.65 (d, J = 
7.4 Hz, 4H), 7.447.35 (m, 6H), 6.49 (d, J = 10.2 Hz, 1H), 5.78 (d, J = 10.2 Hz, 1H), 
5.405.35 (m, 2H), 4.53 (d, J = 12.9 Hz, 1H), 4.02 (d, J = 12.9 Hz, 1H), 3.68 (t, J = 6.3 
Hz, 2H), 2.79 (d, J = 5.9 Hz, 1H), 2.40 (q, J = 7.0 Hz, 2H), 1.04 (s, 9H); 
13
C NMR (100 
MHz, CDCl3)  135.6, 133.8, 130.4, 129.6, 127.6, 126.3, 124.6, 124.3, 89.3, 63.2, 63.2, 
30.2, 26.8, 19.2. HRMS m/z 394.2028 (calcd for C24H30O3Si, 394.1964). 
 
(E)-tert-Butyl(3-(6-methoxy-2H-pyran-3(6H)-
ylidene)propoxy)diphenylsilane (3-169c) 
The title compound was obtained from lactol 3-169b using the reaction 
conditions described above in the procedure to obtain compound 3-
162. This procedure provided the title compound as colorless oil (94% yield). Rf 0.68 
(40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.65 (d, J = 6.4 Hz, 4H), 
7.437.40 (m, 2H), 7.387.36 (m, 4H), 6.47 (d, J = 9.9 Hz, 1H), 5.73 (ddd, J = 9.9, 2.9, 
1.8 Hz, 1H), 5.45 (t, J = 7.6 Hz, 1H), 4.88 (d, J = 2.9 Hz, 1H), 4.45 (d, J = 12.9 Hz, 1H), 
3.95 (d, J = 12.9 Hz, 1H), 3.67 (t, J = 6.7 Hz, 2H), 3.43 (s, 3H), 2.39 (q, J = 6.7 Hz, 2H), 
1.03 (s, 9H); 
13
C NMR (100 MHz, CDCl3)  135.6, 133.8, 130.7, 129.6, 127.6, 125.4, 
124.5, 124.0, 95.6, 63.3, 62.9, 55.3, 30.1, 26.8, 19.2. HRMS m/z 408.3647 (calcd for 
C25H32O3Si, 408.2121). 
 
2-(tert-Butyldimethylsilyloxy)ethanol (3-170b) 
The title compound was obtained from ethylene glycol using the standard TBS protection 
reaction conditions described above in the procedure to obtain compound 3-67a. This 
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procedure provided the title compound as colorless oil (98% yi  eld). Rf 0.50 (40% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  3.70-3.68 (m, 2H), 2.63-3.61 (m, 2H), 
2.09 (bs, 1H), 0.09 (s, 9H), 0.06 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  64.1, 63.7, 25.9, 
18.3, −5.4.   
 
2-(4-Methoxybenzyloxy)ethanol (3-170c) 
Ethylene glycol (1.74 mL, 31.1 mmol) in 70.0 mL THF was added NaH 
(753 mg, 31.4 mmol) portionwise at 0 °C and allowed to stir for 1 h at that temperature. 
To the cold solution, Bu4NI (1.14 g, 3.11 mmol) was added, followed by PMBBr and 
allowed to stir at RT for 2 h. The reaction was quenched by the addition of 70.0 mL H2O. 
The aqueous layer was then extracted with EtOAc (3 x 50.0 mL), and the combined 
organic layers were washed with brine, dried (MgSO4), filtered through Celite and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel 
using EtOAc-hexanes for elution provided the title compound as colorless oil (87% yield, 
4.92 g). Rf 0.33 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  7.26 (d, J = 8.8 
Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.49 (s, 2H), 3.80 (s, 3H), 3.74−3.73 (m, 2H), 
3.57−3.56 (m, 2H); 13C NMR (100 MHz, CDCl3)  159.3, 130.0, 129.4, 113.8, 73.0, 
71.0, 61.9, 55.3. 
 
2-(tert-Butyldimethylsilyloxy)acetaldehyde (3-171) 
The title compound was obtained from alcohol 3-170b using the standard 
IBX oxidation reaction conditions described above in the procedure to obtain compound 
3-76. This procedure provided the title compound as colorless oil (98% yield). Rf 0.70 
(40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  9.69 (s, 1H), 4.21 (s, 2H), 0.91 (s, 
9H), 0.09 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  207.7, 75.0, 31.2, 23.8, 0.0.  
 
2-(4-Methoxybenzyloxy)acetaldehyde (3-173) 
The title compound was obtained from alcohol 3-170c using the standard 
IBX oxidation reaction conditions described above in the procedure to obtain compound 
3-76. This procedure provided the title compound as colorless oil (97% yield). Rf 0.50 
(60% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  9.68 (s, 1H), 7.27 (d, J = 8.8 Hz, 
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2H), 6.88 (d, J = 8.2 Hz, 2H), 4.54 (s, 2H), 4.05 (s, 2H), 3.79 (s, 3H); 
13
C NMR (100 
MHz, CDCl3)  200.5, 159.5, 129.7, 128.8, 74.9, 73.2, 55.2.  
 
(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-3-(4-
methoxyphenyl)propanoyl)oxazolidin-2-one (3-176) 
The title compound was obtained from auxilliary (S)-3-87 and 
aldehyde 3-173 using the aldol reaction conditions described above in the procedure to 
obtain compound 3-88. This procedure provided the title compound as colorless oil 
(64%). Rf 0.50 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.27−7.23 (m, 5H), 
6.99−6.97 (m, 2H), 6.87−6.83 (m, 2H), 5.87−5.83 (m, 1H), 4.72−4.66 (m, 1H), 4.25−4.21 
(m, 1H), 4.15−4.13 (m, 1H), 3.76 (s, 3H) 3.45 (dd, J = 13.7, 7.8 Hz, 1H), 3.14 (dd, J = 
13.7, 7.0 Hz, 1H), 3.07 (dd, J = 13.7, 3.1 Hz, 1H), 2.64 (dd, J = 13.7, 8.9 Hz, 1H); 
13
C 
NMR (100 MHz, CDCl3)  168.7, 158.9, 152.5, 134.5, 130.8, 129.3, 128.9, 127.8, 127.4, 
114.0, 66.2, 55.3, 55.2, 54.5, 39.7, 37.4.  
     
2-(4-Methoxyphenoxy)ethanol (3-177b) 
NaOH (2.48 g, 62.1 mmol) in 25.0 mL H2O was added 4-methoxyphenol 
(8.48 g, 62.1 mmol) followed by 2-chloroethanol (448 mg, 7.06 mmol) and the solution 
was allowed to stir for 24 h at RT. The reaction was quenched by the addition of 25.0 mL 
EtOAc. The aqueous layer was then extracted with EtOAc (3 x 20.0 mL), and the 
combined organic layers were washed with brine, dried (MgSO4), filtered through Celite 
and concentrated under reduced pressure. Purification by flash chromatography on silica 
gel using EtOAc-hexanes for elution provided the title compound as a white solid (88% 
yield, 1.04 g). Rf 0.32 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  6.87−6.82 
(m, 4H), 4.04−4.02 (m, 2H), 3.94−3.91 (m, 2H), 3.76 (s, 3H), 2.01 (t, J = 6.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  154.1, 152.7, 115.6, 114.7, 69.9, 61.6, 55.7.  
 
2-(4-Methoxyphenoxy)acetaldehyde (3-178) 
The title compound was obtained from alcohol 3-177b using the standard 
IBX oxidation reaction conditions described above in the procedure to obtain compound 
3-76. This procedure provided the title compound as colorless oil (95% yield). Rf 0.33 
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(40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  9.77 (s, 1H), 6.81 (bs, 4H), 4.47 
(s, 2H), 3.72 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  199.8, 115.7, 114.9, 73.5, 55.7.  
 
(S)-4-Benzyl-3-((2S,3R)-2-chloro-3-hydroxy-4-(4-
methoxyphenoxy)butanoyl)oxazolidin-2-one (3-179) 
The title compound was obtained from auxilliary (S)-3-87 and 
aldehyde 3-178 using the aldol reaction conditions described above in the procedure to 
obtain compound 3-88. This procedure provided the title compound as pale yellow oil 
(74% yield, >20:1 dr). Rf 0.27 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  
7.36−7.26 (m, 3H), 7.22−7.20 (m, 2H), 6.87−6.79 (m, 4H), 5.96 (d, J = 4.3 Hz, 1H), 
4.71−4.66 (m, 1H), 4.53−4.49 (m, 1H), 4.22−4.15 (m, 2H), 4.12 (d, J = 5.9 Hz, 2H), 3.75 
(s, 3H), 3.28 (dd, J = 13.5, 3.3 Hz, 1H), 2.83 (dd, J = 13.7, 9.4 Hz, 1H); 
13
C NMR (100 
MHz, CDCl3)  168.3, 154.3, 152.1, 134.5, 129.4, 129.1, 127.5, 115.6, 114.7, 70.2, 68.6, 
66.4, 56.1, 55.7, 55.3, 37.2. HRMS m/z 419.1132 (calcd for C21H22ClNO6, 419.1136). 
 
(S)-4-Benzyl-3-((S)-3-hydroxy-4-(4-
methoxyphenoxy)butanoyl)oxazolidin-2-one (3-180) 
The title compound was obtained from alcohol 3-179 using the 
chloride cleavage reaction conditions described above in the procedure to obtain 
compound 3-89. This procedure provided the title compound as pale yellow oil (93% 
yield). Rf 0.14 (40% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  7.34−7.23 (m, 3H), 
7.21−7.19 (m, 2H), 6.87−6.81 (m, 4H), 4.72−4.66 (m, 1H), 4.48−4.53 (m, 1H), 4.23−4.16 
(m, 2H), 4.03−3.97 (m, 2H), 3.75 (s, 3H), 3.36−3.22 (m, 3H), 3.19 (bs, 1H), 2.79 (dd, J = 
13.5, 9.6 Hz, 1H); 
13
C NMR (100 MHz, CDCl3)  171.8, 154.1, 153.4, 152.6, 135.0, 
129.4, 129.0, 127.4, 115.6, 114.6, 71.5, 66.7, 66.3, 55.7, 55.0, 39.4, 37.7. HRMS m/z 
385.1518 (calcd for C21H23NO6, 385.1525). 
 
(S)-3-Hydroxy-N-methoxy-4-(4-methoxyphenoxy)-N-
methylbutanamide (3-181) 
The title compound was obtained from alcohol 3-180 using the 
auxilliary cleavage reaction conditions described above in the procedure to obtain 
168 
 
168 
 
compound 3-90. This procedure provided the title compound as colorless oil (91% yield). 
Rf 0.26 (70% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.84−6.77 (m, 4H), 
4.41−4.34 (m, 1H), 3.99−3.90 (m, 3H), 3.72 (s, 3H), 3.66 (s, 3H), 3.17 (s, 3H), 2.82−2.69 
(m, 2H); 
13
C NMR (100 MHz, CDCl3)  172.9, 153.9, 152.6, 115.3, 114.5, 71.3, 66.6, 
61.2, 55.6, 34.9, 31.7. HRMS m/z 269.1261 (calcd for C13H19NO5, 269.1263). All of the 
auxiliary ((S)-3-86) was also recovered from the reaction mixture. 
 
(S)-5-Hydroxy-6-(4-methoxyphenoxy)hex-1-en-3-one (3-182) 
The title compound was obtained from amide 3-181 using the 
Grignard addition conditions, as described above in the procedure to obtain compound 3-
70. This procedure provided the title compound as colorless oil (72% yield). Rf 0.47 
(70% EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.85−6.80 (m, 4H), 6.37 (dd, J = 
16.0, 12.0 Hz, 1H), 6.27 (dd, J = 16.0, 1.2 Hz, 1H), 5.91   (d, J = 11.3 Hz, 1H), 4.47 (dq, 
J = 10.8, 5.4 Hz, 1H), 3.94 (d, J = 5.1 Hz, 1H), 3.75 (s, 3H), 3.19 (d, J = 4.3 Hz, 1H), 
3.95−3.93 (m, 2H); 13C NMR (100 MHz, CDCl3)  200.1, 154.1, 152.6, 136.6, 129.4, 
115.5, 114.6, 71.5, 66.4, 55.7, 42.4. HRMS m/z 236.1042 (calcd for C13H16O4, 236.1049). 
 
(2S,4R)-1-(4-Methoxyphenoxy)hex-5-ene-2,4-diol (3-183) 
The title compound was obtained from ketone 3-182 using the 
Prasad reduction reaction conditions, as described above in the procedure to obtain 
compound 3-72. This procedure provided the title compound as colorless oil (95% yield). 
Rf 0.20 (40% EtOAc/hexanes). 
1
H NMR (600 MHz, CDCl3)  6.85−6.80 (m, 4H), 5.89 
(ddd, J = 17.0, 10.8, 5.9 Hz, 1H), 5.28 (dt, J = 17.2, 1.4 Hz, 1H), 5.12 (dt, J = 10.5, 1.2 
Hz, 1H), 4.46−4.41 (m, 1H), 4.26−4.20 (m, 1H), 3.88−3.82 (m, 2H), 3.75 (s, 3H), 3.37 
(bs, 1H), 3.14 (bs, 1H), 1.18−1.69 (m, 2H); 13C NMR (100 MHz, CDCl3)  154.1, 152.6, 
140.3, 115.5, 114.8, 114.7, 72.8, 72.6, 70.3, 55.7, 39.3. HRMS m/z 238.1196 (calcd for 
C13H18O4, 238.1205). 
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(2R,3R,5S)-2-(Hydroxymethyl)-5-((4-methoxyphenoxy) 
methyl)tetrahydrofuran-3-ol (3-184) 
To a flask charged with Co(nmp)2 (6.00 mg, 0.01 mmol) and 
iPrOH (1.30 mL) was added tBuOOH (5.74 M, 2.00 L, 0.01 mmol). The reaction was 
heated to 55 °C under oxygen for 1 h, and the solvent was removed completely under 
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum while 
stirring to ensure that all traces of peroxide have been removed). Diol 3-183 (25.0 g, 0.10 
mmol) was added as a solution in 1.00 mL iPrOH to a flask charged with preactivated 
Co(nmp)2 under 1 atm of O2 (balloon). The resulting solution was heated at 55 °C for 16 
h. The solution was cooled to RT, and the solvent was removed completely under 
reduced pressure (rotary evaporator followed by 5 min under 0.1 mm Hg vacuum while 
stirring). The resulting residue was then dissolved in 5.00 mL EtOAc and filtered through 
a pad of Celite and washed with 10.0 mL EtOAc. Solvent removal under reduced 
pressure provided the title compound as colorless oil (87% yield, 23.0 mg). Rf 0.03 (40% 
EtOAc/hexanes). 
1
H NMR (400 MHz, CDCl3)  6.84−6.79 (m, 4H), 4.66−4.61 (m, 1H), 
4.59−4.55 (m, 1H), 4.00−3.89 (m, 5H), 3.74 (s, 3H), 3.74 (bs, 1H), 3.03 (bs, 1H), 
2.14−2.11 (m, 1H), 2.04−2.02 (m, 1H); 13C NMR (100 MHz, CDCl3)  153.9, 152.8, 
115.6, 114.6, 81.2, 76.6, 74.0, 71.1, 61.7, 55.7, 38.2. HRMS m/z 254.1144 (calcd for 
C13H18O5, 254.1154). 
 
tert-Butyl(((2R,3R,5S)-3-(tert-butyldimethylsilyloxy)-5-((4-
methoxyphenoxy)methyl)tetrahydrofuran-2-yl)methoxy) 
dimethylsilane (3-185) 
Diol 3-183 (45.0 mg, 0.18 mmol) in 0.50 mL DMF was added imidazole (61.0 mg, 0.90 
mmol) followed by TBSCl (80.0 mg, 0.90 mmol). After stirring for 16 h, 10.0 mL of H2O 
was added. The mixture was separated and the aqueous layer was extracted with EtOAc 
(3 x 10.0 mL). The combined organic layers were washed with brine, dried (MgSO4), 
filtered through Celite and concentrated under reduced pressure. Purification by flash 
chromatography on silica gel using EtOAc-hexanes for elution provided the title 
compound as colorless oil (90% yield). Rf 0.45 (10% EtOAc/hexanes). 
1
H NMR (600 
MHz, CDCl3)  6.86−6.79 (m, 4H), 4.55−4.51 (m, 1H), 4.46−4.42 (m, 1H), 3.97−3.92 
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(m, 3H), 3.84−3.79 (m, 1H), 3.76−3.73 (m, 1H), 3.75 (s, 3H), 2.02−1.94 (m, 2H), 0.90 (s, 
9H), 0.88 (s, 9H), 0.08 (s, 6H), 0.05 (s, 6H); 
13
C NMR (150 MHz, CDCl3)  153.9, 153.2, 
115.5, 114.5, 83.8, 76.1, 72.2, 71.2, 61.3, 55.7, 38.5, 26.0, 25.8, 18.1, −4.7, −5.1, −5.3. 
HRMS m/z 482.2878 (calcd for C25H46O5Si2, 482.2884). 
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Appendix I. NMR Data for Compounds Prepared in Chapter 1 
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Appendix II. NMR Data for Compounds Prepared in Chapter 2 
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Appendix III. NMR Data for Compounds Prepared in Chapter 3 
 
240 
 
240 
 
241 
 
241 
 
242 
 
242 
 
243 
 
243 
 
244 
 
244 
 
245 
 
245 
 
246 
 
246 
 
247 
 
247 
 
248 
 
248 
 
249 
 
249 
 
250 
 
250 
 
251 
 
251 
 
252 
 
252 
 
253 
 
253 
 
254 
 
254 
 
255 
 
255 
 
256 
 
256 
 
257 
 
257 
 
258 
 
258 
 
259 
 
259 
 
260 
 
260 
 
261 
 
261 
 
262 
 
262 
 
263 
 
263 
 
264 
 
264 
 
265 
 
265 
 
266 
 
266 
 
267 
 
267 
 
268 
 
268 
 
269 
 
269 
 
270 
 
270 
 
271 
 
271 
 
272 
 
272 
 
273 
 
273 
 
274 
 
274 
 
275 
 
275 
 
276 
 
276 
 
277 
 
277 
 
278 
 
278 
 
279 
 
279 
 
280 
 
280 
 
281 
 
281 
 
282 
 
282 
 
283 
 
283 
 
284 
 
284 
 
285 
 
285 
 
286 
 
286 
 
287 
 
287 
 
288 
 
288 
 
289 
 
289 
 
290 
 
290 
 
291 
 
291 
 
292 
 
292 
 
293 
 
293 
 
294 
 
294 
 
295 
 
295 
 
296 
 
296 
 
297 
 
297 
 
298 
 
298 
 
299 
 
299 
 
300 
 
300 
 
301 
 
301 
 
302 
 
302 
 
303 
 
303 
 
304 
 
304 
 
305 
 
305 
 
306 
 
306 
 
307 
 
307 
 
 
 
 
308 
 
308 
 
 
309 
 
309 
 
310 
 
310 
 
311 
 
311 
 
312 
 
312 
 
313 
 
313 
 
314 
 
314 
 
315 
 
315 
 
316 
 
316 
 
 
317 
 
317 
 
318 
 
318 
 
319 
 
319 
 
320 
 
320 
 
321 
 
321 
 
322 
 
322 
 
323 
 
323 
 
324 
 
324 
 
325 
 
325 
 
326 
 
326 
 
327 
 
327 
 
328 
 
328 
 
329 
 
329 
 
330 
 
330 
 
331 
 
331 
 
332 
 
332 
 
333 
 
333 
 
334 
 
334 
 
335 
 
335 
 
336 
 
336 
 
337 
 
337 
 
338 
 
338 
 
339 
 
339 
 
340 
 
340 
 
 
341 
 
341 
 
Curriculum Vitae 
 
Barbora (Bajtos) Morra  
 
 
 
ACADEMIC INFORMATION 
 
Doctor of Philosophy Candidate                        September 2007 – April 2012 
Synthetic Organic Chemistry 
University of Western Ontario, London, Ontario 
Research Advisor: Dr. Brian L. Pagenkopf 
 
 
Bachelor of Science                  April 2007 
Honors Specialization of Chemistry 
University of Western Ontario, London, Ontario 
 Dean’s Honor List September 2005 – April 2007 
Undergraduate Research Thesis: 
Formal [3+2] Cycloadditions of Donor-Acceptor Cyclopropanes with Nitriles, 
Imines, and Indoles 
Research Advisor: Brian L. Pagenkopf 
 
 
 
RESEARCH AND TEACHING EXPERIENCE 
 
Graduate Student Researcher                                        September 2007 – March 2012 
University of Western Ontario, London, Ontario 
Research Advisor: Dr. Brian L. Pagenkopf  
 
Undergraduate Student Supervisor                                  September 2008 – April 2011 
University of Western Ontario, London, Ontario  
 
342 
 
342 
 
Graduate Teaching Assistant                                            September 2007 – April 2009 
University of Western Ontario, London, Ontario 
 
Research Assistant                                                                     May 2007 – August 2007 
University of Western Ontario, London, Ontario 
Supervisor: Dr. Brian L. Pagenkopf 
 
Undergraduate Research Thesis Student                         September 2006 – April 2007 
University of Western Ontario, London, Ontario 
Supervisor: Dr. Brian L. Pagenkopf 
 
Research Assistant                                                                     May 2006 – August 2006 
University of Western Ontario, London, Ontario 
Supervisor: Dr. Brian L. Pagenkopf 
 
Research Assistant                                                                     May 2005 – August 2005 
University of Western Ontario, London, Ontario 
Supervisor: Dr. Mark S. Workentin 
 
 
PUBLICATIONS 
(7) Synthesis and Oxidative Cyclization of 1-(Benzyloxy)hex-5-en-2-ol using 
Co(nmp)2.  
Barbora Morra and Brian L. Pagenkopf, Org. Synth., submitted, DOI #P-1601. 
(6) Improved Yields and Simplified Purification with a Second Generation Cobalt 
Catalyst for the Oxidative Formation of trans-THF Rings. Cory Palmer, 
Nicholas A. Morra, Andrew C. Stevens, Barbora Bajtos, Benjamin P. Machin 
and Brian L. Pagenkopf, Org. Lett. 2009, 11, 5614-5617. 
(5) Synthesis of Tetrahydroisoquinocarbazoles via C-2 Alkylation of Indoles with                         
2-Alkoxycyclopropanoate Esters. Barbora Bajtos and Brian L. Pagenkopf, Org. 
Lett. 2009, 11, 2780-2783. 
343 
 
343 
 
(4) Total Synthesis of (±)-Quebrachamine via [3+2] Cycloaddition and Efficient 
Chloroacetamide Photocyclization. Barbora Bajtos and Brian L. Pagenkopf, 
Eur. J. Org. Chem. 2009, 1072-1077.  
(3) C-2/C-3 Annulation and C-2 Alkylation of Indoles with 2-
Alkoxycyclopropanoate Esters. Barbora Bajtos, Ming Yu, Hongda Zhao and 
Brian L. Pagenkopf, J. Am. Chem. Soc. 2007, 129, 9631-9634.  
(2) Synthesis of Indolizines and Benzoindolizines by Annulation of Donor-
Acceptor Cyclopropanes with Electron-Deficient Pyridines and Quinolines.  
Nicholas A. Morra, Christian L. Morales, Barbora Bajtos, Xin Wang, Hyosook 
Jang, Jian Wang, Ming Yu and Brian L. Pagenkopf, Adv. Synth. Catal. 2006, 
2385-2390. 
(1) Chemistry 273a Organic Chemistry I Laboratory Manual: Structure and 
Spectroscopy, The University of Western Ontario, 2005. 
 
 
PRESENTATIONS 
 
Oral Presentations 
(7) Barbora Morra, Work Towards the Total Synthesis of Biselide A. 94
th
 Canadian 
Chemistry Conference and Exhibition, Montreal, Quebec, 2011. 
(6) Barbora Bajtos, Cobalt Catalyzed Oxidative Formation of trans-THF Rings in 
Total Synthesis. 93
rd
 Canadian Chemistry Conference and Exhibition, Toronto, 
Ontario, 2010. 
(5)  Barbora Bajtos, The Application of [3+2] Dipolar Annulation and Alkylation 
Reactions in Total Synthesis. 22
nd
 International Congress on Heterocyclic 
Chemistry, St. John’s, Newfoundland and Labrador, 2009. 
(4) Barbora Bajtos, The Application of [3+2] Dipolar Annulation and Alkylation 
Reactions in Total Synthesis. 92
nd
 Canadian Chemistry Conference and 
Exhibition, Hamilton, Ontario, 2009. 
(3) Barbora Bajtos, Annulations of Donor-Acceptor Cyclopropanes and the Total 
Synthesis of (±)-Quebrachamine. 19
th
 Quebec Ontario Minisymposium in 
344 
 
344 
 
Synthetic and Bioorganic Chemistry, The University of Toronto, Toronto, 
Ontario, 2008. 
(2) Barbora Bajtos, C-2/C-3 Annulation and C-2 Alkylation of Indoles with                                        
2-Alkoxycyclopropanoate Esters; 18
th
 Quebec Ontario Minisymposium in 
Synthetic and Bioorganic Chemistry, The University of Montreal, Montreal, 
Quebec, 2007. 
(1) Barbora Bajtos, Formal [3+2] Cycloadditions of Donor-Acceptor 
Cyclopropanes with Nitriles, Imines, and Indoles; 35
th
 Southern Ontario 
Undergraduate Student Chemistry Conference, University of Ontario Institute of 
Technology, Oshawa, Ontario, 2007. 
 
Poster Presentations 
(5) Barbora Morra and Brian L. Pagenkopf, Work Towards the Total Synthesis of 
Biselide A. 21
st
 Quebec Ontario Minisymposium in Synthetic and Bioorganic 
Chemistry, Brock University, Saint Catharines, Ontario, 2010.  
(4) Barbora Morra and Brian L. Pagenkopf, Work Towards the Total Synthesis of 
Biselide A. The 14
th
 Symposium on the Latest Trends in Organic Synthesis, 
Brock University, Saint Catharines, Ontario, 2010. 
(3) Barbora Bajtos and Brian L. Pagenkopf, The Total Synthesis of (±)-
Quebrachamine. The 13
th
 Symposium on the Latest Trends in Organic 
Synthesis, Brock University, Saint Catharines, Ontario, 2008. 
(2) Barbora Bajtos and Brian L. Pagenkopf, The Total Synthesis of (±)-
Quebrachamine. ACS Summer School on Sustainability and Green Chemistry, 
Golden, Colorado, 2008. 
(1) Barbora Bajtos, Nicholas A. Morra and Brian L. Pagenkopf, Synthesis of 
Indolizines and Benzoindolizines by Annulation of Donor-Acceptor 
Cyclopropanes with Electron-Deficient Pyridines and Quinolines. 17
th
 Quebec 
Ontario Minisymposium in Synthetic and Bioorganic Chemistry, The University 
of Western Ontario, London, Ontario, 2006. 
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AWARDS 
Award Value  Location Tenure 
 
Oral Presentation Award  
- 92nd Canadian Chemistry Conference  
(organic division) 
 
$100 
 
Hamilton, 
ON 
 
 
June 2009 
NSERC Vanier  
Canada Graduate Scholarship 
 
$50 000/yr 
 
UWO May 2009 – April 
2012 
Graduate Thesis Research Award 
 
$750 UWO March 2009 
NSERC Alexander Graham Bell 
Canada Graduate Scholarship 
(Masters) 
 
$17 500 UWO May 2008 – April 
2009 
Ontario Graduate Scholarship  
- Declined for NSERC CGS-M 
 
$15 000 UWO N/A 
Oral Presentation Award  
- First prize (organic division) at the 35th 
Southern Ontario Undergraduate Student 
Chemistry Conference 
N/A Oshawa, 
ON 
 
March 2007 
The Chemical Institute of Canada 
Award 
$900 Oshawa, 
ON 
 
March 2007 
N. B. Patel Award 
- Awarded for the highest grade in honors 
undergraduate research thesis 
 
N/A UWO April 2007 
Western Admission Scholarship $2 000 UWO September 2003 
 
 
 
 
